{
  "content": {
    "Tumors": {
      "type": "Tumors",
      "color": "#FFFFFF",
      "path": "Content/Tumors",
      "children": [
        {
          "type": "Heme",
          "color": "#0460a9",
          "path": "Content/Tumors/Heme",
          "children": [
            {
              "type": "Nonmalignant",
              "color": "#5291DD",
              "path": "Content/Tumors/Heme/Nonmalignant",
              "children": [
                {
                  "type": "Rare Disease",
                  "color": "#2797E1",
                  "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease",
                  "children": [
                    {
                      "type": "Immune Thrombocytopenic Purpura",
                      "color": "#78BEFF",
                      "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Immune Thrombocytopenic Purpura",
                      "children": [
                        {
                          "color": "#78BEFF",
                          "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Immune Thrombocytopenic Purpura/*",
                          "studies": [
                            {
                              "nct": "NCT03524612",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Immune Thrombocytopenic Purpura/*/NCT03524612",
                              "title": "A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP (TAPER | ETB115J2411)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>TPO receptor</b> (Eltrombopag<sup>8</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "MF",
                      "color": "#5EAFFF",
                      "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF",
                      "children": [
                        {
                          "color": "#5EAFFF",
                          "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*",
                          "studies": [
                            {
                              "nct": "NCT02370706",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT02370706",
                              "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (PIM447X2104C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Ruxolitinib</i>"
                            },
                            {
                              "nct": "NCT04097821",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT04097821",
                              "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE | INC424H12201)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>) + <i>Ruxolitinib</i>"
                            },
                            {
                              "nct": "NCT02370706",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT02370706",
                              "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (PIM447X2104C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-PIM</b> (PIM447<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib) + <i>Ruxolitinib</i>"
                            },
                            {
                              "nct": "NCT02370706",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT02370706",
                              "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (PIM447X2104C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-PIM</b> (PIM447) + <i>Ruxolitinib</i>"
                            },
                            {
                              "nct": "NCT04097821",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT04097821",
                              "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE | INC424H12201)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453) + <i>Ruxolitinib</i>"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Severe Aplastic Anemia",
                      "color": "#449EED",
                      "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Severe Aplastic Anemia",
                      "children": [
                        {
                          "color": "#449EED",
                          "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Severe Aplastic Anemia/*",
                          "studies": [
                            {
                              "nct": "NCT03025698",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Severe Aplastic Anemia/*/NCT03025698",
                              "title": "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia (ETB115E2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>TPO receptor</b> (Eltrombopag<sup>8</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Sickle Cell Disease",
                      "color": "#176DCF",
                      "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease",
                      "children": [
                        {
                          "type": "Priapism",
                          "color": "#176DCF",
                          "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/Priapism",
                          "studies": [
                            {
                              "nct": "NCT03938454",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/Priapism/NCT03938454",
                              "title": "A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism (SPARTAN | SEG101AUS05)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            }
                          ]
                        },
                        {
                          "color": "#176DCF",
                          "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*",
                          "studies": [
                            {
                              "nct": "NCT03814746",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*/NCT03814746",
                              "title": "Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (STAND | SEG101A2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            },
                            {
                              "nct": "NCT04053764",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*/NCT04053764",
                              "title": "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease (STEADFAST | SEG101A2203)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            },
                            {
                              "nct": "NCT03474965",
                              "path": "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*/NCT03474965",
                              "title": "Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients (SEG101B2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "Malignant",
              "color": "#1E82D1",
              "path": "Content/Tumors/Heme/Malignant",
              "children": [
                {
                  "type": "BPDCN",
                  "color": "#835CD1",
                  "path": "Content/Tumors/Heme/Malignant/BPDCN",
                  "children": [
                    {
                      "color": "#835CD1",
                      "path": "Content/Tumors/Heme/Malignant/BPDCN/*",
                      "children": [
                        {
                          "color": "#835CD1",
                          "path": "Content/Tumors/Heme/Malignant/BPDCN/*/*",
                          "studies": [
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Tumors/Heme/Malignant/BPDCN/*/*/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Leukemia",
                  "color": "#AC7CBD",
                  "path": "Content/Tumors/Heme/Malignant/Leukemia",
                  "children": [
                    {
                      "type": "ALL",
                      "color": "#3B2793",
                      "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL",
                      "children": [
                        {
                          "type": "B Cell",
                          "color": "#3B2793",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/B Cell",
                          "studies": [
                            {
                              "nct": "NCT03876769",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/B Cell/NCT03876769",
                              "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA | CTL019G2201J)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            },
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/B Cell/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Ph+",
                          "color": "#3B2793",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/Ph+",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            }
                          ]
                        },
                        {
                          "color": "#3B2793",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/*",
                          "studies": [
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/ALL/*/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "AML",
                      "color": "#4D3280",
                      "path": "Content/Tumors/Heme/Malignant/Leukemia/AML",
                      "children": [
                        {
                          "type": "de novo",
                          "color": "#4D3280",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/de novo",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453) + <i>Decitabine</i>"
                            }
                          ]
                        },
                        {
                          "type": "FLT3m-",
                          "color": "#4D3280",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m-",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m-/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine / Anthracycline</i>"
                            }
                          ]
                        },
                        {
                          "type": "FLT3m+",
                          "color": "#4D3280",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201<sup>14</sup>) + <b>Multikinase</b> (Midostaurin) + <i>Cytarabine / Anthracycline</i>"
                            },
                            {
                              "nct": "NCT03379727",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03379727",
                              "title": "Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia. (PKC412A2408)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>) + <i>Chemo</i>"
                            },
                            {
                              "nct": "NCT03591510",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03591510",
                              "title": "A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (PKC412A2218)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>) + <i>Chemo</i>"
                            },
                            {
                              "nct": "NCT03280030",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03280030",
                              "title": "A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML (PKC412A2220)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>) + <i>Daunorubicin/Cytarabine</i>"
                            }
                          ]
                        },
                        {
                          "type": "r/r",
                          "color": "#4D3280",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453) + <i>Decitabine</i>"
                            }
                          ]
                        },
                        {
                          "color": "#4D3280",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*",
                          "studies": [
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            },
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            },
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine / Anthracycline</i>"
                            },
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine / Daunorubicin</i>"
                            },
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201) + <b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201) + <i>Venetoclax</i>"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "CLL",
                      "color": "#6A499C",
                      "path": "Content/Tumors/Heme/Malignant/Leukemia/CLL",
                      "children": [
                        {
                          "color": "#6A499C",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/CLL/*",
                          "studies": [
                            {
                              "nct": "NCT03400176",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CLL/*/NCT03400176",
                              "title": "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib (VAY736Y2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BAFF-R</b> (VAY736) + <i>Ibrutinib</i>"
                            },
                            {
                              "nct": "NCT03960840",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CLL/*/NCT03960840",
                              "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL (YTB323A12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (YTB323)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "CML",
                      "color": "#9568AF",
                      "path": "Content/Tumors/Heme/Malignant/Leukemia/CML",
                      "children": [
                        {
                          "type": "Ph+",
                          "color": "#9568AF",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Dasatinib</i>"
                            },
                            {
                              "nct": "NCT03578367",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+/NCT03578367",
                              "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (ABL001E2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Imatinib</i><sup>11</sup>"
                            },
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Imatinib</i><sup>11</sup>"
                            },
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Nilotinib</i><sup>18</sup>"
                            }
                          ]
                        },
                        {
                          "color": "#9568AF",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/*",
                          "studies": [
                            {
                              "nct": "NCT03106779",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/*/NCT03106779",
                              "title": "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (ABL001A2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            },
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/*/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            },
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/CML/*/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "MDS High Risk",
                      "color": "#8C4198",
                      "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*",
                          "studies": [
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            },
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201) + <b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201) + <i>Venetoclax</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453) + <i>Decitabine</i>"
                            },
                            {
                              "nct": "NCT03946670",
                              "path": "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03946670",
                              "title": "A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1 | MBG453B12201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>TIM-3</b> (MBG453) + <i>Decitabine / Azacitidine</i>"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lymphoma",
                  "color": "#890680",
                  "path": "Content/Tumors/Heme/Malignant/Lymphoma",
                  "children": [
                    {
                      "type": "Lymphoma",
                      "color": "#890680",
                      "path": "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma",
                      "children": [
                        {
                          "color": "#890680",
                          "path": "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*",
                          "studies": [
                            {
                              "nct": "NCT02992483",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*/NCT02992483",
                              "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (MIK665X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MCL1</b> (MIK665<sup>15</sup>)"
                            },
                            {
                              "nct": "NCT03172936",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*/NCT03172936",
                              "title": "Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (MIW815X2102J)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>STING</b> (MIW815<sup>16</sup>)"
                            },
                            {
                              "nct": "NCT02675439",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*/NCT02675439",
                              "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Non-Hodgkin Lymphoma",
                      "color": "#A4006A",
                      "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03570892",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03570892",
                              "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA | CTL019H2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            },
                            {
                              "nct": "NCT03876028",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03876028",
                              "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients (CTL019L12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>) + <i>Ibrutinib</i>"
                            },
                            {
                              "nct": "NCT03630159",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03630159",
                              "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA | CTL019J2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>) + <i>Pembrolizumab</i>"
                            },
                            {
                              "nct": "NCT03960840",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03960840",
                              "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL (YTB323A12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (YTB323) + <i>Ibrutinib</i>"
                            },
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            },
                            {
                              "nct": "NCT02992483",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT02992483",
                              "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (MIK665X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MCL1</b> (MIK665<sup>15</sup>)"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "type": "FL",
                          "color": "#A4006A",
                          "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/FL",
                          "studies": [
                            {
                              "nct": "NCT03568461",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/FL/NCT03568461",
                              "title": "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA | CTL019E2202)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "SLL",
                          "color": "#A4006A",
                          "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/SLL",
                          "studies": [
                            {
                              "nct": "NCT03960840",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/SLL/NCT03960840",
                              "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL (YTB323A12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (YTB323)"
                            }
                          ]
                        },
                        {
                          "color": "#A4006A",
                          "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/*",
                          "studies": [
                            {
                              "nct": "NCT03610724",
                              "path": "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/*/NCT03610724",
                              "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA | CTL019C2202)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Myeloma",
                  "color": "#BD1E86",
                  "path": "Content/Tumors/Heme/Malignant/Myeloma",
                  "children": [
                    {
                      "type": "Multiple Myeloma",
                      "color": "#BD1E86",
                      "path": "Content/Tumors/Heme/Malignant/Myeloma/Multiple Myeloma",
                      "children": [
                        {
                          "color": "#BD1E86",
                          "path": "Content/Tumors/Heme/Malignant/Myeloma/Multiple Myeloma/*",
                          "studies": [
                            {
                              "nct": "NCT02992483",
                              "path": "Content/Tumors/Heme/Malignant/Myeloma/Multiple Myeloma/*/NCT02992483",
                              "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (MIK665X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MCL1</b> (MIK665<sup>15</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "Solid Tumors",
          "color": "#023761",
          "path": "Content/Tumors/Solid Tumors",
          "children": [
            {
              "color": "#023761",
              "path": "Content/Tumors/Solid Tumors/*",
              "children": [
                {
                  "color": "#023761",
                  "path": "Content/Tumors/Solid Tumors/*/*",
                  "children": [
                    {
                      "type": "Brain",
                      "color": "#E060B0",
                      "path": "Content/Tumors/Solid Tumors/*/*/Brain",
                      "children": [
                        {
                          "type": "Gliobastoma",
                          "color": "#E060B0",
                          "path": "Content/Tumors/Solid Tumors/*/*/Brain/Gliobastoma",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Tumors/Solid Tumors/*/*/Brain/Gliobastoma/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1R</b> (BLZ945)"
                            }
                          ]
                        },
                        {
                          "type": "Glioma (high and low risk)",
                          "color": "#E060B0",
                          "path": "Content/Tumors/Solid Tumors/*/*/Brain/Glioma (high and low risk)",
                          "studies": [
                            {
                              "nct": "NCT02684058",
                              "path": "Content/Tumors/Solid Tumors/*/*/Brain/Glioma (high and low risk)/NCT02684058",
                              "title": "Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG (DRB436G2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Neurofibroma",
                          "color": "#E060B0",
                          "path": "Content/Tumors/Solid Tumors/*/*/Brain/Neurofibroma",
                          "studies": [
                            {
                              "nct": "NCT02124772",
                              "path": "Content/Tumors/Solid Tumors/*/*/Brain/Neurofibroma/NCT02124772",
                              "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Breast",
                      "color": "#EC008C",
                      "path": "Content/Tumors/Solid Tumors/*/*/Breast",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#FF5990",
                          "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT03701334",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03701334",
                              "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE | LEE011O12301C)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Endocrine therapy</i>"
                            },
                            {
                              "nct": "NCT01857193",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT01857193",
                              "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (LEE011X2106)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Everolimus</i><sup>9</sup> + <i>Exemestane</i>"
                            },
                            {
                              "nct": "NCT01857193",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT01857193",
                              "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (LEE011X2106)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Exemestane</i>"
                            },
                            {
                              "nct": "NCT02333370",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02333370",
                              "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (LEE011A2115C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Fulvestrant</i>"
                            },
                            {
                              "nct": "NCT03671330",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03671330",
                              "title": "Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (LEE011A2206)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole</i><sup>13</sup>"
                            },
                            {
                              "nct": "NCT02333370",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02333370",
                              "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (LEE011A2115C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole</i><sup>13</sup>"
                            },
                            {
                              "nct": "NCT03671330",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03671330",
                              "title": "Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (LEE011A2206)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole or Anastrazole</i> + <i>Goserlin</i>"
                            },
                            {
                              "nct": "NCT03822468",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03822468",
                              "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR | LEE011A2207)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole or Anastrazole</i> + <i>Goserlin</i>"
                            },
                            {
                              "nct": "NCT03822468",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03822468",
                              "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR | LEE011A2207)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole or Anastrazole</i> + <i>Goserlin</i>"
                            },
                            {
                              "nct": "NCT02333370",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02333370",
                              "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (LEE011A2115C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Tamoxifen</i>"
                            },
                            {
                              "nct": "NCT02437318",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02437318",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1 | BYL719C2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Fulvestrant</i>"
                            },
                            {
                              "nct": "NCT03056755",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03056755",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve | BYL719X2402)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Fulvestrant</i>"
                            },
                            {
                              "nct": "NCT03056755",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03056755",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve | BYL719X2402)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Fulvestrant</i>"
                            },
                            {
                              "nct": "NCT01219699",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT01219699",
                              "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene (BYL719X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Fulvestrant</i>"
                            },
                            {
                              "nct": "NCT03056755",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03056755",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve | BYL719X2402)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Letrozole</i><sup>13</sup>"
                            },
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SERD</b> (LSZ102)"
                            },
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SERD</b> (LSZ102<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            },
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SERD</b> (LSZ102<sup>1</sup>) + <b>PI3Kα</b> (Alpelisib)"
                            }
                          ]
                        },
                        {
                          "type": "TNBC",
                          "color": "#FF66B0",
                          "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525) + <i>Carboplatin</i>"
                            },
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>1L-17A</b> (CJM112)"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            },
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1R</b> (BLZ945)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CXCR2</b> (QBM076)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Everolimus</i><sup>9</sup>"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IAP</b> (LCL161)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>19</sup>) + <b>A2AR</b> (NIR178)"
                            },
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525) + <i>Carboplatin</i>"
                            },
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>12</sup>) + <b>CSF-1</b> (Lacnotuzumab)"
                            },
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>3</sup>) + <b>IL-1β</b> (Canakinumab)"
                            },
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>4</sup>) + <b>MET</b> (Capmatinib)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Panobinostat</i><sup>23</sup>"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Colorectal",
                      "color": "#EC1C24",
                      "path": "Content/Tumors/Solid Tumors/*/*/Colorectal",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        },
                        {
                          "color": "#EC1C24",
                          "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Bevacizumab</i> + <i>FOLFIRI</i>"
                            },
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Bevacizumab</i> + <i>FOLFOX6</i>"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>1L-17A</b> (CJM112)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CXCR2</b> (QBM076)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Everolimus</i><sup>9</sup>"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>HDM2-p53</b> (HDM201)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IAP</b> (LCL161)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Panobinostat</i><sup>23</sup>"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Gastrointestinal",
                      "color": "#EF4930",
                      "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Paciltaxel</i> + <i>Ramucirumab</i>"
                            },
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            }
                          ]
                        },
                        {
                          "type": "Gastric",
                          "color": "#EF4930",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        },
                        {
                          "type": "Gastric Adenocarcinoma",
                          "color": "#EF4930",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric Adenocarcinoma",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric Adenocarcinoma/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "type": "GIST",
                          "color": "#EF4930",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/GIST",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/GIST/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Gynecologic",
                      "color": "#F26322",
                      "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic",
                      "children": [
                        {
                          "type": "Cervical",
                          "color": "#F26322",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Cervical",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Cervical/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Endometrial",
                          "color": "#F26322",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Endometrial",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Endometrial/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Ovarian",
                          "color": "#F26322",
                          "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            },
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            },
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Head and Neck",
                      "color": "#F89B1C",
                      "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck",
                      "children": [
                        {
                          "type": "NPC",
                          "color": "#F89B1C",
                          "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT02605967",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT02605967",
                              "title": "Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PDR001X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IKZF2</b> (DKY709)"
                            }
                          ]
                        },
                        {
                          "color": "#F89B1C",
                          "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Liver",
                      "color": "#F7C114",
                      "path": "Content/Tumors/Solid Tumors/*/*/Liver",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Tumors/Solid Tumors/*/*/Liver/HCC",
                          "studies": [
                            {
                              "nct": "NCT02795429",
                              "path": "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02795429",
                              "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC (INC280X2108)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02795429",
                              "path": "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02795429",
                              "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC (INC280X2108)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02988440",
                              "path": "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02988440",
                              "title": "Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients (PDR001G2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Sorafenib</i>"
                            },
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Lung",
                      "color": "#FBDE3C",
                      "path": "Content/Tumors/Solid Tumors/*/*/Lung",
                      "children": [
                        {
                          "type": "Mesothelioma",
                          "color": "#FBDE3C",
                          "path": "Content/Tumors/Solid Tumors/*/*/Lung/Mesothelioma",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/Mesothelioma/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02403193",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02403193",
                              "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) ",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT01336634",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT01336634",
                              "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            },
                            {
                              "nct": "NCT01336634",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT01336634",
                              "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            },
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <i>Gefitinib</i>"
                            },
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT02335944",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02335944",
                              "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. (INC280X2105C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02323126",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02323126",
                              "title": "Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer (EGF816 | EGF816X2201C)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <i>Nivolumab</i>"
                            },
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>pan-RAF</b> (LXH254)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT03447769",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03447769",
                              "title": "Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A | ACZ885T2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03968419",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03968419",
                              "title": "Study to Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N | ACZ885V2201C)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03626545",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03626545",
                              "title": "Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2 | ACZ885V2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Docetaxel</i>"
                            },
                            {
                              "nct": "NCT03968419",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03968419",
                              "title": "Study to Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N | ACZ885V2201C)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Pembrolizumab</i>"
                            },
                            {
                              "nct": "NCT03631199",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03631199",
                              "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1 | ACZ885U2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Pembrolizumab</i> + <i>Platinum-based doublet chemotherapy</i>"
                            },
                            {
                              "nct": "NCT02276027",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02276027",
                              "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (INC280X2205)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02414139",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02414139",
                              "title": "Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (INC280A2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02323126",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02323126",
                              "title": "Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer (EGF816 | EGF816X2201C)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>) + <i>Nivolumab</i>"
                            },
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            },
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254) + <b>ERK</b> (LTT462)"
                            },
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254<sup>28</sup>) + <b>MEK</b> (Trametinib)"
                            },
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>1L-17A</b> (CJM112)"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02403193",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02403193",
                              "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) ",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CXCR2</b> (QBM076)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Everolimus</i><sup>9</sup>"
                            },
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Gemcitabine / Cisplatin</i>"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IAP</b> (LCL161)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Pemetrexed / Cisplatin or Carboplatin</i>"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT03647488",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03647488",
                              "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer (INC280D2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Paciltaxel / Carboplatin</i>"
                            },
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>pan-RAF</b> (LXH254)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Panobinostat</i><sup>23</sup>"
                            },
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Pemetrexed / Cisplatin</i>"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)"
                            },
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT02276027",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02276027",
                              "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (INC280X2205)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            },
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B12101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            }
                          ]
                        },
                        {
                          "type": "SCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Tumors/Solid Tumors/*/*/Lung/SCLC",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Lung/SCLC/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Melanoma",
                      "color": "#DBD36E",
                      "path": "Content/Tumors/Solid Tumors/*/*/Melanoma",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*",
                          "studies": [
                            {
                              "nct": "NCT03551626",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03551626",
                              "title": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus | DRB436F2410)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT02083354",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02083354",
                              "title": "Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            },
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)"
                            },
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254<sup>28</sup>) + <b>MEK</b> (Trametinib)"
                            },
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02967692",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02967692",
                              "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i | PDR001F2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            },
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            },
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A12101C)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IKZF2</b> (DKY709)"
                            },
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>pan-RAF</b> (LXH254)"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Neuroendocrine",
                      "color": "#7FC14C",
                      "path": "Content/Tumors/Solid Tumors/*/*/Neuroendocrine",
                      "children": [
                        {
                          "color": "#7FC14C",
                          "path": "Content/Tumors/Solid Tumors/*/*/Neuroendocrine/*",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Neuroendocrine/*/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Pancreatic",
                      "color": "#49A848",
                      "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            },
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1R</b> (BLZ945)"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)"
                            },
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)"
                            },
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Prostate",
                      "color": "#009B4F",
                      "path": "Content/Tumors/Solid Tumors/*/*/Prostate",
                      "children": [
                        {
                          "color": "#009B4F",
                          "path": "Content/Tumors/Solid Tumors/*/*/Prostate/*",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Tumors/Solid Tumors/*/*/Prostate/*/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            },
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Prostate/*/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Renal",
                      "color": "#008A6F",
                      "path": "Content/Tumors/Solid Tumors/*/*/Renal",
                      "children": [
                        {
                          "type": "ccRCC",
                          "color": "#008A6F",
                          "path": "Content/Tumors/Solid Tumors/*/*/Renal/ccRCC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Renal/ccRCC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Tumors/Solid Tumors/*/*/Renal/RCC",
                          "studies": [
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Cabozantinib</i>"
                            },
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>HDM2-p53</b> (HDM201)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Sarcoma",
                      "color": "#00A584",
                      "path": "Content/Tumors/Solid Tumors/*/*/Sarcoma",
                      "children": [
                        {
                          "type": "Soft Tissue Sarcoma",
                          "color": "#00A584",
                          "path": "Content/Tumors/Solid Tumors/*/*/Sarcoma/Soft Tissue Sarcoma",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Tumors/Solid Tumors/*/*/Sarcoma/Soft Tissue Sarcoma/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "color": "#00A584",
                          "path": "Content/Tumors/Solid Tumors/*/*/Sarcoma/*",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Tumors/Solid Tumors/*/*/Sarcoma/*/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Solid Tumors",
                      "color": "#00A4AB",
                      "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD73</b> (NZV930<sup>22</sup>)"
                            },
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD73</b> (NZV930<sup>22</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1R</b> (BLZ945)"
                            },
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            },
                            {
                              "nct": "NCT02452268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02452268",
                              "title": "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NIZ985X2102J)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-15</b> (NIZ985<sup>21</sup>)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>) + <b>CD73</b> (NZV930<sup>22</sup>)"
                            },
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CD73</b> (NZV930<sup>22</sup>)"
                            },
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1R</b> (BLZ945)"
                            },
                            {
                              "nct": "NCT02452268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02452268",
                              "title": "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NIZ985X2102J)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-15</b> (NIZ985<sup>21</sup>)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101C)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03301896",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03301896",
                              "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (LHC165X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TLR7</b> (LHC165)"
                            },
                            {
                              "nct": "NCT01219699",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT01219699",
                              "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene (BYL719X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            },
                            {
                              "nct": "NCT02675439",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02675439",
                              "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            },
                            {
                              "nct": "NCT02675439",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02675439",
                              "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>) + <i>Ipilimumab</i>"
                            },
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            },
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03301896",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03301896",
                              "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (LHC165X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TLR7</b> (LHC165)"
                            }
                          ]
                        },
                        {
                          "type": "Non-Breast HER2+",
                          "color": "#00A4AB",
                          "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Non-Breast HER2+",
                          "studies": [
                            {
                              "nct": "NCT03696771",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Non-Breast HER2+/NCT03696771",
                              "title": "Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer (NJH395X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HER2-TLR7</b> (NJH395)"
                            }
                          ]
                        },
                        {
                          "type": "RAS/RAF wild-type",
                          "color": "#00A4AB",
                          "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/RAS#RAF wild-type",
                          "studies": [
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/RAS#RAF wild-type/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        },
                        {
                          "type": "Wnt Pathway Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Wnt Pathway Tumors",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Wnt Pathway Tumors/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        },
                        {
                          "color": "#00A4AB",
                          "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/*",
                          "studies": [
                            {
                              "nct": "NCT03172936",
                              "path": "Content/Tumors/Solid Tumors/*/*/Solid Tumors/*/NCT03172936",
                              "title": "Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (MIW815X2102J)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Thyroid",
                      "color": "#0096AA",
                      "path": "Content/Tumors/Solid Tumors/*/*/Thyroid",
                      "children": [
                        {
                          "type": "ATC",
                          "color": "#0096AA",
                          "path": "Content/Tumors/Solid Tumors/*/*/Thyroid/ATC",
                          "studies": [
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Tumors/Solid Tumors/*/*/Thyroid/ATC/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "Urology",
                      "color": "#297793",
                      "path": "Content/Tumors/Solid Tumors/*/*/Urology",
                      "children": [
                        {
                          "type": "Urothelial",
                          "color": "#297793",
                          "path": "Content/Tumors/Solid Tumors/*/*/Urology/Urothelial",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Tumors/Solid Tumors/*/*/Urology/Urothelial/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "Compounds": {
      "type": "Compounds",
      "color": "#FFFFFF",
      "path": "Content/Compounds",
      "children": [
        {
          "type": "CAR-T",
          "color": "#5291dd",
          "path": "Content/Compounds/CAR-T",
          "children": [
            {
              "type": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)",
              "color": "#5291dd",
              "path": "Content/Compounds/CAR-T/Tisagenlecleucel",
              "children": [
                {
                  "type": "ALL",
                  "color": "#3B2793",
                  "path": "Content/Compounds/CAR-T/Tisagenlecleucel/ALL",
                  "children": [
                    {
                      "type": "<b>CAR-T CD19</b>",
                      "color": "#3B2793",
                      "path": "Content/Compounds/CAR-T/Tisagenlecleucel/ALL/*",
                      "children": [
                        {
                          "type": "B Cell",
                          "color": "#3B2793",
                          "path": "Content/Compounds/CAR-T/Tisagenlecleucel/ALL/*/B Cell",
                          "studies": [
                            {
                              "nct": "NCT03876769",
                              "path": "Content/Compounds/CAR-T/Tisagenlecleucel/ALL/*/B Cell/NCT03876769",
                              "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA | CTL019G2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>CAR-T CD19</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03570892",
                              "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/DLBCL/NCT03570892",
                              "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA | CTL019H2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CAR-T CD19</b> + <i>Ibrutinib</i>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Ibrutinib",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03876028",
                              "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL/NCT03876028",
                              "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients (CTL019L1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CAR-T CD19</b> + <i>Pembrolizumab</i>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Pembrolizumab",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Pembrolizumab/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03630159",
                              "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Pembrolizumab/DLBCL/NCT03630159",
                              "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA | CTL019J2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "FL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/FL",
                          "studies": [
                            {
                              "nct": "NCT03568461",
                              "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/FL/NCT03568461",
                              "title": "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA | CTL019E2202)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        },
                        {
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT03610724",
                              "path": "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/*/NCT03610724",
                              "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA | CTL019C2202)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CAR-T CD19</b> (YTB323)",
              "color": "#5291dd",
              "path": "Content/Compounds/CAR-T/YTB323",
              "children": [
                {
                  "type": "CLL",
                  "color": "#6A499C",
                  "path": "Content/Compounds/CAR-T/YTB323/CLL",
                  "children": [
                    {
                      "type": "<b>CAR-T CD19</b>",
                      "color": "#6A499C",
                      "path": "Content/Compounds/CAR-T/YTB323/CLL/*",
                      "children": [
                        {
                          "color": "#6A499C",
                          "path": "Content/Compounds/CAR-T/YTB323/CLL/*/*",
                          "studies": [
                            {
                              "nct": "NCT03960840",
                              "path": "Content/Compounds/CAR-T/YTB323/CLL/*/*/NCT03960840",
                              "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL (YTB323A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (YTB323)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>CAR-T CD19</b> + <i>Ibrutinib</i>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/Ibrutinib",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03960840",
                              "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL/NCT03960840",
                              "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL (YTB323A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (YTB323)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CAR-T CD19</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/*",
                      "children": [
                        {
                          "type": "SLL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/*/SLL",
                          "studies": [
                            {
                              "nct": "NCT03960840",
                              "path": "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/*/SLL/NCT03960840",
                              "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL (YTB323A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CAR-T CD19</b> (YTB323)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "IO",
          "color": "#0460a9",
          "path": "Content/Compounds/IO",
          "children": [
            {
              "type": "<b>A2AR</b> (NIR178<sup>19</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/NIR178",
              "children": [
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma/Spartalizumab",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/NIR178/Breast",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/NIR178/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/NIR178/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Breast/Spartalizumab/TNBC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/IO/NIR178/Colorectal",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/NIR178/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/NIR178/Colorectal/Spartalizumab/MSS",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Colorectal/Spartalizumab/MSS/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/IO/NIR178/Head and Neck",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/IO/NIR178/Head and Neck/Spartalizumab",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/IO/NIR178/Head and Neck/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Head and Neck/Spartalizumab/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/IO/NIR178/Lung",
                  "children": [
                    {
                      "type": "<b>A2AR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/NIR178/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/NIR178/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02403193",
                              "path": "Content/Compounds/IO/NIR178/Lung/*/NSCLC/NCT02403193",
                              "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) ",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/NIR178/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/NIR178/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Lung/Spartalizumab/NSCLC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            },
                            {
                              "nct": "NCT02403193",
                              "path": "Content/Compounds/IO/NIR178/Lung/Spartalizumab/NSCLC/NCT02403193",
                              "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) ",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/IO/NIR178/Melanoma",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/NIR178/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/NIR178/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Melanoma/Spartalizumab/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/IO/NIR178/Pancreatic",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/NIR178/Pancreatic/Spartalizumab",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/NIR178/Pancreatic/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Pancreatic/Spartalizumab/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/IO/NIR178/Renal",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/NIR178/Renal/Spartalizumab",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/NIR178/Renal/Spartalizumab/RCC",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Renal/Spartalizumab/RCC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/NIR178/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>CD73</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NIR178/Solid Tumors/NZV930",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NIR178/Solid Tumors/NZV930/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/NIR178/Solid Tumors/NZV930/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b> + <b>CD73</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NIR178/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NIR178/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/NIR178/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Urology",
                  "color": "#297793",
                  "path": "Content/Compounds/IO/NIR178/Urology",
                  "children": [
                    {
                      "type": "<b>A2AR</b> + <b>PD-1</b>",
                      "color": "#297793",
                      "path": "Content/Compounds/IO/NIR178/Urology/Spartalizumab",
                      "children": [
                        {
                          "type": "Urothelial",
                          "color": "#297793",
                          "path": "Content/Compounds/IO/NIR178/Urology/Spartalizumab/Urothelial",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/NIR178/Urology/Spartalizumab/Urothelial/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>A2AR</b> (NIR178<sup>19</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>BAFF-R</b> (VAY736)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/VAY736",
              "children": [
                {
                  "type": "CLL",
                  "color": "#6A499C",
                  "path": "Content/Compounds/IO/VAY736/CLL",
                  "children": [
                    {
                      "type": "<b>BAFF-R</b> + <i>Ibrutinib</i>",
                      "color": "#6A499C",
                      "path": "Content/Compounds/IO/VAY736/CLL/Ibrutinib",
                      "children": [
                        {
                          "color": "#6A499C",
                          "path": "Content/Compounds/IO/VAY736/CLL/Ibrutinib/*",
                          "studies": [
                            {
                              "nct": "NCT03400176",
                              "path": "Content/Compounds/IO/VAY736/CLL/Ibrutinib/*/NCT03400176",
                              "title": "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib (VAY736Y2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BAFF-R</b> (VAY736)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/SQZ622",
              "children": [
                {
                  "color": "#0460a9",
                  "path": "Content/Compounds/IO/SQZ622/*",
                  "children": [
                    {
                      "type": "<b>CD123 x CD3</b>",
                      "color": "#0460a9",
                      "path": "Content/Compounds/IO/SQZ622/*/*",
                      "children": [
                        {
                          "color": "#0460a9",
                          "path": "Content/Compounds/IO/SQZ622/*/*/*",
                          "studies": [
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Compounds/IO/SQZ622/*/*/*/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "ALL",
                  "color": "#3B2793",
                  "path": "Content/Compounds/IO/SQZ622/ALL",
                  "children": [
                    {
                      "type": "<b>CD123 x CD3</b>",
                      "color": "#3B2793",
                      "path": "Content/Compounds/IO/SQZ622/ALL/*",
                      "children": [
                        {
                          "type": "B Cell",
                          "color": "#3B2793",
                          "path": "Content/Compounds/IO/SQZ622/ALL/*/B Cell",
                          "studies": [
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Compounds/IO/SQZ622/ALL/*/B Cell/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "AML",
                  "color": "#4D3280",
                  "path": "Content/Compounds/IO/SQZ622/AML",
                  "children": [
                    {
                      "type": "<b>CD123 x CD3</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/SQZ622/AML/*",
                      "children": [
                        {
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/SQZ622/AML/*/*",
                          "studies": [
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Compounds/IO/SQZ622/AML/*/*/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "CML",
                  "color": "#9568AF",
                  "path": "Content/Compounds/IO/SQZ622/CML",
                  "children": [
                    {
                      "type": "<b>CD123 x CD3</b>",
                      "color": "#9568AF",
                      "path": "Content/Compounds/IO/SQZ622/CML/*",
                      "children": [
                        {
                          "color": "#9568AF",
                          "path": "Content/Compounds/IO/SQZ622/CML/*/*",
                          "studies": [
                            {
                              "nct": "NCT02730312",
                              "path": "Content/Compounds/IO/SQZ622/CML/*/*/NCT02730312",
                              "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CD73</b> (NZV930<sup>22</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/NZV930",
              "children": [
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/NZV930/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>CD73</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NZV930/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NZV930/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/NZV930/Solid Tumors/*/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD73</b> (NZV930<sup>22</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CD73</b> + <b>A2AR</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NZV930/Solid Tumors/NIR178",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NZV930/Solid Tumors/NIR178/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/NZV930/Solid Tumors/NIR178/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD73</b> (NZV930<sup>22</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CD73</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NZV930/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NZV930/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/NZV930/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CD73</b> (NZV930<sup>22</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/Lacnotuzumab",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/Lacnotuzumab/Breast",
                  "children": [
                    {
                      "type": "<b>CSF-1</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Lacnotuzumab/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Lacnotuzumab/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Lacnotuzumab/Breast/Spartalizumab/TNBC/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gynecologic",
                  "color": "#F26322",
                  "path": "Content/Compounds/IO/Lacnotuzumab/Gynecologic",
                  "children": [
                    {
                      "type": "<b>CSF-1</b> + <b>PD-1</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/IO/Lacnotuzumab/Gynecologic/Spartalizumab",
                      "children": [
                        {
                          "type": "Endometrial",
                          "color": "#F26322",
                          "path": "Content/Compounds/IO/Lacnotuzumab/Gynecologic/Spartalizumab/Endometrial",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Lacnotuzumab/Gynecologic/Spartalizumab/Endometrial/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/IO/Lacnotuzumab/Melanoma",
                  "children": [
                    {
                      "type": "<b>CSF-1</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Lacnotuzumab/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Lacnotuzumab/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Lacnotuzumab/Melanoma/Spartalizumab/*/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/IO/Lacnotuzumab/Pancreatic",
                  "children": [
                    {
                      "type": "<b>CSF-1</b> + <b>PD-1</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/Lacnotuzumab/Pancreatic/Spartalizumab",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/Lacnotuzumab/Pancreatic/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Lacnotuzumab/Pancreatic/Spartalizumab/*/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CSF-1R</b> (BLZ945)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/BLZ945",
              "children": [
                {
                  "type": "Brain",
                  "color": "#E060B0",
                  "path": "Content/Compounds/IO/BLZ945/Brain",
                  "children": [
                    {
                      "type": "<b>CSF-1R</b> + <b>PD-1</b>",
                      "color": "#E060B0",
                      "path": "Content/Compounds/IO/BLZ945/Brain/Spartalizumab",
                      "children": [
                        {
                          "type": "Gliobastoma",
                          "color": "#E060B0",
                          "path": "Content/Compounds/IO/BLZ945/Brain/Spartalizumab/Gliobastoma",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/BLZ945/Brain/Spartalizumab/Gliobastoma/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1R</b> (BLZ945)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/BLZ945/Breast",
                  "children": [
                    {
                      "type": "<b>CSF-1R</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/BLZ945/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/BLZ945/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/BLZ945/Breast/Spartalizumab/TNBC/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1R</b> (BLZ945)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/IO/BLZ945/Pancreatic",
                  "children": [
                    {
                      "type": "<b>CSF-1R</b> + <b>PD-1</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/BLZ945/Pancreatic/Spartalizumab",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/BLZ945/Pancreatic/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/BLZ945/Pancreatic/Spartalizumab/*/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1R</b> (BLZ945)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/BLZ945/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>CSF-1R</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/BLZ945/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/BLZ945/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/BLZ945/Solid Tumors/*/Advanced Solid Tumors/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1R</b> (BLZ945)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CSF-1R</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/BLZ945/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/BLZ945/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/BLZ945/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CSF-1R</b> (BLZ945)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>IL-15</b> (NIZ985<sup>21</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/NIZ985",
              "children": [
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/NIZ985/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>IL-15</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NIZ985/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NIZ985/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02452268",
                              "path": "Content/Compounds/IO/NIZ985/Solid Tumors/*/Advanced Solid Tumors/NCT02452268",
                              "title": "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NIZ985X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-15</b> (NIZ985<sup>21</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-15</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NIZ985/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NIZ985/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02452268",
                              "path": "Content/Compounds/IO/NIZ985/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02452268",
                              "title": "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NIZ985X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-15</b> (NIZ985<sup>21</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/Canakinumab",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/Canakinumab/Breast",
                  "children": [
                    {
                      "type": "<b>IL-1β</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Canakinumab/Breast/*",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Canakinumab/Breast/*/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Canakinumab/Breast/*/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Canakinumab/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Canakinumab/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Canakinumab/Breast/Spartalizumab/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/IO/Canakinumab/Colorectal",
                  "children": [
                    {
                      "type": "<b>IL-1β</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Canakinumab/Colorectal/*",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Canakinumab/Colorectal/*/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Canakinumab/Colorectal/*/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Canakinumab/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Canakinumab/Colorectal/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Canakinumab/Colorectal/Spartalizumab/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/IO/Canakinumab/Lung",
                  "children": [
                    {
                      "type": "<b>IL-1β</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Canakinumab/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03968419",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC/NCT03968419",
                              "title": "Study to Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N | ACZ885V2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            },
                            {
                              "nct": "NCT03447769",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC/NCT03447769",
                              "title": "Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A | ACZ885T2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <i>Docetaxel</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Canakinumab/Lung/Docetaxel",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Canakinumab/Lung/Docetaxel/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03626545",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/Docetaxel/NSCLC/NCT03626545",
                              "title": "Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2 | ACZ885V2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <b>PD-1</b> + <i>Pemetrexed / Cisplatin or Carboplatin</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <i>Pembrolizumab</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03968419",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC/NCT03968419",
                              "title": "Study to Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N | ACZ885V2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <i>Pembrolizumab</i> + <i>Platinum-based doublet chemotherapy</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03631199",
                              "path": "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC/NCT03631199",
                              "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1 | ACZ885U2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/IO/Canakinumab/Melanoma",
                  "children": [
                    {
                      "type": "<b>IL-1β</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Canakinumab/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Canakinumab/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/IO/Canakinumab/Melanoma/Spartalizumab/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>IL-1β</b> (Canakinumab<sup>3</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/Gevokizumab",
              "children": [
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/IO/Gevokizumab/Colorectal",
                  "children": [
                    {
                      "type": "<b>IL-1β</b> + <i>Bevacizumab</i> + <i>FOLFIRI</i>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab/*/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IL-1β</b> + <i>Bevacizumab</i> + <i>FOLFOX6</i>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab/*/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/IO/Gevokizumab/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>IL-1β</b> + <i>Paciltaxel</i> + <i>Ramucirumab</i>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/IO/Gevokizumab/Gastrointestinal/Paciltaxel",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/Gevokizumab/Gastrointestinal/Paciltaxel/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Compounds/IO/Gevokizumab/Gastrointestinal/Paciltaxel/Esophageal/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/IO/Gevokizumab/Renal",
                  "children": [
                    {
                      "type": "<b>IL-1β</b> + <i>Cabozantinib</i>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/Gevokizumab/Renal/Cabozantinib",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/Gevokizumab/Renal/Cabozantinib/RCC",
                          "studies": [
                            {
                              "nct": "NCT03798626",
                              "path": "Content/Compounds/IO/Gevokizumab/Renal/Cabozantinib/RCC/NCT03798626",
                              "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (VPM087A2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IL-1β</b> (Gevokizumab<sup>10</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>LAG-3</b> (LAG525)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/LAG525",
              "children": [
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma/Spartalizumab",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/LAG525/Breast",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <i>Carboplatin</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Carboplatin",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Carboplatin/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Compounds/IO/LAG525/Breast/Carboplatin/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b> + <b>A2AR</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b> + <i>Carboplatin</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b> + <b>CSF-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b> + <b>IL-1β</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b> + <b>MET</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/IO/LAG525/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Esophageal/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "type": "Gastric Adenocarcinoma",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Gastric Adenocarcinoma",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Gastric Adenocarcinoma/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gynecologic",
                  "color": "#F26322",
                  "path": "Content/Compounds/IO/LAG525/Gynecologic",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/IO/LAG525/Gynecologic/Spartalizumab",
                      "children": [
                        {
                          "type": "Ovarian",
                          "color": "#F26322",
                          "path": "Content/Compounds/IO/LAG525/Gynecologic/Spartalizumab/Ovarian",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Gynecologic/Spartalizumab/Ovarian/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/IO/LAG525/Lung",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "Mesothelioma",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab/Mesothelioma",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab/Mesothelioma/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab/NSCLC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        },
                        {
                          "type": "SCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab/SCLC",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Lung/Spartalizumab/SCLC/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/IO/LAG525/Melanoma",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab/*/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Neuroendocrine",
                  "color": "#7FC14C",
                  "path": "Content/Compounds/IO/LAG525/Neuroendocrine",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#7FC14C",
                      "path": "Content/Compounds/IO/LAG525/Neuroendocrine/Spartalizumab",
                      "children": [
                        {
                          "color": "#7FC14C",
                          "path": "Content/Compounds/IO/LAG525/Neuroendocrine/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Neuroendocrine/Spartalizumab/*/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Prostate",
                  "color": "#009B4F",
                  "path": "Content/Compounds/IO/LAG525/Prostate",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#009B4F",
                      "path": "Content/Compounds/IO/LAG525/Prostate/Spartalizumab",
                      "children": [
                        {
                          "color": "#009B4F",
                          "path": "Content/Compounds/IO/LAG525/Prostate/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Prostate/Spartalizumab/*/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/IO/LAG525/Renal",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/LAG525/Renal/Spartalizumab",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/LAG525/Renal/Spartalizumab/RCC",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Renal/Spartalizumab/RCC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Sarcoma",
                  "color": "#00A584",
                  "path": "Content/Compounds/IO/LAG525/Sarcoma",
                  "children": [
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#00A584",
                      "path": "Content/Compounds/IO/LAG525/Sarcoma/Spartalizumab",
                      "children": [
                        {
                          "type": "Soft Tissue Sarcoma",
                          "color": "#00A584",
                          "path": "Content/Compounds/IO/LAG525/Sarcoma/Spartalizumab/Soft Tissue Sarcoma",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/LAG525/Sarcoma/Spartalizumab/Soft Tissue Sarcoma/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/LAG525/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>LAG-3</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/LAG525/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/LAG525/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Solid Tumors/*/Advanced Solid Tumors/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>LAG-3</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/LAG525/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/LAG525/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/LAG525/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>LAG-3</b> (LAG525)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/Spartalizumab",
              "children": [
                {
                  "type": "AML",
                  "color": "#4D3280",
                  "path": "Content/Compounds/IO/Spartalizumab/AML",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <i>Decitabine</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/Spartalizumab/AML/Decitabine",
                      "children": [
                        {
                          "type": "de novo",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/Spartalizumab/AML/Decitabine/de novo",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/AML/Decitabine/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b> + <i>Decitabine</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453",
                      "children": [
                        {
                          "type": "de novo",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453/de novo",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "r/r",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/Spartalizumab/AML/Decitabine/r#r",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/AML/Decitabine/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453",
                      "children": [
                        {
                          "type": "r/r",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453/r#r",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/AML/MBG453/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "MDS High Risk",
                  "color": "#8C4198",
                  "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <i>Decitabine</i>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/Decitabine",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/Decitabine/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/Decitabine/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b> + <i>Decitabine</i>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lymphoma",
                  "color": "#890680",
                  "path": "Content/Compounds/IO/Spartalizumab/Lymphoma",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>STING</b>",
                      "color": "#890680",
                      "path": "Content/Compounds/IO/Spartalizumab/Lymphoma/MIW815",
                      "children": [
                        {
                          "color": "#890680",
                          "path": "Content/Compounds/IO/Spartalizumab/Lymphoma/MIW815/*",
                          "studies": [
                            {
                              "nct": "NCT03172936",
                              "path": "Content/Compounds/IO/Spartalizumab/Lymphoma/MIW815/*/NCT03172936",
                              "title": "Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (MIW815X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/NIR178",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/NIR178/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/NIR178/DLBCL/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/LAG525",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/LAG525/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/LAG525/DLBCL/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Brain",
                  "color": "#E060B0",
                  "path": "Content/Compounds/IO/Spartalizumab/Brain",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1R</b>",
                      "color": "#E060B0",
                      "path": "Content/Compounds/IO/Spartalizumab/Brain/BLZ945",
                      "children": [
                        {
                          "type": "Gliobastoma",
                          "color": "#E060B0",
                          "path": "Content/Compounds/IO/Spartalizumab/Brain/BLZ945/Gliobastoma",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/Spartalizumab/Brain/BLZ945/Gliobastoma/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/Spartalizumab/Breast",
                  "children": [
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/*",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/*/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/*/TNBC/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>1L-17A</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/CJM112",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/CJM112/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/CJM112/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/NIR178",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b> + <b>LAG-3</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/NIR178",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1</b> + <b>LAG-3</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1R</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/BLZ945",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/BLZ945/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/BLZ945/TNBC/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CXCR2</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/QBM076",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/QBM076/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/QBM076/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>EGFR</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Nazartinib",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Nazartinib/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Nazartinib/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Everolimus</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Everolimus",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Everolimus/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Everolimus/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IAP</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LCL161",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LCL161/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LCL161/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IKZF2</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/DKY709",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/DKY709/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/DKY709/TNBC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-1β</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-1β</b> + <b>LAG-3</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b> + <b>A2AR</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b> + <i>Carboplatin</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03499899",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03499899",
                              "title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (LAG525B2101)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b> + <b>CSF-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b> + <b>IL-1β</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b> + <b>MET</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MEK</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Trametinib",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Trametinib/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Trametinib/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MET</b> + <b>LAG-3</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Capmatinib",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Capmatinib/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03742349",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Capmatinib/TNBC/NCT03742349",
                              "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (ADPT01A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Panobinostat</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/Panobinostat",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/Panobinostat/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/Panobinostat/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/WNT974",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/WNT974/TNBC",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/WNT974/TNBC/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TGF-β</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/Spartalizumab/Breast/NIS793",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/Spartalizumab/Breast/NIS793/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/Spartalizumab/Breast/NIS793/TNBC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/IO/Spartalizumab/Colorectal",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/NIR178",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/NIR178/MSS",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/NIR178/MSS/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IKZF2</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/DKY709",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/DKY709/MSS",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/DKY709/MSS/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TGF-β</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/NIS793",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/NIS793/MSS",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/NIS793/MSS/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>1L-17A</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/CJM112",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/CJM112/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/CJM112/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CXCR2</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/QBM076",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/QBM076/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/QBM076/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>EGFR</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Nazartinib",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Nazartinib/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Nazartinib/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Everolimus</i>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Everolimus",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Everolimus/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Everolimus/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>HDM2-p53</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/HDM201",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/HDM201/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/HDM201/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IAP</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/LCL161",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/LCL161/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/LCL161/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-1β</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Canakinumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Canakinumab/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Canakinumab/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MEK</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Trametinib",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Trametinib/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Trametinib/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Panobinostat</i>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Panobinostat",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Panobinostat/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/Panobinostat/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>SHP2</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/Spartalizumab/Colorectal/TNO155",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/Spartalizumab/Colorectal/TNO155/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/IO/Spartalizumab/Colorectal/TNO155/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Esophageal/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/WNT974",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/WNT974/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/WNT974/Esophageal/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>SHP2</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/TNO155",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/TNO155/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/TNO155/Esophageal/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Gastric Adenocarcinoma",
                          "color": "#EF4930",
                          "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Gastric Adenocarcinoma",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Gastric Adenocarcinoma/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gynecologic",
                  "color": "#F26322",
                  "path": "Content/Compounds/IO/Spartalizumab/Gynecologic",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/WNT974",
                      "children": [
                        {
                          "type": "Cervical",
                          "color": "#F26322",
                          "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/WNT974/Cervical",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/WNT974/Cervical/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/Lacnotuzumab",
                      "children": [
                        {
                          "type": "Endometrial",
                          "color": "#F26322",
                          "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/Lacnotuzumab/Endometrial",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/Lacnotuzumab/Endometrial/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/LAG525",
                      "children": [
                        {
                          "type": "Ovarian",
                          "color": "#F26322",
                          "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/LAG525/Ovarian",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Gynecologic/LAG525/Ovarian/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/IO/Spartalizumab/Head and Neck",
                  "children": [
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/*",
                      "children": [
                        {
                          "type": "NPC",
                          "color": "#F89B1C",
                          "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/*/NPC",
                          "studies": [
                            {
                              "nct": "NCT02605967",
                              "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/*/NPC/NCT02605967",
                              "title": "Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PDR001X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IKZF2</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/DKY709",
                      "children": [
                        {
                          "type": "NPC",
                          "color": "#F89B1C",
                          "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/DKY709/NPC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/DKY709/NPC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/NIR178",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/NIR178/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/NIR178/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/WNT974",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/WNT974/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/WNT974/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>SHP2</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/TNO155",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/TNO155/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/IO/Spartalizumab/Head and Neck/TNO155/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Liver",
                  "color": "#F7C114",
                  "path": "Content/Compounds/IO/Spartalizumab/Liver",
                  "children": [
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#F7C114",
                      "path": "Content/Compounds/IO/Spartalizumab/Liver/*",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Compounds/IO/Spartalizumab/Liver/*/HCC",
                          "studies": [
                            {
                              "nct": "NCT02795429",
                              "path": "Content/Compounds/IO/Spartalizumab/Liver/*/HCC/NCT02795429",
                              "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC (INC280X2108)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MET</b>",
                      "color": "#F7C114",
                      "path": "Content/Compounds/IO/Spartalizumab/Liver/Capmatinib",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Compounds/IO/Spartalizumab/Liver/Capmatinib/HCC",
                          "studies": [
                            {
                              "nct": "NCT02795429",
                              "path": "Content/Compounds/IO/Spartalizumab/Liver/Capmatinib/HCC/NCT02795429",
                              "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC (INC280X2108)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Sorafenib</i>",
                      "color": "#F7C114",
                      "path": "Content/Compounds/IO/Spartalizumab/Liver/Sorafenib",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Compounds/IO/Spartalizumab/Liver/Sorafenib/HCC",
                          "studies": [
                            {
                              "nct": "NCT02988440",
                              "path": "Content/Compounds/IO/Spartalizumab/Liver/Sorafenib/HCC/NCT02988440",
                              "title": "Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients (PDR001G2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TGF-β</b>",
                      "color": "#F7C114",
                      "path": "Content/Compounds/IO/Spartalizumab/Liver/NIS793",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Compounds/IO/Spartalizumab/Liver/NIS793/HCC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/Spartalizumab/Liver/NIS793/HCC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/IO/Spartalizumab/Lung",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/LAG525",
                      "children": [
                        {
                          "type": "Mesothelioma",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/LAG525/Mesothelioma",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/LAG525/Mesothelioma/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/*/NSCLC/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>1L-17A</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/CJM112",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/CJM112/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/CJM112/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/NIR178",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/NIR178/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/NIR178/NSCLC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02403193",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/NIR178/NSCLC/NCT02403193",
                              "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) ",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CXCR2</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/QBM076",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/QBM076/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/QBM076/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>EGFR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Nazartinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Nazartinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Nazartinib/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Everolimus</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Everolimus",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Everolimus/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Everolimus/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Gemcitabine / Cisplatin</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Gemcitabine # Cisplatin",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Gemcitabine # Cisplatin/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Gemcitabine # Cisplatin/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IAP</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/LCL161",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/LCL161/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/LCL161/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IKZF2</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/DKY709",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/DKY709/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/DKY709/NSCLC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-1β</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-1β</b> + <i>Pemetrexed / Cisplatin or Carboplatin</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/LAG525/NSCLC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MEK</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Trametinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Trametinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Trametinib/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MET</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Capmatinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Capmatinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03647488",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Capmatinib/NSCLC/NCT03647488",
                              "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer (INC280D2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Paciltaxel / Carboplatin</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Paciltaxel # Carboplatin",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Paciltaxel # Carboplatin/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Paciltaxel # Carboplatin/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>pan-RAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/LXH254",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/LXH254/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/LXH254/NSCLC/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Panobinostat</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Panobinostat",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Panobinostat/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Panobinostat/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <i>Pemetrexed / Cisplatin</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/Pemetrexed # Cisplatin",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/Pemetrexed # Cisplatin/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03064854",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/Pemetrexed # Cisplatin/NSCLC/NCT03064854",
                              "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (PDR001C2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/WNT974",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/WNT974/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/WNT974/NSCLC/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>SHP2</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/TNO155",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/TNO155/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/TNO155/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/TNO155/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TGF-β</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/NIS793",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/NIS793/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/NIS793/NSCLC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/Spartalizumab/Lung/MBG453",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/MBG453/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/MBG453/NSCLC/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "SCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/Spartalizumab/Lung/LAG525/SCLC",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Lung/LAG525/SCLC/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/IO/Spartalizumab/Melanoma",
                  "children": [
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/*",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/*/*/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/NIR178",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/NIR178/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/NIR178/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>BRAF</b> + <b>MEK</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Dabrafenib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Dabrafenib/*",
                          "studies": [
                            {
                              "nct": "NCT02967692",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Dabrafenib/*/NCT02967692",
                              "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i | PDR001F2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CDK4/6</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Ribociclib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Ribociclib/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Ribociclib/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Lacnotuzumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Lacnotuzumab/*",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Lacnotuzumab/*/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IKZF2</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/DKY709",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/DKY709/*",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/DKY709/*/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-1β</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Canakinumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Canakinumab/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Canakinumab/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            },
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525/*/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MEK</b> + <b>BRAF</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Trametinib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Trametinib/*",
                          "studies": [
                            {
                              "nct": "NCT02967692",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Trametinib/*/NCT02967692",
                              "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i | PDR001F2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>MET</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Capmatinib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Capmatinib/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/Capmatinib/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>pan-RAF</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LXH254",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LXH254/*",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/LXH254/*/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/WNT974",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/WNT974/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/WNT974/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/Spartalizumab/Melanoma/MBG453",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/Spartalizumab/Melanoma/MBG453/*",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/Spartalizumab/Melanoma/MBG453/*/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Neuroendocrine",
                  "color": "#7FC14C",
                  "path": "Content/Compounds/IO/Spartalizumab/Neuroendocrine",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#7FC14C",
                      "path": "Content/Compounds/IO/Spartalizumab/Neuroendocrine/LAG525",
                      "children": [
                        {
                          "color": "#7FC14C",
                          "path": "Content/Compounds/IO/Spartalizumab/Neuroendocrine/LAG525/*",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Neuroendocrine/LAG525/*/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/IO/Spartalizumab/Pancreatic",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/NIR178",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/NIR178/*",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/NIR178/*/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/Lacnotuzumab",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/Lacnotuzumab/*",
                          "studies": [
                            {
                              "nct": "NCT02807844",
                              "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/Lacnotuzumab/*/NCT02807844",
                              "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (MCS110Z2102)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1R</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/BLZ945",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/BLZ945/*",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/BLZ945/*/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>Porcupine</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/WNT974",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/WNT974/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/WNT974/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TGF-β</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/NIS793",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/NIS793/*",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/Spartalizumab/Pancreatic/NIS793/*/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Prostate",
                  "color": "#009B4F",
                  "path": "Content/Compounds/IO/Spartalizumab/Prostate",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#009B4F",
                      "path": "Content/Compounds/IO/Spartalizumab/Prostate/LAG525",
                      "children": [
                        {
                          "color": "#009B4F",
                          "path": "Content/Compounds/IO/Spartalizumab/Prostate/LAG525/*",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Prostate/LAG525/*/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/IO/Spartalizumab/Renal",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>TGF-β</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/Spartalizumab/Renal/NIS793",
                      "children": [
                        {
                          "type": "ccRCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/Spartalizumab/Renal/NIS793/ccRCC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/Spartalizumab/Renal/NIS793/ccRCC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/Spartalizumab/Renal/NIR178",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/Spartalizumab/Renal/NIR178/RCC",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Renal/NIR178/RCC/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>HDM2-p53</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/Spartalizumab/Renal/HDM201",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/Spartalizumab/Renal/HDM201/RCC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/IO/Spartalizumab/Renal/HDM201/RCC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/Spartalizumab/Renal/LAG525",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/Spartalizumab/Renal/LAG525/RCC",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/Spartalizumab/Renal/LAG525/RCC/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/Spartalizumab/Renal/MBG453",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/Spartalizumab/Renal/MBG453/RCC",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/Spartalizumab/Renal/MBG453/RCC/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Sarcoma",
                  "color": "#00A584",
                  "path": "Content/Compounds/IO/Spartalizumab/Sarcoma",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#00A584",
                      "path": "Content/Compounds/IO/Spartalizumab/Sarcoma/LAG525",
                      "children": [
                        {
                          "type": "Soft Tissue Sarcoma",
                          "color": "#00A584",
                          "path": "Content/Compounds/IO/Spartalizumab/Sarcoma/LAG525/Soft Tissue Sarcoma",
                          "studies": [
                            {
                              "nct": "NCT03365791",
                              "path": "Content/Compounds/IO/Spartalizumab/Sarcoma/LAG525/Soft Tissue Sarcoma/NCT03365791",
                              "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (PDR001XUS01)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/*/Advanced Solid Tumors/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b> + <b>CD73</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIR178",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIR178/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIR178/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CD73</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CD73</b> + <b>A2AR</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03549000",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930/Advanced Solid Tumors/NCT03549000",
                              "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NZV930X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>CSF-1R</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/BLZ945",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/BLZ945/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02829723",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/BLZ945/Advanced Solid Tumors/NCT02829723",
                              "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (BLZ945X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>IL-15</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIZ985",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIZ985/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02452268",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIZ985/Advanced Solid Tumors/NCT02452268",
                              "title": "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NIZ985X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>LAG-3</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/LAG525",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/LAG525/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02460224",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/LAG525/Advanced Solid Tumors/NCT02460224",
                              "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (LAG525X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TIM-3</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/MBG453",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/MBG453/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/MBG453/Advanced Solid Tumors/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>TLR7</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/LHC165",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/LHC165/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03301896",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/LHC165/Advanced Solid Tumors/NCT03301896",
                              "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (LHC165X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PD-1</b> + <b>STING</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/MIW815",
                      "children": [
                        {
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/MIW815/*",
                          "studies": [
                            {
                              "nct": "NCT03172936",
                              "path": "Content/Compounds/IO/Spartalizumab/Solid Tumors/MIW815/*/NCT03172936",
                              "title": "Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (MIW815X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Thyroid",
                  "color": "#0096AA",
                  "path": "Content/Compounds/IO/Spartalizumab/Thyroid",
                  "children": [
                    {
                      "type": "<b>PD-1</b>",
                      "color": "#0096AA",
                      "path": "Content/Compounds/IO/Spartalizumab/Thyroid/*",
                      "children": [
                        {
                          "type": "ATC",
                          "color": "#0096AA",
                          "path": "Content/Compounds/IO/Spartalizumab/Thyroid/*/ATC",
                          "studies": [
                            {
                              "nct": "NCT02404441",
                              "path": "Content/Compounds/IO/Spartalizumab/Thyroid/*/ATC/NCT02404441",
                              "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies (PDR001X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Urology",
                  "color": "#297793",
                  "path": "Content/Compounds/IO/Spartalizumab/Urology",
                  "children": [
                    {
                      "type": "<b>PD-1</b> + <b>A2AR</b>",
                      "color": "#297793",
                      "path": "Content/Compounds/IO/Spartalizumab/Urology/NIR178",
                      "children": [
                        {
                          "type": "Urothelial",
                          "color": "#297793",
                          "path": "Content/Compounds/IO/Spartalizumab/Urology/NIR178/Urothelial",
                          "studies": [
                            {
                              "nct": "NCT03207867",
                              "path": "Content/Compounds/IO/Spartalizumab/Urology/NIR178/Urothelial/NCT03207867",
                              "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NIR178X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PD-1</b> (Spartalizumab<sup>25</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>STING</b> (MIW815<sup>16</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/MIW815",
              "children": [
                {
                  "type": "Lymphoma",
                  "color": "#890680",
                  "path": "Content/Compounds/IO/MIW815/Lymphoma",
                  "children": [
                    {
                      "type": "<b>STING</b>",
                      "color": "#890680",
                      "path": "Content/Compounds/IO/MIW815/Lymphoma/*",
                      "children": [
                        {
                          "color": "#890680",
                          "path": "Content/Compounds/IO/MIW815/Lymphoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT02675439",
                              "path": "Content/Compounds/IO/MIW815/Lymphoma/*/*/NCT02675439",
                              "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>STING</b> + <b>PD-1</b>",
                      "color": "#890680",
                      "path": "Content/Compounds/IO/MIW815/Lymphoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#890680",
                          "path": "Content/Compounds/IO/MIW815/Lymphoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03172936",
                              "path": "Content/Compounds/IO/MIW815/Lymphoma/Spartalizumab/*/NCT03172936",
                              "title": "Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (MIW815X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/MIW815/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>STING</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/MIW815/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/MIW815/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02675439",
                              "path": "Content/Compounds/IO/MIW815/Solid Tumors/*/Advanced Solid Tumors/NCT02675439",
                              "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>STING</b> + <i>Ipilimumab</i>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/MIW815/Solid Tumors/Ipilimumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/MIW815/Solid Tumors/Ipilimumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02675439",
                              "path": "Content/Compounds/IO/MIW815/Solid Tumors/Ipilimumab/Advanced Solid Tumors/NCT02675439",
                              "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>STING</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/MIW815/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/MIW815/Solid Tumors/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03172936",
                              "path": "Content/Compounds/IO/MIW815/Solid Tumors/Spartalizumab/*/NCT03172936",
                              "title": "Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (MIW815X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>STING</b> (MIW815<sup>16</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>TGF-β</b> (NIS793<sup>20</sup>)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/NIS793",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/IO/NIS793/Breast",
                  "children": [
                    {
                      "type": "<b>TGF-β</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/IO/NIS793/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/IO/NIS793/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Breast/Spartalizumab/TNBC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/IO/NIS793/Colorectal",
                  "children": [
                    {
                      "type": "<b>TGF-β</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/IO/NIS793/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/IO/NIS793/Colorectal/Spartalizumab/MSS",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Colorectal/Spartalizumab/MSS/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Liver",
                  "color": "#F7C114",
                  "path": "Content/Compounds/IO/NIS793/Liver",
                  "children": [
                    {
                      "type": "<b>TGF-β</b> + <b>PD-1</b>",
                      "color": "#F7C114",
                      "path": "Content/Compounds/IO/NIS793/Liver/Spartalizumab",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Compounds/IO/NIS793/Liver/Spartalizumab/HCC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Liver/Spartalizumab/HCC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/IO/NIS793/Lung",
                  "children": [
                    {
                      "type": "<b>TGF-β</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/NIS793/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/NIS793/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Lung/Spartalizumab/NSCLC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/IO/NIS793/Pancreatic",
                  "children": [
                    {
                      "type": "<b>TGF-β</b> + <b>PD-1</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/IO/NIS793/Pancreatic/Spartalizumab",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/IO/NIS793/Pancreatic/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Pancreatic/Spartalizumab/*/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/IO/NIS793/Renal",
                  "children": [
                    {
                      "type": "<b>TGF-β</b> + <b>PD-1</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/NIS793/Renal/Spartalizumab",
                      "children": [
                        {
                          "type": "ccRCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/NIS793/Renal/Spartalizumab/ccRCC",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Renal/Spartalizumab/ccRCC/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/NIS793/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>TGF-β</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/NIS793/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/NIS793/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02947165",
                              "path": "Content/Compounds/IO/NIS793/Solid Tumors/*/Advanced Solid Tumors/NCT02947165",
                              "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NIS793X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TGF-β</b> (NIS793<sup>20</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>TIM-3</b> (MBG453)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/MBG453",
              "children": [
                {
                  "type": "AML",
                  "color": "#4D3280",
                  "path": "Content/Compounds/IO/MBG453/AML",
                  "children": [
                    {
                      "type": "<b>TIM-3</b> + <i>Decitabine</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/MBG453/AML/Decitabine",
                      "children": [
                        {
                          "type": "de novo",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/MBG453/AML/Decitabine/de novo",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/AML/Decitabine/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b> + <i>Decitabine</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab",
                      "children": [
                        {
                          "type": "de novo",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab/de novo",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab/de novo/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/MBG453/AML/*",
                      "children": [
                        {
                          "type": "r/r",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/MBG453/AML/*/r#r",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/AML/*/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/AML/Decitabine/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab",
                      "children": [
                        {
                          "type": "r/r",
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab/r#r",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            },
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/AML/Spartalizumab/r#r/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>HDM2-p53</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/IO/MBG453/AML/HDM201",
                      "children": [
                        {
                          "color": "#4D3280",
                          "path": "Content/Compounds/IO/MBG453/AML/HDM201/*",
                          "studies": [
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Compounds/IO/MBG453/AML/HDM201/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "MDS High Risk",
                  "color": "#8C4198",
                  "path": "Content/Compounds/IO/MBG453/MDS High Risk",
                  "children": [
                    {
                      "type": "<b>TIM-3</b>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/MBG453/MDS High Risk/*",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/MBG453/MDS High Risk/*/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/MDS High Risk/*/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <i>Decitabine</i>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <i>Decitabine / Azacitidine</i>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine # Azacitidine",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine # Azacitidine/*",
                          "studies": [
                            {
                              "nct": "NCT03946670",
                              "path": "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine # Azacitidine/*/NCT03946670",
                              "title": "A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1 | MBG453B1220)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>HDM2-p53</b>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/MBG453/MDS High Risk/HDM201",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/MBG453/MDS High Risk/HDM201/*",
                          "studies": [
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Compounds/IO/MBG453/MDS High Risk/HDM201/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b> + <i>Decitabine</i>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03066648",
                              "path": "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab/*/NCT03066648",
                              "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (PDR001X2105)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "MF",
                  "color": "#0460a9",
                  "path": "Content/Compounds/IO/MBG453/MF",
                  "children": [
                    {
                      "type": "<b>TIM-3</b> + <i>Ruxolitinib</i>",
                      "color": "#0460a9",
                      "path": "Content/Compounds/IO/MBG453/MF/Ruxolitinib",
                      "children": [
                        {
                          "color": "#0460a9",
                          "path": "Content/Compounds/IO/MBG453/MF/Ruxolitinib/*",
                          "studies": [
                            {
                              "nct": "NCT04097821",
                              "path": "Content/Compounds/IO/MBG453/MF/Ruxolitinib/*/NCT04097821",
                              "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE | INC424H1220)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/IO/MBG453/Lung",
                  "children": [
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/IO/MBG453/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/IO/MBG453/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/MBG453/Lung/Spartalizumab/NSCLC/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/IO/MBG453/Melanoma",
                  "children": [
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/IO/MBG453/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/IO/MBG453/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/MBG453/Melanoma/Spartalizumab/*/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/IO/MBG453/Renal",
                  "children": [
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/IO/MBG453/Renal/Spartalizumab",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/IO/MBG453/Renal/Spartalizumab/RCC",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/MBG453/Renal/Spartalizumab/RCC/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/MBG453/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>TIM-3</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/MBG453/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/MBG453/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/MBG453/Solid Tumors/*/Advanced Solid Tumors/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TIM-3</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/MBG453/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/MBG453/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02608268",
                              "path": "Content/Compounds/IO/MBG453/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02608268",
                              "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (MBG453X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>TIM-3</b> (MBG453)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>TLR7</b> (LHC165)",
              "color": "#0460a9",
              "path": "Content/Compounds/IO/LHC165",
              "children": [
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/IO/LHC165/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>TLR7</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/LHC165/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/LHC165/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03301896",
                              "path": "Content/Compounds/IO/LHC165/Solid Tumors/*/Advanced Solid Tumors/NCT03301896",
                              "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (LHC165X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TLR7</b> (LHC165)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>TLR7</b> + <b>PD-1</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/IO/LHC165/Solid Tumors/Spartalizumab",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/IO/LHC165/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT03301896",
                              "path": "Content/Compounds/IO/LHC165/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT03301896",
                              "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (LHC165X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>TLR7</b> (LHC165)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "Targeted",
          "color": "#023761",
          "path": "Content/Compounds/Targeted",
          "children": [
            {
              "type": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Asciminib",
              "children": [
                {
                  "type": "ALL",
                  "color": "#3B2793",
                  "path": "Content/Compounds/Targeted/Asciminib/ALL",
                  "children": [
                    {
                      "type": "<b>BCR-ABL</b>",
                      "color": "#3B2793",
                      "path": "Content/Compounds/Targeted/Asciminib/ALL/*",
                      "children": [
                        {
                          "type": "Ph+",
                          "color": "#3B2793",
                          "path": "Content/Compounds/Targeted/Asciminib/ALL/*/Ph+",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Compounds/Targeted/Asciminib/ALL/*/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "CML",
                  "color": "#9568AF",
                  "path": "Content/Compounds/Targeted/Asciminib/CML",
                  "children": [
                    {
                      "type": "<b>BCR-ABL</b> + <i>Dasatinib</i>",
                      "color": "#9568AF",
                      "path": "Content/Compounds/Targeted/Asciminib/CML/Dasatinib",
                      "children": [
                        {
                          "type": "Ph+",
                          "color": "#9568AF",
                          "path": "Content/Compounds/Targeted/Asciminib/CML/Dasatinib/Ph+",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Compounds/Targeted/Asciminib/CML/Dasatinib/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>BCR-ABL</b> + <i>Imatinib</i>",
                      "color": "#9568AF",
                      "path": "Content/Compounds/Targeted/Asciminib/CML/Imatinib",
                      "children": [
                        {
                          "type": "Ph+",
                          "color": "#9568AF",
                          "path": "Content/Compounds/Targeted/Asciminib/CML/Imatinib/Ph+",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Compounds/Targeted/Asciminib/CML/Imatinib/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            },
                            {
                              "nct": "NCT03578367",
                              "path": "Content/Compounds/Targeted/Asciminib/CML/Imatinib/Ph+/NCT03578367",
                              "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (ABL001E2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>BCR-ABL</b> + <i>Nilotinib</i>",
                      "color": "#9568AF",
                      "path": "Content/Compounds/Targeted/Asciminib/CML/Nilotinib",
                      "children": [
                        {
                          "type": "Ph+",
                          "color": "#9568AF",
                          "path": "Content/Compounds/Targeted/Asciminib/CML/Nilotinib/Ph+",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Compounds/Targeted/Asciminib/CML/Nilotinib/Ph+/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>BCR-ABL</b>",
                      "color": "#9568AF",
                      "path": "Content/Compounds/Targeted/Asciminib/CML/*",
                      "children": [
                        {
                          "color": "#9568AF",
                          "path": "Content/Compounds/Targeted/Asciminib/CML/*/*",
                          "studies": [
                            {
                              "nct": "NCT02081378",
                              "path": "Content/Compounds/Targeted/Asciminib/CML/*/*/NCT02081378",
                              "title": "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL (ABL001X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            },
                            {
                              "nct": "NCT03106779",
                              "path": "Content/Compounds/Targeted/Asciminib/CML/*/*/NCT03106779",
                              "title": "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (ABL001A2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Dabrafenib",
              "children": [
                {
                  "type": "Brain",
                  "color": "#E060B0",
                  "path": "Content/Compounds/Targeted/Dabrafenib/Brain",
                  "children": [
                    {
                      "type": "<b>BRAF</b> + <b>MEK</b>",
                      "color": "#E060B0",
                      "path": "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib",
                      "children": [
                        {
                          "type": "Glioma (high and low risk)",
                          "color": "#E060B0",
                          "path": "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Glioma (high and low risk)",
                          "studies": [
                            {
                              "nct": "NCT02684058",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Glioma (high and low risk)/NCT02684058",
                              "title": "Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG (DRB436G2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Neurofibroma",
                          "color": "#E060B0",
                          "path": "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Neurofibroma",
                          "studies": [
                            {
                              "nct": "NCT02124772",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Neurofibroma/NCT02124772",
                              "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/Dabrafenib/Lung",
                  "children": [
                    {
                      "type": "<b>BRAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Dabrafenib/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Dabrafenib/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT01336634",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Lung/*/NSCLC/NCT01336634",
                              "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>BRAF</b> + <b>MEK</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Dabrafenib/Lung/Trametinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Dabrafenib/Lung/Trametinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT01336634",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Lung/Trametinib/NSCLC/NCT01336634",
                              "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma",
                  "children": [
                    {
                      "type": "<b>BRAF</b> + <b>MEK</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib/*",
                          "studies": [
                            {
                              "nct": "NCT02083354",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib/*/NCT02083354",
                              "title": "Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            },
                            {
                              "nct": "NCT03551626",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib/*/NCT03551626",
                              "title": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus | DRB436F2410)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>BRAF</b> + <b>PD-1</b> + <b>MEK</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02967692",
                              "path": "Content/Compounds/Targeted/Dabrafenib/Melanoma/Spartalizumab/*/NCT02967692",
                              "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i | PDR001F2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>BRAF</b> (Dabrafenib<sup>7</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Ribociclib",
              "children": [
                {
                  "type": "MF",
                  "color": "#5EAFFF",
                  "path": "Content/Compounds/Targeted/Ribociclib/MF",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>pan-PIM</b> + <i>Ruxolitinib</i>",
                      "color": "#5EAFFF",
                      "path": "Content/Compounds/Targeted/Ribociclib/MF/PIM447",
                      "children": [
                        {
                          "color": "#5EAFFF",
                          "path": "Content/Compounds/Targeted/Ribociclib/MF/PIM447/*",
                          "studies": [
                            {
                              "nct": "NCT02370706",
                              "path": "Content/Compounds/Targeted/Ribociclib/MF/PIM447/*/NCT02370706",
                              "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (PIM447X2104)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Ruxolitinib</i>",
                      "color": "#5EAFFF",
                      "path": "Content/Compounds/Targeted/Ribociclib/MF/Ruxolitinib",
                      "children": [
                        {
                          "color": "#5EAFFF",
                          "path": "Content/Compounds/Targeted/Ribociclib/MF/Ruxolitinib/*",
                          "studies": [
                            {
                              "nct": "NCT02370706",
                              "path": "Content/Compounds/Targeted/Ribociclib/MF/Ruxolitinib/*/NCT02370706",
                              "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (PIM447X2104)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/Ribociclib/Breast",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <i>Endocrine therapy</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Endocrine therapy",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Endocrine therapy/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT03701334",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Endocrine therapy/HR+#HER2-/NCT03701334",
                              "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE | LEE011O1230)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Everolimus</i> + <i>Exemestane</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Everolimus",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Everolimus/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT01857193",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Everolimus/HR+#HER2-/NCT01857193",
                              "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (LEE011X2106)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Exemestane</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Exemestane",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Exemestane/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT01857193",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Exemestane/HR+#HER2-/NCT01857193",
                              "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (LEE011X2106)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Fulvestrant</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Fulvestrant",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Fulvestrant/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02333370",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Fulvestrant/HR+#HER2-/NCT02333370",
                              "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (LEE011A2115)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Letrozole</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02333370",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole/HR+#HER2-/NCT02333370",
                              "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (LEE011A2115)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            },
                            {
                              "nct": "NCT03671330",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole/HR+#HER2-/NCT03671330",
                              "title": "Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (LEE011A2206)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Letrozole or Anastrazole</i> + <i>Goserlin</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT03671330",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-/NCT03671330",
                              "title": "Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (LEE011A2206)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            },
                            {
                              "nct": "NCT03822468",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-/NCT03822468",
                              "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR | LEE011A2207)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            },
                            {
                              "nct": "NCT03822468",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-/NCT03822468",
                              "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR | LEE011A2207)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <b>SERD</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/LSZ102",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/LSZ102/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/LSZ102/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <i>Tamoxifen</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Breast/Tamoxifen",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Breast/Tamoxifen/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02333370",
                              "path": "Content/Compounds/Targeted/Ribociclib/Breast/Tamoxifen/HR+#HER2-/NCT02333370",
                              "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (LEE011A2115)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/Ribociclib/Colorectal",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>MEK</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/Ribociclib/Colorectal/Trametinib",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/Ribociclib/Colorectal/Trametinib/*",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Compounds/Targeted/Ribociclib/Colorectal/Trametinib/*/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <b>SHP2</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/Ribociclib/Colorectal/TNO155",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/Ribociclib/Colorectal/TNO155/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/Ribociclib/Colorectal/TNO155/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/Targeted/Ribociclib/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>SHP2</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/Esophageal/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "GIST",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/GIST",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/GIST/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/Targeted/Ribociclib/Head and Neck",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>SHP2</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Head and Neck/TNO155",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Head and Neck/TNO155/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/Ribociclib/Head and Neck/TNO155/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/Ribociclib/Lung",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>EGFR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Lung/Nazartinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Lung/Nazartinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Ribociclib/Lung/Nazartinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <b>SHP2</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Ribociclib/Lung/TNO155",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Ribociclib/Lung/TNO155/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/Ribociclib/Lung/TNO155/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/Ribociclib/Melanoma",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>pan-RAF</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Ribociclib/Melanoma/LXH254",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Ribociclib/Melanoma/LXH254/*",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/Ribociclib/Melanoma/LXH254/*/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>CDK4/6</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Ribociclib/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Ribociclib/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/Targeted/Ribociclib/Melanoma/Spartalizumab/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/Targeted/Ribociclib/Pancreatic",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>MEK</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/Targeted/Ribociclib/Pancreatic/Trametinib",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/Targeted/Ribociclib/Pancreatic/Trametinib/*",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Compounds/Targeted/Ribociclib/Pancreatic/Trametinib/*/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/Ribociclib/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>CDK4/6</b> + <b>MEK</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/Ribociclib/Solid Tumors/Trametinib",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/Ribociclib/Solid Tumors/Trametinib/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Compounds/Targeted/Ribociclib/Solid Tumors/Trametinib/Advanced Solid Tumors/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>CXCR2</b> (QBM076)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/QBM076",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/QBM076/Breast",
                  "children": [
                    {
                      "type": "<b>CXCR2</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/QBM076/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/QBM076/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/Targeted/QBM076/Breast/Spartalizumab/TNBC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CXCR2</b> (QBM076)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/QBM076/Colorectal",
                  "children": [
                    {
                      "type": "<b>CXCR2</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/QBM076/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/QBM076/Colorectal/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/Targeted/QBM076/Colorectal/Spartalizumab/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CXCR2</b> (QBM076)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/QBM076/Lung",
                  "children": [
                    {
                      "type": "<b>CXCR2</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/QBM076/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/QBM076/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/Targeted/QBM076/Lung/Spartalizumab/NSCLC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>CXCR2</b> (QBM076)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>EED</b> (MAK683)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/MAK683",
              "children": [
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>EED</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma/*",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma/*/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma/*/DLBCL/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/Targeted/MAK683/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>EED</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/Targeted/MAK683/Gastrointestinal/*",
                      "children": [
                        {
                          "type": "Gastric",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/MAK683/Gastrointestinal/*/Gastric",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Compounds/Targeted/MAK683/Gastrointestinal/*/Gastric/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gynecologic",
                  "color": "#F26322",
                  "path": "Content/Compounds/Targeted/MAK683/Gynecologic",
                  "children": [
                    {
                      "type": "<b>EED</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/Targeted/MAK683/Gynecologic/*",
                      "children": [
                        {
                          "type": "Ovarian",
                          "color": "#F26322",
                          "path": "Content/Compounds/Targeted/MAK683/Gynecologic/*/Ovarian",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Compounds/Targeted/MAK683/Gynecologic/*/Ovarian/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/Targeted/MAK683/Head and Neck",
                  "children": [
                    {
                      "type": "<b>EED</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/MAK683/Head and Neck/*",
                      "children": [
                        {
                          "type": "NPC",
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/MAK683/Head and Neck/*/NPC",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Compounds/Targeted/MAK683/Head and Neck/*/NPC/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Prostate",
                  "color": "#009B4F",
                  "path": "Content/Compounds/Targeted/MAK683/Prostate",
                  "children": [
                    {
                      "type": "<b>EED</b>",
                      "color": "#009B4F",
                      "path": "Content/Compounds/Targeted/MAK683/Prostate/*",
                      "children": [
                        {
                          "color": "#009B4F",
                          "path": "Content/Compounds/Targeted/MAK683/Prostate/*/*",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Compounds/Targeted/MAK683/Prostate/*/*/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Sarcoma",
                  "color": "#00A584",
                  "path": "Content/Compounds/Targeted/MAK683/Sarcoma",
                  "children": [
                    {
                      "type": "<b>EED</b>",
                      "color": "#00A584",
                      "path": "Content/Compounds/Targeted/MAK683/Sarcoma/*",
                      "children": [
                        {
                          "color": "#00A584",
                          "path": "Content/Compounds/Targeted/MAK683/Sarcoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT02900651",
                              "path": "Content/Compounds/Targeted/MAK683/Sarcoma/*/*/NCT02900651",
                              "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (MAK683X2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EED</b> (MAK683)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>EGFR</b> (Nazartinib<sup>17</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Nazartinib",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/Nazartinib/Breast",
                  "children": [
                    {
                      "type": "<b>EGFR</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/Targeted/Nazartinib/Breast/Spartalizumab/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/Nazartinib/Colorectal",
                  "children": [
                    {
                      "type": "<b>EGFR</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/Nazartinib/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/Nazartinib/Colorectal/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/Targeted/Nazartinib/Colorectal/Spartalizumab/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/Nazartinib/Lung",
                  "children": [
                    {
                      "type": "<b>EGFR</b> + <b>CDK4/6</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/Ribociclib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/Ribociclib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Ribociclib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>EGFR</b> + <i>Gefitinib</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/Gefitinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/Gefitinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Gefitinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>EGFR</b> + <b>MEK</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/Trametinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/Trametinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Trametinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>EGFR</b> + <b>MET</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            },
                            {
                              "nct": "NCT02335944",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib/NSCLC/NCT02335944",
                              "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. (INC280X2105)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>EGFR</b> + <i>Nivolumab</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/Nivolumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/Nivolumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02323126",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Nivolumab/NSCLC/NCT02323126",
                              "title": "Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer (EGF816 | EGF816X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>EGFR</b> + <b>pan-RAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/LXH254",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/LXH254/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/LXH254/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>EGFR</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Nazartinib/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Nazartinib/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/Targeted/Nazartinib/Lung/Spartalizumab/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>EGFR</b> (Nazartinib<sup>17</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>ERK</b> (LTT462)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/LTT462",
              "children": [
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/LTT462/Lung",
                  "children": [
                    {
                      "type": "<b>ERK</b> + <b>pan-RAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/LTT462/Lung/LXH254",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/LTT462/Lung/LXH254/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/LTT462/Lung/LXH254/NSCLC/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>ERK</b> (LTT462)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>HDM2-p53</b> (HDM201)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/HDM201",
              "children": [
                {
                  "type": "ALL",
                  "color": "#3B2793",
                  "path": "Content/Compounds/Targeted/HDM201/ALL",
                  "children": [
                    {
                      "type": "<b>HDM2-p53</b>",
                      "color": "#3B2793",
                      "path": "Content/Compounds/Targeted/HDM201/ALL/*",
                      "children": [
                        {
                          "color": "#3B2793",
                          "path": "Content/Compounds/Targeted/HDM201/ALL/*/*",
                          "studies": [
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Compounds/Targeted/HDM201/ALL/*/*/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "AML",
                  "color": "#4D3280",
                  "path": "Content/Compounds/Targeted/HDM201/AML",
                  "children": [
                    {
                      "type": "<b>HDM2-p53</b> + <i>Cytarabine / Anthracycline</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline",
                      "children": [
                        {
                          "type": "FLT3m-",
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/FLT3m-",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/FLT3m-/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <b>Multikinase</b> + <i>Cytarabine / Anthracycline</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/Midostaurin",
                      "children": [
                        {
                          "type": "FLT3m+",
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/Midostaurin/FLT3m+",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Compounds/Targeted/HDM201/AML/Midostaurin/FLT3m+/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <i>Cytarabine</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine",
                      "children": [
                        {
                          "type": "r/r",
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine/r#r",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine/r#r/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/*",
                      "children": [
                        {
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/*/*",
                          "studies": [
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Compounds/Targeted/HDM201/AML/*/*/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            },
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/*/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <i>Cytarabine / Daunorubicin</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Daunorubicin",
                      "children": [
                        {
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Daunorubicin/*",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Daunorubicin/*/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <b>TIM-3</b>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/MBG453",
                      "children": [
                        {
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/MBG453/*",
                          "studies": [
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Compounds/Targeted/HDM201/AML/MBG453/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <i>Venetoclax</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/HDM201/AML/Venetoclax",
                      "children": [
                        {
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/HDM201/AML/Venetoclax/*",
                          "studies": [
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Compounds/Targeted/HDM201/AML/Venetoclax/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "MDS High Risk",
                  "color": "#8C4198",
                  "path": "Content/Compounds/Targeted/HDM201/MDS High Risk",
                  "children": [
                    {
                      "type": "<b>HDM2-p53</b>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/*",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/*/*",
                          "studies": [
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/*/*/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <b>TIM-3</b>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/MBG453",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/MBG453/*",
                          "studies": [
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/MBG453/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>HDM2-p53</b> + <i>Venetoclax</i>",
                      "color": "#8C4198",
                      "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/Venetoclax",
                      "children": [
                        {
                          "color": "#8C4198",
                          "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/Venetoclax/*",
                          "studies": [
                            {
                              "nct": "NCT03940352",
                              "path": "Content/Compounds/Targeted/HDM201/MDS High Risk/Venetoclax/*/NCT03940352",
                              "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (HDM201H1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/HDM201/Colorectal",
                  "children": [
                    {
                      "type": "<b>HDM2-p53</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/HDM201/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/HDM201/Colorectal/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/Targeted/HDM201/Colorectal/Spartalizumab/*/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Renal",
                  "color": "#008A6F",
                  "path": "Content/Compounds/Targeted/HDM201/Renal",
                  "children": [
                    {
                      "type": "<b>HDM2-p53</b> + <b>PD-1</b>",
                      "color": "#008A6F",
                      "path": "Content/Compounds/Targeted/HDM201/Renal/Spartalizumab",
                      "children": [
                        {
                          "type": "RCC",
                          "color": "#008A6F",
                          "path": "Content/Compounds/Targeted/HDM201/Renal/Spartalizumab/RCC",
                          "studies": [
                            {
                              "nct": "NCT02890069",
                              "path": "Content/Compounds/Targeted/HDM201/Renal/Spartalizumab/RCC/NCT02890069",
                              "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (PDR001X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/HDM201/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>HDM2-p53</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/HDM201/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/HDM201/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02143635",
                              "path": "Content/Compounds/Targeted/HDM201/Solid Tumors/*/Advanced Solid Tumors/NCT02143635",
                              "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (HDM201X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HDM2-p53</b> (HDM201)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>HER2-TLR7</b> (NJH395)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/NJH395",
              "children": [
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/NJH395/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>HER2-TLR7</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/NJH395/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Non-Breast HER2+",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/NJH395/Solid Tumors/*/Non-Breast HER2+",
                          "studies": [
                            {
                              "nct": "NCT03696771",
                              "path": "Content/Compounds/Targeted/NJH395/Solid Tumors/*/Non-Breast HER2+/NCT03696771",
                              "title": "Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer (NJH395X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>HER2-TLR7</b> (NJH395)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>IKZF2</b> (DKY709)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/DKY709",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/DKY709/Breast",
                  "children": [
                    {
                      "type": "<b>IKZF2</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/DKY709/Breast/*",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/DKY709/Breast/*/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Breast/*/TNBC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IKZF2</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/DKY709/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/DKY709/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Breast/Spartalizumab/TNBC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/DKY709/Colorectal",
                  "children": [
                    {
                      "type": "<b>IKZF2</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/DKY709/Colorectal/*",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/DKY709/Colorectal/*/MSS",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Colorectal/*/MSS/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IKZF2</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/DKY709/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "type": "MSS",
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/DKY709/Colorectal/Spartalizumab/MSS",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Colorectal/Spartalizumab/MSS/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/Targeted/DKY709/Head and Neck",
                  "children": [
                    {
                      "type": "<b>IKZF2</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/DKY709/Head and Neck/*",
                      "children": [
                        {
                          "type": "NPC",
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/DKY709/Head and Neck/*/NPC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Head and Neck/*/NPC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IKZF2</b> + <b>PD-1</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/DKY709/Head and Neck/Spartalizumab",
                      "children": [
                        {
                          "type": "NPC",
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/DKY709/Head and Neck/Spartalizumab/NPC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Head and Neck/Spartalizumab/NPC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/DKY709/Lung",
                  "children": [
                    {
                      "type": "<b>IKZF2</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/DKY709/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/DKY709/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Lung/*/NSCLC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IKZF2</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/DKY709/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/DKY709/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Lung/Spartalizumab/NSCLC/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/DKY709/Melanoma",
                  "children": [
                    {
                      "type": "<b>IKZF2</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/DKY709/Melanoma/*",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/DKY709/Melanoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Melanoma/*/*/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>IKZF2</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/DKY709/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/DKY709/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03891953",
                              "path": "Content/Compounds/Targeted/DKY709/Melanoma/Spartalizumab/*/NCT03891953",
                              "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (DKY709A1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>IKZF2</b> (DKY709)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>MCL1</b> (MIK665<sup>15</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/MIK665",
              "children": [
                {
                  "type": "Lymphoma",
                  "color": "#890680",
                  "path": "Content/Compounds/Targeted/MIK665/Lymphoma",
                  "children": [
                    {
                      "type": "<b>MCL1</b>",
                      "color": "#890680",
                      "path": "Content/Compounds/Targeted/MIK665/Lymphoma/*",
                      "children": [
                        {
                          "color": "#890680",
                          "path": "Content/Compounds/Targeted/MIK665/Lymphoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT02992483",
                              "path": "Content/Compounds/Targeted/MIK665/Lymphoma/*/*/NCT02992483",
                              "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (MIK665X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MCL1</b> (MIK665<sup>15</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Non-Hodgkin Lymphoma",
                  "color": "#A4006A",
                  "path": "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma",
                  "children": [
                    {
                      "type": "<b>MCL1</b>",
                      "color": "#A4006A",
                      "path": "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma/*",
                      "children": [
                        {
                          "type": "DLBCL",
                          "color": "#A4006A",
                          "path": "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma/*/DLBCL",
                          "studies": [
                            {
                              "nct": "NCT02992483",
                              "path": "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma/*/DLBCL/NCT02992483",
                              "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (MIK665X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MCL1</b> (MIK665<sup>15</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Multiple Myeloma",
                  "color": "#BD1E86",
                  "path": "Content/Compounds/Targeted/MIK665/Multiple Myeloma",
                  "children": [
                    {
                      "type": "<b>MCL1</b>",
                      "color": "#BD1E86",
                      "path": "Content/Compounds/Targeted/MIK665/Multiple Myeloma/*",
                      "children": [
                        {
                          "color": "#BD1E86",
                          "path": "Content/Compounds/Targeted/MIK665/Multiple Myeloma/*/*",
                          "studies": [
                            {
                              "nct": "NCT02992483",
                              "path": "Content/Compounds/Targeted/MIK665/Multiple Myeloma/*/*/NCT02992483",
                              "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (MIK665X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MCL1</b> (MIK665<sup>15</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>MEK</b> (Trametinib<sup>28</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Trametinib",
              "children": [
                {
                  "type": "Brain",
                  "color": "#E060B0",
                  "path": "Content/Compounds/Targeted/Trametinib/Brain",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>BRAF</b>",
                      "color": "#E060B0",
                      "path": "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib",
                      "children": [
                        {
                          "type": "Glioma (high and low risk)",
                          "color": "#E060B0",
                          "path": "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Glioma (high and low risk)",
                          "studies": [
                            {
                              "nct": "NCT02684058",
                              "path": "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Glioma (high and low risk)/NCT02684058",
                              "title": "Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG (DRB436G2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        },
                        {
                          "type": "Neurofibroma",
                          "color": "#E060B0",
                          "path": "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Neurofibroma",
                          "studies": [
                            {
                              "nct": "NCT02124772",
                              "path": "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Neurofibroma/NCT02124772",
                              "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations ",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/Trametinib/Breast",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Trametinib/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Trametinib/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/Targeted/Trametinib/Breast/Spartalizumab/TNBC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/Trametinib/Colorectal",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>CDK4/6</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/Trametinib/Colorectal/Ribociclib",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/Trametinib/Colorectal/Ribociclib/*",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Compounds/Targeted/Trametinib/Colorectal/Ribociclib/*/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MEK</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/Trametinib/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/Trametinib/Colorectal/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/Targeted/Trametinib/Colorectal/Spartalizumab/*/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/Trametinib/Lung",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>BRAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Trametinib/Lung/Dabrafenib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Trametinib/Lung/Dabrafenib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT01336634",
                              "path": "Content/Compounds/Targeted/Trametinib/Lung/Dabrafenib/NSCLC/NCT01336634",
                              "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MEK</b> + <b>EGFR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Trametinib/Lung/Nazartinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Trametinib/Lung/Nazartinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Trametinib/Lung/Nazartinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MEK</b> + <b>pan-RAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Trametinib/Lung/LXH254",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Trametinib/Lung/LXH254/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/Trametinib/Lung/LXH254/NSCLC/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MEK</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Trametinib/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Trametinib/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02900664",
                              "path": "Content/Compounds/Targeted/Trametinib/Lung/Spartalizumab/NSCLC/NCT02900664",
                              "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PDR001X2103)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/Trametinib/Melanoma",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>BRAF</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib/*",
                          "studies": [
                            {
                              "nct": "NCT02083354",
                              "path": "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib/*/NCT02083354",
                              "title": "Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma ",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            },
                            {
                              "nct": "NCT03551626",
                              "path": "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib/*/NCT03551626",
                              "title": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus | DRB436F2410)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MEK</b> + <b>pan-RAF</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Trametinib/Melanoma/LXH254",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Trametinib/Melanoma/LXH254/*",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/Trametinib/Melanoma/LXH254/*/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/Targeted/Trametinib/Pancreatic",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>CDK4/6</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/Targeted/Trametinib/Pancreatic/Ribociclib",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/Targeted/Trametinib/Pancreatic/Ribociclib/*",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Compounds/Targeted/Trametinib/Pancreatic/Ribociclib/*/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/Trametinib/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>MEK</b> + <b>CDK4/6</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/Trametinib/Solid Tumors/Ribociclib",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/Trametinib/Solid Tumors/Ribociclib/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT02703571",
                              "path": "Content/Compounds/Targeted/Trametinib/Solid Tumors/Ribociclib/Advanced Solid Tumors/NCT02703571",
                              "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (TMT212X2106)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>MEK</b> (Trametinib<sup>28</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>MET</b> (Capmatinib<sup>4</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Capmatinib",
              "children": [
                {
                  "type": "Liver",
                  "color": "#F7C114",
                  "path": "Content/Compounds/Targeted/Capmatinib/Liver",
                  "children": [
                    {
                      "type": "<b>MET</b> + <b>PD-1</b>",
                      "color": "#F7C114",
                      "path": "Content/Compounds/Targeted/Capmatinib/Liver/Spartalizumab",
                      "children": [
                        {
                          "type": "HCC",
                          "color": "#F7C114",
                          "path": "Content/Compounds/Targeted/Capmatinib/Liver/Spartalizumab/HCC",
                          "studies": [
                            {
                              "nct": "NCT02795429",
                              "path": "Content/Compounds/Targeted/Capmatinib/Liver/Spartalizumab/HCC/NCT02795429",
                              "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC (INC280X2108)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/Capmatinib/Lung",
                  "children": [
                    {
                      "type": "<b>MET</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Capmatinib/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Capmatinib/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02276027",
                              "path": "Content/Compounds/Targeted/Capmatinib/Lung/*/NSCLC/NCT02276027",
                              "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (INC280X2205)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02414139",
                              "path": "Content/Compounds/Targeted/Capmatinib/Lung/*/NSCLC/NCT02414139",
                              "title": "Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (INC280A2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MET</b> + <b>EGFR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            },
                            {
                              "nct": "NCT02335944",
                              "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib/NSCLC/NCT02335944",
                              "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. (INC280X2105)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MET</b> + <i>Nivolumab</i>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nivolumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nivolumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02323126",
                              "path": "Content/Compounds/Targeted/Capmatinib/Lung/Nivolumab/NSCLC/NCT02323126",
                              "title": "Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer (EGF816 | EGF816X2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>MET</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Capmatinib/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Capmatinib/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03647488",
                              "path": "Content/Compounds/Targeted/Capmatinib/Lung/Spartalizumab/NSCLC/NCT03647488",
                              "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer (INC280D2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/Capmatinib/Melanoma",
                  "children": [
                    {
                      "type": "<b>MET</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/Capmatinib/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/Capmatinib/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT03484923",
                              "path": "Content/Compounds/Targeted/Capmatinib/Melanoma/Spartalizumab/*/NCT03484923",
                              "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM | PDR001J2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>MET</b> (Capmatinib<sup>4</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>Multikinase</b> (Midostaurin<sup>14</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Midostaurin",
              "children": [
                {
                  "type": "AML",
                  "color": "#4D3280",
                  "path": "Content/Compounds/Targeted/Midostaurin/AML",
                  "children": [
                    {
                      "type": "<b>Multikinase</b> + <i>Chemo</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/Midostaurin/AML/Chemo",
                      "children": [
                        {
                          "type": "FLT3m+",
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/Midostaurin/AML/Chemo/FLT3m+",
                          "studies": [
                            {
                              "nct": "NCT03591510",
                              "path": "Content/Compounds/Targeted/Midostaurin/AML/Chemo/FLT3m+/NCT03591510",
                              "title": "A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (PKC412A2218)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>)"
                            },
                            {
                              "nct": "NCT03379727",
                              "path": "Content/Compounds/Targeted/Midostaurin/AML/Chemo/FLT3m+/NCT03379727",
                              "title": "Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia. (PKC412A2408)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>Multikinase</b> + <i>Daunorubicin/Cytarabine</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/Midostaurin/AML/Daunorubicin#Cytarabine",
                      "children": [
                        {
                          "type": "FLT3m+",
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/Midostaurin/AML/Daunorubicin#Cytarabine/FLT3m+",
                          "studies": [
                            {
                              "nct": "NCT03280030",
                              "path": "Content/Compounds/Targeted/Midostaurin/AML/Daunorubicin#Cytarabine/FLT3m+/NCT03280030",
                              "title": "A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML (PKC412A2220)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>Multikinase</b> + <b>HDM2-p53</b> + <i>Cytarabine / Anthracycline</i>",
                      "color": "#4D3280",
                      "path": "Content/Compounds/Targeted/Midostaurin/AML/HDM201",
                      "children": [
                        {
                          "type": "FLT3m+",
                          "color": "#4D3280",
                          "path": "Content/Compounds/Targeted/Midostaurin/AML/HDM201/FLT3m+",
                          "studies": [
                            {
                              "nct": "NCT03760445",
                              "path": "Content/Compounds/Targeted/Midostaurin/AML/HDM201/FLT3m+/NCT03760445",
                              "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML (HDM201A2101)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>Multikinase</b> (Midostaurin<sup>14</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Crizanlizumab",
              "children": [
                {
                  "type": "MF",
                  "color": "#023761",
                  "path": "Content/Compounds/Targeted/Crizanlizumab/MF",
                  "children": [
                    {
                      "type": "<b>P-selectin</b> + <i>Ruxolitinib</i>",
                      "color": "#023761",
                      "path": "Content/Compounds/Targeted/Crizanlizumab/MF/Ruxolitinib",
                      "children": [
                        {
                          "color": "#023761",
                          "path": "Content/Compounds/Targeted/Crizanlizumab/MF/Ruxolitinib/*",
                          "studies": [
                            {
                              "nct": "NCT04097821",
                              "path": "Content/Compounds/Targeted/Crizanlizumab/MF/Ruxolitinib/*/NCT04097821",
                              "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE | INC424H1220)",
                              "phase": 1.5,
                              "phaseList": "I/II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Sickle Cell Disease",
                  "color": "#176DCF",
                  "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease",
                  "children": [
                    {
                      "type": "<b>P-selectin</b>",
                      "color": "#176DCF",
                      "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*",
                      "children": [
                        {
                          "type": "Priapism",
                          "color": "#176DCF",
                          "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/Priapism",
                          "studies": [
                            {
                              "nct": "NCT03938454",
                              "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/Priapism/NCT03938454",
                              "title": "A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism (SPARTAN | SEG101AUS05)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            }
                          ]
                        },
                        {
                          "color": "#176DCF",
                          "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*",
                          "studies": [
                            {
                              "nct": "NCT03474965",
                              "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*/NCT03474965",
                              "title": "Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients (SEG101B2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            },
                            {
                              "nct": "NCT04053764",
                              "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*/NCT04053764",
                              "title": "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease (STEADFAST | SEG101A2203)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            },
                            {
                              "nct": "NCT03814746",
                              "path": "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*/NCT03814746",
                              "title": "Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (STAND | SEG101A2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>pan-RAF</b> (LXH254)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/LXH254",
              "children": [
                {
                  "type": "Gynecologic",
                  "color": "#F26322",
                  "path": "Content/Compounds/Targeted/LXH254/Gynecologic",
                  "children": [
                    {
                      "type": "<b>pan-RAF</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/Targeted/LXH254/Gynecologic/*",
                      "children": [
                        {
                          "type": "Ovarian",
                          "color": "#F26322",
                          "path": "Content/Compounds/Targeted/LXH254/Gynecologic/*/Ovarian",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/Targeted/LXH254/Gynecologic/*/Ovarian/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/LXH254/Lung",
                  "children": [
                    {
                      "type": "<b>pan-RAF</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/LXH254/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/LXH254/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/Targeted/LXH254/Lung/*/NSCLC/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>EGFR</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/LXH254/Lung/Nazartinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/LXH254/Lung/Nazartinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03333343",
                              "path": "Content/Compounds/Targeted/LXH254/Lung/Nazartinib/NSCLC/NCT03333343",
                              "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (EGF816X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>ERK</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/LXH254/Lung/LTT462",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/LXH254/Lung/LTT462/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/LXH254/Lung/LTT462/NSCLC/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>MEK</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/LXH254/Lung/Trametinib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/LXH254/Lung/Trametinib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/LXH254/Lung/Trametinib/NSCLC/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/LXH254/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/LXH254/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/Targeted/LXH254/Lung/Spartalizumab/NSCLC/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/LXH254/Melanoma",
                  "children": [
                    {
                      "type": "<b>pan-RAF</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/LXH254/Melanoma/*",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/LXH254/Melanoma/*/*",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/Targeted/LXH254/Melanoma/*/*/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>CDK4/6</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/LXH254/Melanoma/Ribociclib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/LXH254/Melanoma/Ribociclib/*",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/LXH254/Melanoma/Ribociclib/*/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>MEK</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/LXH254/Melanoma/Trametinib",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/LXH254/Melanoma/Trametinib/*",
                          "studies": [
                            {
                              "nct": "NCT02974725",
                              "path": "Content/Compounds/Targeted/LXH254/Melanoma/Trametinib/*/NCT02974725",
                              "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (LXH254X2102)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>pan-RAF</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/LXH254/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/LXH254/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT02607813",
                              "path": "Content/Compounds/Targeted/LXH254/Melanoma/Spartalizumab/*/NCT02607813",
                              "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (LXH254X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>pan-RAF</b> (LXH254)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Alpelisib",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/Alpelisib/Breast",
                  "children": [
                    {
                      "type": "<b>PI3Kα</b> + <i>Fulvestrant</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT01219699",
                              "path": "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT01219699",
                              "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene (BYL719X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            },
                            {
                              "nct": "NCT03056755",
                              "path": "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT03056755",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve | BYL719X2402)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            },
                            {
                              "nct": "NCT03056755",
                              "path": "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT03056755",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve | BYL719X2402)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            },
                            {
                              "nct": "NCT02437318",
                              "path": "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT02437318",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1 | BYL719C2301)",
                              "phase": 3,
                              "phaseList": "III",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PI3Kα</b> + <i>Letrozole</i>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Alpelisib/Breast/Letrozole",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Alpelisib/Breast/Letrozole/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT03056755",
                              "path": "Content/Compounds/Targeted/Alpelisib/Breast/Letrozole/HR+#HER2-/NCT03056755",
                              "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve | BYL719X2402)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>PI3Kα</b> + <b>SERD</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/Alpelisib/Breast/LSZ102",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/Alpelisib/Breast/LSZ102/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Compounds/Targeted/Alpelisib/Breast/LSZ102/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/Alpelisib/Lung",
                  "children": [
                    {
                      "type": "<b>PI3Kα</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/Alpelisib/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/Alpelisib/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT02276027",
                              "path": "Content/Compounds/Targeted/Alpelisib/Lung/*/NSCLC/NCT02276027",
                              "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (INC280X2205)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/Alpelisib/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>PI3Kα</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/Alpelisib/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Advanced Solid Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/Alpelisib/Solid Tumors/*/Advanced Solid Tumors",
                          "studies": [
                            {
                              "nct": "NCT01219699",
                              "path": "Content/Compounds/Targeted/Alpelisib/Solid Tumors/*/Advanced Solid Tumors/NCT01219699",
                              "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene (BYL719X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>Porcupine</b> (WNT974<sup>29</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/WNT974",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/WNT974/Breast",
                  "children": [
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/WNT974/Breast/Spartalizumab",
                      "children": [
                        {
                          "type": "TNBC",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/WNT974/Breast/Spartalizumab/TNBC",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Breast/Spartalizumab/TNBC/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/WNT974/Colorectal",
                  "children": [
                    {
                      "type": "<b>Porcupine</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/WNT974/Colorectal/*",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/WNT974/Colorectal/*/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Colorectal/*/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/Targeted/WNT974/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/Targeted/WNT974/Gastrointestinal/Spartalizumab",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/WNT974/Gastrointestinal/Spartalizumab/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Gastrointestinal/Spartalizumab/Esophageal/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gynecologic",
                  "color": "#F26322",
                  "path": "Content/Compounds/Targeted/WNT974/Gynecologic",
                  "children": [
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#F26322",
                      "path": "Content/Compounds/Targeted/WNT974/Gynecologic/Spartalizumab",
                      "children": [
                        {
                          "type": "Cervical",
                          "color": "#F26322",
                          "path": "Content/Compounds/Targeted/WNT974/Gynecologic/Spartalizumab/Cervical",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Gynecologic/Spartalizumab/Cervical/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/Targeted/WNT974/Head and Neck",
                  "children": [
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/WNT974/Head and Neck/Spartalizumab",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/WNT974/Head and Neck/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Head and Neck/Spartalizumab/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/WNT974/Lung",
                  "children": [
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/WNT974/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/WNT974/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Lung/Spartalizumab/NSCLC/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Melanoma",
                  "color": "#DBD36E",
                  "path": "Content/Compounds/Targeted/WNT974/Melanoma",
                  "children": [
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#DBD36E",
                      "path": "Content/Compounds/Targeted/WNT974/Melanoma/Spartalizumab",
                      "children": [
                        {
                          "color": "#DBD36E",
                          "path": "Content/Compounds/Targeted/WNT974/Melanoma/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Melanoma/Spartalizumab/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Pancreatic",
                  "color": "#49A848",
                  "path": "Content/Compounds/Targeted/WNT974/Pancreatic",
                  "children": [
                    {
                      "type": "<b>Porcupine</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/Targeted/WNT974/Pancreatic/*",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/Targeted/WNT974/Pancreatic/*/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Pancreatic/*/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>Porcupine</b> + <b>PD-1</b>",
                      "color": "#49A848",
                      "path": "Content/Compounds/Targeted/WNT974/Pancreatic/Spartalizumab",
                      "children": [
                        {
                          "color": "#49A848",
                          "path": "Content/Compounds/Targeted/WNT974/Pancreatic/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Pancreatic/Spartalizumab/*/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/WNT974/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>Porcupine</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/WNT974/Solid Tumors/*",
                      "children": [
                        {
                          "type": "Wnt Pathway Tumors",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/WNT974/Solid Tumors/*/Wnt Pathway Tumors",
                          "studies": [
                            {
                              "nct": "NCT01351103",
                              "path": "Content/Compounds/Targeted/WNT974/Solid Tumors/*/Wnt Pathway Tumors/NCT01351103",
                              "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (LGK974X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>Porcupine</b> (WNT974<sup>29</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>SERD</b> (LSZ102)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/LSZ102",
              "children": [
                {
                  "type": "Breast",
                  "color": "#EC008C",
                  "path": "Content/Compounds/Targeted/LSZ102/Breast",
                  "children": [
                    {
                      "type": "<b>SERD</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/LSZ102/Breast/*",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/LSZ102/Breast/*/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Compounds/Targeted/LSZ102/Breast/*/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SERD</b> (LSZ102)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SERD</b> + <b>CDK4/6</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/LSZ102/Breast/Ribociclib",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/LSZ102/Breast/Ribociclib/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Compounds/Targeted/LSZ102/Breast/Ribociclib/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SERD</b> (LSZ102)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SERD</b> + <b>PI3Kα</b>",
                      "color": "#EC008C",
                      "path": "Content/Compounds/Targeted/LSZ102/Breast/Alpelisib",
                      "children": [
                        {
                          "type": "HR+/HER2-",
                          "color": "#EC008C",
                          "path": "Content/Compounds/Targeted/LSZ102/Breast/Alpelisib/HR+#HER2-",
                          "studies": [
                            {
                              "nct": "NCT02734615",
                              "path": "Content/Compounds/Targeted/LSZ102/Breast/Alpelisib/HR+#HER2-/NCT02734615",
                              "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (LSZ102X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SERD</b> (LSZ102)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>SHP2</b> (TNO155)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/TNO155",
              "children": [
                {
                  "type": "Colorectal",
                  "color": "#EC1C24",
                  "path": "Content/Compounds/Targeted/TNO155/Colorectal",
                  "children": [
                    {
                      "type": "<b>SHP2</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/TNO155/Colorectal/*",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/TNO155/Colorectal/*/*",
                          "studies": [
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Compounds/Targeted/TNO155/Colorectal/*/*/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>CDK4/6</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/TNO155/Colorectal/Ribociclib",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/TNO155/Colorectal/Ribociclib/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Colorectal/Ribociclib/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>PD-1</b>",
                      "color": "#EC1C24",
                      "path": "Content/Compounds/Targeted/TNO155/Colorectal/Spartalizumab",
                      "children": [
                        {
                          "color": "#EC1C24",
                          "path": "Content/Compounds/Targeted/TNO155/Colorectal/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Colorectal/Spartalizumab/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Gastrointestinal",
                  "color": "#EF4930",
                  "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal",
                  "children": [
                    {
                      "type": "<b>SHP2</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/*",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/*/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/*/Esophageal/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>CDK4/6</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/Esophageal/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>PD-1</b>",
                      "color": "#EF4930",
                      "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Spartalizumab",
                      "children": [
                        {
                          "type": "Esophageal",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Spartalizumab/Esophageal",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Spartalizumab/Esophageal/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        },
                        {
                          "type": "GIST",
                          "color": "#EF4930",
                          "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/GIST",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/GIST/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Head and Neck",
                  "color": "#F89B1C",
                  "path": "Content/Compounds/Targeted/TNO155/Head and Neck",
                  "children": [
                    {
                      "type": "<b>SHP2</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/TNO155/Head and Neck/*",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/TNO155/Head and Neck/*/*",
                          "studies": [
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Compounds/Targeted/TNO155/Head and Neck/*/*/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>CDK4/6</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/TNO155/Head and Neck/Ribociclib",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/TNO155/Head and Neck/Ribociclib/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Head and Neck/Ribociclib/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>PD-1</b>",
                      "color": "#F89B1C",
                      "path": "Content/Compounds/Targeted/TNO155/Head and Neck/Spartalizumab",
                      "children": [
                        {
                          "color": "#F89B1C",
                          "path": "Content/Compounds/Targeted/TNO155/Head and Neck/Spartalizumab/*",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Head and Neck/Spartalizumab/*/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Lung",
                  "color": "#FBDE3C",
                  "path": "Content/Compounds/Targeted/TNO155/Lung",
                  "children": [
                    {
                      "type": "<b>SHP2</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/TNO155/Lung/*",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/TNO155/Lung/*/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Compounds/Targeted/TNO155/Lung/*/NSCLC/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>CDK4/6</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/TNO155/Lung/Ribociclib",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/TNO155/Lung/Ribociclib/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Lung/Ribociclib/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "type": "<b>SHP2</b> + <b>PD-1</b>",
                      "color": "#FBDE3C",
                      "path": "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab",
                      "children": [
                        {
                          "type": "NSCLC",
                          "color": "#FBDE3C",
                          "path": "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab/NSCLC",
                          "studies": [
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            },
                            {
                              "nct": "NCT04000529",
                              "path": "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab/NSCLC/NCT04000529",
                              "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (TNO155B1210)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Solid Tumors",
                  "color": "#00A4AB",
                  "path": "Content/Compounds/Targeted/TNO155/Solid Tumors",
                  "children": [
                    {
                      "type": "<b>SHP2</b>",
                      "color": "#00A4AB",
                      "path": "Content/Compounds/Targeted/TNO155/Solid Tumors/*",
                      "children": [
                        {
                          "type": "RAS/RAF wild-type",
                          "color": "#00A4AB",
                          "path": "Content/Compounds/Targeted/TNO155/Solid Tumors/*/RAS#RAF wild-type",
                          "studies": [
                            {
                              "nct": "NCT03114319",
                              "path": "Content/Compounds/Targeted/TNO155/Solid Tumors/*/RAS#RAF wild-type/NCT03114319",
                              "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (TNO155X2101)",
                              "phase": 1,
                              "phaseList": "I",
                              "target": "<b>SHP2</b> (TNO155)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "<b>TPO receptor</b> (Eltrombopag<sup>8</sup>)",
              "color": "#023761",
              "path": "Content/Compounds/Targeted/Eltrombopag",
              "children": [
                {
                  "type": "Immune Thrombocytopenic Purpura",
                  "color": "#78BEFF",
                  "path": "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura",
                  "children": [
                    {
                      "type": "<b>TPO receptor</b>",
                      "color": "#78BEFF",
                      "path": "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura/*",
                      "children": [
                        {
                          "color": "#78BEFF",
                          "path": "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura/*/*",
                          "studies": [
                            {
                              "nct": "NCT03524612",
                              "path": "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura/*/*/NCT03524612",
                              "title": "A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP (TAPER | ETB115J2411)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>TPO receptor</b> (Eltrombopag<sup>8</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "type": "Severe Aplastic Anemia",
                  "color": "#449EED",
                  "path": "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia",
                  "children": [
                    {
                      "type": "<b>TPO receptor</b>",
                      "color": "#449EED",
                      "path": "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia/*",
                      "children": [
                        {
                          "color": "#449EED",
                          "path": "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia/*/*",
                          "studies": [
                            {
                              "nct": "NCT03025698",
                              "path": "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia/*/*/NCT03025698",
                              "title": "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia (ETB115E2201)",
                              "phase": 2,
                              "phaseList": "II",
                              "target": "<b>TPO receptor</b> (Eltrombopag<sup>8</sup>)"
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  },
  "paths": [
    "Content/Tumors/Heme",
    "Content/Tumors/Heme/Nonmalignant",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Immune Thrombocytopenic Purpura",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Immune Thrombocytopenic Purpura/*",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Immune Thrombocytopenic Purpura/*/NCT03524612",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT02370706",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/MF/*/NCT04097821",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Severe Aplastic Anemia",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Severe Aplastic Anemia/*",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Severe Aplastic Anemia/*/NCT03025698",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/Priapism",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/Priapism/NCT03938454",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*/NCT03814746",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*/NCT04053764",
    "Content/Tumors/Heme/Nonmalignant/Rare Disease/Sickle Cell Disease/*/NCT03474965",
    "Content/Tumors/Heme/Malignant",
    "Content/Tumors/Heme/Malignant/BPDCN",
    "Content/Tumors/Heme/Malignant/BPDCN/*",
    "Content/Tumors/Heme/Malignant/BPDCN/*/*",
    "Content/Tumors/Heme/Malignant/BPDCN/*/*/NCT02730312",
    "Content/Tumors/Heme/Malignant/Leukemia",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/B Cell",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/B Cell/NCT03876769",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/B Cell/NCT02730312",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/Ph+",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/Ph+/NCT02081378",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/*",
    "Content/Tumors/Heme/Malignant/Leukemia/ALL/*/NCT02143635",
    "Content/Tumors/Heme/Malignant/Leukemia/AML",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/de novo",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/de novo/NCT03066648",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m-",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m-/NCT03760445",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03760445",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03379727",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03591510",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/FLT3m+/NCT03280030",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03760445",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/r#r/NCT03066648",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/*",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT02730312",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT02143635",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT03760445",
    "Content/Tumors/Heme/Malignant/Leukemia/AML/*/NCT03940352",
    "Content/Tumors/Heme/Malignant/Leukemia/CLL",
    "Content/Tumors/Heme/Malignant/Leukemia/CLL/*",
    "Content/Tumors/Heme/Malignant/Leukemia/CLL/*/NCT03400176",
    "Content/Tumors/Heme/Malignant/Leukemia/CLL/*/NCT03960840",
    "Content/Tumors/Heme/Malignant/Leukemia/CML",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+/NCT02081378",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/Ph+/NCT03578367",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/*",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/*/NCT03106779",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/*/NCT02081378",
    "Content/Tumors/Heme/Malignant/Leukemia/CML/*/NCT02730312",
    "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk",
    "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*",
    "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT02143635",
    "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03940352",
    "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03066648",
    "Content/Tumors/Heme/Malignant/Leukemia/MDS High Risk/*/NCT03946670",
    "Content/Tumors/Heme/Malignant/Lymphoma",
    "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma",
    "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*",
    "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*/NCT02992483",
    "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*/NCT03172936",
    "Content/Tumors/Heme/Malignant/Lymphoma/Lymphoma/*/NCT02675439",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03570892",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03876028",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03630159",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03960840",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT02900651",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT02992483",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03207867",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/DLBCL/NCT03365791",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/FL",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/FL/NCT03568461",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/SLL",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/SLL/NCT03960840",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/*",
    "Content/Tumors/Heme/Malignant/Lymphoma/Non-Hodgkin Lymphoma/*/NCT03610724",
    "Content/Tumors/Heme/Malignant/Myeloma",
    "Content/Tumors/Heme/Malignant/Myeloma/Multiple Myeloma",
    "Content/Tumors/Heme/Malignant/Myeloma/Multiple Myeloma/*",
    "Content/Tumors/Heme/Malignant/Myeloma/Multiple Myeloma/*/NCT02992483",
    "Content/Tumors/Solid Tumors",
    "Content/Tumors/Solid Tumors/*",
    "Content/Tumors/Solid Tumors/*/*",
    "Content/Tumors/Solid Tumors/*/*/Brain",
    "Content/Tumors/Solid Tumors/*/*/Brain/Gliobastoma",
    "Content/Tumors/Solid Tumors/*/*/Brain/Gliobastoma/NCT02829723",
    "Content/Tumors/Solid Tumors/*/*/Brain/Glioma (high and low risk)",
    "Content/Tumors/Solid Tumors/*/*/Brain/Glioma (high and low risk)/NCT02684058",
    "Content/Tumors/Solid Tumors/*/*/Brain/Neurofibroma",
    "Content/Tumors/Solid Tumors/*/*/Brain/Neurofibroma/NCT02124772",
    "Content/Tumors/Solid Tumors/*/*/Breast",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03701334",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT01857193",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02333370",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03671330",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03822468",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02437318",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT03056755",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT01219699",
    "Content/Tumors/Solid Tumors/*/*/Breast/HR+#HER2-/NCT02734615",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03891953",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02900664",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03499899",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02404441",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02807844",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02829723",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02890069",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02460224",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT03742349",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Breast/TNBC/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Colorectal",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT03891953",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/MSS/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02703571",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02900664",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT03798626",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT02890069",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT04000529",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Colorectal/*/NCT03114319",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT03798626",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT04000529",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Esophageal/NCT03114319",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric/NCT02900651",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric Adenocarcinoma",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/Gastric Adenocarcinoma/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/GIST",
    "Content/Tumors/Solid Tumors/*/*/Gastrointestinal/GIST/NCT04000529",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Cervical",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Cervical/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Endometrial",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Endometrial/NCT02807844",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian/NCT02900651",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian/NCT02607813",
    "Content/Tumors/Solid Tumors/*/*/Gynecologic/Ovarian/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT02900651",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT03891953",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/NPC/NCT02605967",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/*",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT04000529",
    "Content/Tumors/Solid Tumors/*/*/Head and Neck/*/NCT03114319",
    "Content/Tumors/Solid Tumors/*/*/Liver",
    "Content/Tumors/Solid Tumors/*/*/Liver/HCC",
    "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02795429",
    "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02988440",
    "Content/Tumors/Solid Tumors/*/*/Liver/HCC/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Lung",
    "Content/Tumors/Solid Tumors/*/*/Lung/Mesothelioma",
    "Content/Tumors/Solid Tumors/*/*/Lung/Mesothelioma/NCT02460224",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02403193",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT01336634",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03333343",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02335944",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02323126",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03891953",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03447769",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03968419",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02900664",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03626545",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03631199",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02276027",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02414139",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02607813",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02974725",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02404441",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02890069",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03064854",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02460224",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03647488",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT04000529",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT02608268",
    "Content/Tumors/Solid Tumors/*/*/Lung/NSCLC/NCT03114319",
    "Content/Tumors/Solid Tumors/*/*/Lung/SCLC",
    "Content/Tumors/Solid Tumors/*/*/Lung/SCLC/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Melanoma",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03551626",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02083354",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03891953",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02607813",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02974725",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02404441",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02967692",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT03484923",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02807844",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02460224",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Melanoma/*/NCT02608268",
    "Content/Tumors/Solid Tumors/*/*/Neuroendocrine",
    "Content/Tumors/Solid Tumors/*/*/Neuroendocrine/*",
    "Content/Tumors/Solid Tumors/*/*/Neuroendocrine/*/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02703571",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02807844",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02829723",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Pancreatic/*/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Prostate",
    "Content/Tumors/Solid Tumors/*/*/Prostate/*",
    "Content/Tumors/Solid Tumors/*/*/Prostate/*/NCT02900651",
    "Content/Tumors/Solid Tumors/*/*/Prostate/*/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Renal",
    "Content/Tumors/Solid Tumors/*/*/Renal/ccRCC",
    "Content/Tumors/Solid Tumors/*/*/Renal/ccRCC/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Renal/RCC",
    "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT03798626",
    "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT03207867",
    "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT02890069",
    "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT02460224",
    "Content/Tumors/Solid Tumors/*/*/Renal/RCC/NCT02608268",
    "Content/Tumors/Solid Tumors/*/*/Sarcoma",
    "Content/Tumors/Solid Tumors/*/*/Sarcoma/Soft Tissue Sarcoma",
    "Content/Tumors/Solid Tumors/*/*/Sarcoma/Soft Tissue Sarcoma/NCT03365791",
    "Content/Tumors/Solid Tumors/*/*/Sarcoma/*",
    "Content/Tumors/Solid Tumors/*/*/Sarcoma/*/NCT02900651",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03549000",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02703571",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02829723",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02143635",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02452268",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02460224",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02404441",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02608268",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT03301896",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT01219699",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02675439",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Advanced Solid Tumors/NCT02947165",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Non-Breast HER2+",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Non-Breast HER2+/NCT03696771",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/RAS#RAF wild-type",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/RAS#RAF wild-type/NCT03114319",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Wnt Pathway Tumors",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/Wnt Pathway Tumors/NCT01351103",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/*",
    "Content/Tumors/Solid Tumors/*/*/Solid Tumors/*/NCT03172936",
    "Content/Tumors/Solid Tumors/*/*/Thyroid",
    "Content/Tumors/Solid Tumors/*/*/Thyroid/ATC",
    "Content/Tumors/Solid Tumors/*/*/Thyroid/ATC/NCT02404441",
    "Content/Tumors/Solid Tumors/*/*/Urology",
    "Content/Tumors/Solid Tumors/*/*/Urology/Urothelial",
    "Content/Tumors/Solid Tumors/*/*/Urology/Urothelial/NCT03207867",
    "Content/Compounds/CAR-T",
    "Content/Compounds/CAR-T/Tisagenlecleucel",
    "Content/Compounds/CAR-T/Tisagenlecleucel/ALL",
    "Content/Compounds/CAR-T/Tisagenlecleucel/ALL/*",
    "Content/Compounds/CAR-T/Tisagenlecleucel/ALL/*/B Cell",
    "Content/Compounds/CAR-T/Tisagenlecleucel/ALL/*/B Cell/NCT03876769",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/DLBCL",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/DLBCL/NCT03570892",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Ibrutinib",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL/NCT03876028",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Pembrolizumab",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Pembrolizumab/DLBCL",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/Pembrolizumab/DLBCL/NCT03630159",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/FL",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/FL/NCT03568461",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/*",
    "Content/Compounds/CAR-T/Tisagenlecleucel/Non-Hodgkin Lymphoma/*/*/NCT03610724",
    "Content/Compounds/CAR-T/YTB323",
    "Content/Compounds/CAR-T/YTB323/CLL",
    "Content/Compounds/CAR-T/YTB323/CLL/*",
    "Content/Compounds/CAR-T/YTB323/CLL/*/*",
    "Content/Compounds/CAR-T/YTB323/CLL/*/*/NCT03960840",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/Ibrutinib",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/Ibrutinib/DLBCL/NCT03960840",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/*",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/*/SLL",
    "Content/Compounds/CAR-T/YTB323/Non-Hodgkin Lymphoma/*/SLL/NCT03960840",
    "Content/Compounds/IO",
    "Content/Compounds/IO/NIR178",
    "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma",
    "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma/Spartalizumab",
    "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL",
    "Content/Compounds/IO/NIR178/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL/NCT03207867",
    "Content/Compounds/IO/NIR178/Breast",
    "Content/Compounds/IO/NIR178/Breast/Spartalizumab",
    "Content/Compounds/IO/NIR178/Breast/Spartalizumab/TNBC",
    "Content/Compounds/IO/NIR178/Breast/Spartalizumab/TNBC/NCT03207867",
    "Content/Compounds/IO/NIR178/Colorectal",
    "Content/Compounds/IO/NIR178/Colorectal/Spartalizumab",
    "Content/Compounds/IO/NIR178/Colorectal/Spartalizumab/MSS",
    "Content/Compounds/IO/NIR178/Colorectal/Spartalizumab/MSS/NCT03207867",
    "Content/Compounds/IO/NIR178/Head and Neck",
    "Content/Compounds/IO/NIR178/Head and Neck/Spartalizumab",
    "Content/Compounds/IO/NIR178/Head and Neck/Spartalizumab/*",
    "Content/Compounds/IO/NIR178/Head and Neck/Spartalizumab/*/NCT03207867",
    "Content/Compounds/IO/NIR178/Lung",
    "Content/Compounds/IO/NIR178/Lung/*",
    "Content/Compounds/IO/NIR178/Lung/*/NSCLC",
    "Content/Compounds/IO/NIR178/Lung/*/NSCLC/NCT02403193",
    "Content/Compounds/IO/NIR178/Lung/Spartalizumab",
    "Content/Compounds/IO/NIR178/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/IO/NIR178/Lung/Spartalizumab/NSCLC/NCT03207867",
    "Content/Compounds/IO/NIR178/Lung/Spartalizumab/NSCLC/NCT02403193",
    "Content/Compounds/IO/NIR178/Melanoma",
    "Content/Compounds/IO/NIR178/Melanoma/Spartalizumab",
    "Content/Compounds/IO/NIR178/Melanoma/Spartalizumab/*",
    "Content/Compounds/IO/NIR178/Melanoma/Spartalizumab/*/NCT03207867",
    "Content/Compounds/IO/NIR178/Pancreatic",
    "Content/Compounds/IO/NIR178/Pancreatic/Spartalizumab",
    "Content/Compounds/IO/NIR178/Pancreatic/Spartalizumab/*",
    "Content/Compounds/IO/NIR178/Pancreatic/Spartalizumab/*/NCT03207867",
    "Content/Compounds/IO/NIR178/Renal",
    "Content/Compounds/IO/NIR178/Renal/Spartalizumab",
    "Content/Compounds/IO/NIR178/Renal/Spartalizumab/RCC",
    "Content/Compounds/IO/NIR178/Renal/Spartalizumab/RCC/NCT03207867",
    "Content/Compounds/IO/NIR178/Solid Tumors",
    "Content/Compounds/IO/NIR178/Solid Tumors/NZV930",
    "Content/Compounds/IO/NIR178/Solid Tumors/NZV930/Advanced Solid Tumors",
    "Content/Compounds/IO/NIR178/Solid Tumors/NZV930/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/NIR178/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/NIR178/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/NIR178/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/NIR178/Urology",
    "Content/Compounds/IO/NIR178/Urology/Spartalizumab",
    "Content/Compounds/IO/NIR178/Urology/Spartalizumab/Urothelial",
    "Content/Compounds/IO/NIR178/Urology/Spartalizumab/Urothelial/NCT03207867",
    "Content/Compounds/IO/VAY736",
    "Content/Compounds/IO/VAY736/CLL",
    "Content/Compounds/IO/VAY736/CLL/Ibrutinib",
    "Content/Compounds/IO/VAY736/CLL/Ibrutinib/*",
    "Content/Compounds/IO/VAY736/CLL/Ibrutinib/*/NCT03400176",
    "Content/Compounds/IO/SQZ622",
    "Content/Compounds/IO/SQZ622/*",
    "Content/Compounds/IO/SQZ622/*/*",
    "Content/Compounds/IO/SQZ622/*/*/*",
    "Content/Compounds/IO/SQZ622/*/*/*/NCT02730312",
    "Content/Compounds/IO/SQZ622/ALL",
    "Content/Compounds/IO/SQZ622/ALL/*",
    "Content/Compounds/IO/SQZ622/ALL/*/B Cell",
    "Content/Compounds/IO/SQZ622/ALL/*/B Cell/NCT02730312",
    "Content/Compounds/IO/SQZ622/AML",
    "Content/Compounds/IO/SQZ622/AML/*",
    "Content/Compounds/IO/SQZ622/AML/*/*",
    "Content/Compounds/IO/SQZ622/AML/*/*/NCT02730312",
    "Content/Compounds/IO/SQZ622/CML",
    "Content/Compounds/IO/SQZ622/CML/*",
    "Content/Compounds/IO/SQZ622/CML/*/*",
    "Content/Compounds/IO/SQZ622/CML/*/*/NCT02730312",
    "Content/Compounds/IO/NZV930",
    "Content/Compounds/IO/NZV930/Solid Tumors",
    "Content/Compounds/IO/NZV930/Solid Tumors/*",
    "Content/Compounds/IO/NZV930/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/NZV930/Solid Tumors/*/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/NZV930/Solid Tumors/NIR178",
    "Content/Compounds/IO/NZV930/Solid Tumors/NIR178/Advanced Solid Tumors",
    "Content/Compounds/IO/NZV930/Solid Tumors/NIR178/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/NZV930/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/NZV930/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/NZV930/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/Lacnotuzumab",
    "Content/Compounds/IO/Lacnotuzumab/Breast",
    "Content/Compounds/IO/Lacnotuzumab/Breast/Spartalizumab",
    "Content/Compounds/IO/Lacnotuzumab/Breast/Spartalizumab/TNBC",
    "Content/Compounds/IO/Lacnotuzumab/Breast/Spartalizumab/TNBC/NCT02807844",
    "Content/Compounds/IO/Lacnotuzumab/Gynecologic",
    "Content/Compounds/IO/Lacnotuzumab/Gynecologic/Spartalizumab",
    "Content/Compounds/IO/Lacnotuzumab/Gynecologic/Spartalizumab/Endometrial",
    "Content/Compounds/IO/Lacnotuzumab/Gynecologic/Spartalizumab/Endometrial/NCT02807844",
    "Content/Compounds/IO/Lacnotuzumab/Melanoma",
    "Content/Compounds/IO/Lacnotuzumab/Melanoma/Spartalizumab",
    "Content/Compounds/IO/Lacnotuzumab/Melanoma/Spartalizumab/*",
    "Content/Compounds/IO/Lacnotuzumab/Melanoma/Spartalizumab/*/NCT02807844",
    "Content/Compounds/IO/Lacnotuzumab/Pancreatic",
    "Content/Compounds/IO/Lacnotuzumab/Pancreatic/Spartalizumab",
    "Content/Compounds/IO/Lacnotuzumab/Pancreatic/Spartalizumab/*",
    "Content/Compounds/IO/Lacnotuzumab/Pancreatic/Spartalizumab/*/NCT02807844",
    "Content/Compounds/IO/BLZ945",
    "Content/Compounds/IO/BLZ945/Brain",
    "Content/Compounds/IO/BLZ945/Brain/Spartalizumab",
    "Content/Compounds/IO/BLZ945/Brain/Spartalizumab/Gliobastoma",
    "Content/Compounds/IO/BLZ945/Brain/Spartalizumab/Gliobastoma/NCT02829723",
    "Content/Compounds/IO/BLZ945/Breast",
    "Content/Compounds/IO/BLZ945/Breast/Spartalizumab",
    "Content/Compounds/IO/BLZ945/Breast/Spartalizumab/TNBC",
    "Content/Compounds/IO/BLZ945/Breast/Spartalizumab/TNBC/NCT02829723",
    "Content/Compounds/IO/BLZ945/Pancreatic",
    "Content/Compounds/IO/BLZ945/Pancreatic/Spartalizumab",
    "Content/Compounds/IO/BLZ945/Pancreatic/Spartalizumab/*",
    "Content/Compounds/IO/BLZ945/Pancreatic/Spartalizumab/*/NCT02829723",
    "Content/Compounds/IO/BLZ945/Solid Tumors",
    "Content/Compounds/IO/BLZ945/Solid Tumors/*",
    "Content/Compounds/IO/BLZ945/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/BLZ945/Solid Tumors/*/Advanced Solid Tumors/NCT02829723",
    "Content/Compounds/IO/BLZ945/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/BLZ945/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/BLZ945/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02829723",
    "Content/Compounds/IO/NIZ985",
    "Content/Compounds/IO/NIZ985/Solid Tumors",
    "Content/Compounds/IO/NIZ985/Solid Tumors/*",
    "Content/Compounds/IO/NIZ985/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/NIZ985/Solid Tumors/*/Advanced Solid Tumors/NCT02452268",
    "Content/Compounds/IO/NIZ985/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/NIZ985/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/NIZ985/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02452268",
    "Content/Compounds/IO/Canakinumab",
    "Content/Compounds/IO/Canakinumab/Breast",
    "Content/Compounds/IO/Canakinumab/Breast/*",
    "Content/Compounds/IO/Canakinumab/Breast/*/TNBC",
    "Content/Compounds/IO/Canakinumab/Breast/*/TNBC/NCT02900664",
    "Content/Compounds/IO/Canakinumab/Breast/Spartalizumab",
    "Content/Compounds/IO/Canakinumab/Breast/Spartalizumab/TNBC",
    "Content/Compounds/IO/Canakinumab/Breast/Spartalizumab/TNBC/NCT02900664",
    "Content/Compounds/IO/Canakinumab/Colorectal",
    "Content/Compounds/IO/Canakinumab/Colorectal/*",
    "Content/Compounds/IO/Canakinumab/Colorectal/*/*",
    "Content/Compounds/IO/Canakinumab/Colorectal/*/*/NCT02900664",
    "Content/Compounds/IO/Canakinumab/Colorectal/Spartalizumab",
    "Content/Compounds/IO/Canakinumab/Colorectal/Spartalizumab/*",
    "Content/Compounds/IO/Canakinumab/Colorectal/Spartalizumab/*/NCT02900664",
    "Content/Compounds/IO/Canakinumab/Lung",
    "Content/Compounds/IO/Canakinumab/Lung/*",
    "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC",
    "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC/NCT02900664",
    "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC/NCT03968419",
    "Content/Compounds/IO/Canakinumab/Lung/*/NSCLC/NCT03447769",
    "Content/Compounds/IO/Canakinumab/Lung/Docetaxel",
    "Content/Compounds/IO/Canakinumab/Lung/Docetaxel/NSCLC",
    "Content/Compounds/IO/Canakinumab/Lung/Docetaxel/NSCLC/NCT03626545",
    "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab",
    "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC/NCT02900664",
    "Content/Compounds/IO/Canakinumab/Lung/Spartalizumab/NSCLC/NCT03064854",
    "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab",
    "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC",
    "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC/NCT03968419",
    "Content/Compounds/IO/Canakinumab/Lung/Pembrolizumab/NSCLC/NCT03631199",
    "Content/Compounds/IO/Canakinumab/Melanoma",
    "Content/Compounds/IO/Canakinumab/Melanoma/Spartalizumab",
    "Content/Compounds/IO/Canakinumab/Melanoma/Spartalizumab/*",
    "Content/Compounds/IO/Canakinumab/Melanoma/Spartalizumab/*/NCT03484923",
    "Content/Compounds/IO/Gevokizumab",
    "Content/Compounds/IO/Gevokizumab/Colorectal",
    "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab",
    "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab/*",
    "Content/Compounds/IO/Gevokizumab/Colorectal/Bevacizumab/*/NCT03798626",
    "Content/Compounds/IO/Gevokizumab/Gastrointestinal",
    "Content/Compounds/IO/Gevokizumab/Gastrointestinal/Paciltaxel",
    "Content/Compounds/IO/Gevokizumab/Gastrointestinal/Paciltaxel/Esophageal",
    "Content/Compounds/IO/Gevokizumab/Gastrointestinal/Paciltaxel/Esophageal/NCT03798626",
    "Content/Compounds/IO/Gevokizumab/Renal",
    "Content/Compounds/IO/Gevokizumab/Renal/Cabozantinib",
    "Content/Compounds/IO/Gevokizumab/Renal/Cabozantinib/RCC",
    "Content/Compounds/IO/Gevokizumab/Renal/Cabozantinib/RCC/NCT03798626",
    "Content/Compounds/IO/LAG525",
    "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma",
    "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma/Spartalizumab",
    "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL",
    "Content/Compounds/IO/LAG525/Non-Hodgkin Lymphoma/Spartalizumab/DLBCL/NCT03365791",
    "Content/Compounds/IO/LAG525/Breast",
    "Content/Compounds/IO/LAG525/Breast/Carboplatin",
    "Content/Compounds/IO/LAG525/Breast/Carboplatin/TNBC",
    "Content/Compounds/IO/LAG525/Breast/Carboplatin/TNBC/NCT03499899",
    "Content/Compounds/IO/LAG525/Breast/Spartalizumab",
    "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC",
    "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03499899",
    "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT02460224",
    "Content/Compounds/IO/LAG525/Breast/Spartalizumab/TNBC/NCT03742349",
    "Content/Compounds/IO/LAG525/Gastrointestinal",
    "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab",
    "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Esophageal",
    "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Esophageal/NCT03365791",
    "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Gastric Adenocarcinoma",
    "Content/Compounds/IO/LAG525/Gastrointestinal/Spartalizumab/Gastric Adenocarcinoma/NCT03365791",
    "Content/Compounds/IO/LAG525/Gynecologic",
    "Content/Compounds/IO/LAG525/Gynecologic/Spartalizumab",
    "Content/Compounds/IO/LAG525/Gynecologic/Spartalizumab/Ovarian",
    "Content/Compounds/IO/LAG525/Gynecologic/Spartalizumab/Ovarian/NCT03365791",
    "Content/Compounds/IO/LAG525/Lung",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab/Mesothelioma",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab/Mesothelioma/NCT02460224",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab/NSCLC/NCT02460224",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab/SCLC",
    "Content/Compounds/IO/LAG525/Lung/Spartalizumab/SCLC/NCT03365791",
    "Content/Compounds/IO/LAG525/Melanoma",
    "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab",
    "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab/*",
    "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab/*/NCT03484923",
    "Content/Compounds/IO/LAG525/Melanoma/Spartalizumab/*/NCT02460224",
    "Content/Compounds/IO/LAG525/Neuroendocrine",
    "Content/Compounds/IO/LAG525/Neuroendocrine/Spartalizumab",
    "Content/Compounds/IO/LAG525/Neuroendocrine/Spartalizumab/*",
    "Content/Compounds/IO/LAG525/Neuroendocrine/Spartalizumab/*/NCT03365791",
    "Content/Compounds/IO/LAG525/Prostate",
    "Content/Compounds/IO/LAG525/Prostate/Spartalizumab",
    "Content/Compounds/IO/LAG525/Prostate/Spartalizumab/*",
    "Content/Compounds/IO/LAG525/Prostate/Spartalizumab/*/NCT03365791",
    "Content/Compounds/IO/LAG525/Renal",
    "Content/Compounds/IO/LAG525/Renal/Spartalizumab",
    "Content/Compounds/IO/LAG525/Renal/Spartalizumab/RCC",
    "Content/Compounds/IO/LAG525/Renal/Spartalizumab/RCC/NCT02460224",
    "Content/Compounds/IO/LAG525/Sarcoma",
    "Content/Compounds/IO/LAG525/Sarcoma/Spartalizumab",
    "Content/Compounds/IO/LAG525/Sarcoma/Spartalizumab/Soft Tissue Sarcoma",
    "Content/Compounds/IO/LAG525/Sarcoma/Spartalizumab/Soft Tissue Sarcoma/NCT03365791",
    "Content/Compounds/IO/LAG525/Solid Tumors",
    "Content/Compounds/IO/LAG525/Solid Tumors/*",
    "Content/Compounds/IO/LAG525/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/LAG525/Solid Tumors/*/Advanced Solid Tumors/NCT02460224",
    "Content/Compounds/IO/LAG525/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/LAG525/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/LAG525/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02460224",
    "Content/Compounds/IO/Spartalizumab",
    "Content/Compounds/IO/Spartalizumab/AML",
    "Content/Compounds/IO/Spartalizumab/AML/Decitabine",
    "Content/Compounds/IO/Spartalizumab/AML/Decitabine/de novo",
    "Content/Compounds/IO/Spartalizumab/AML/Decitabine/de novo/NCT03066648",
    "Content/Compounds/IO/Spartalizumab/AML/MBG453",
    "Content/Compounds/IO/Spartalizumab/AML/MBG453/de novo",
    "Content/Compounds/IO/Spartalizumab/AML/MBG453/de novo/NCT03066648",
    "Content/Compounds/IO/Spartalizumab/AML/Decitabine/r#r",
    "Content/Compounds/IO/Spartalizumab/AML/Decitabine/r#r/NCT03066648",
    "Content/Compounds/IO/Spartalizumab/AML/MBG453/r#r",
    "Content/Compounds/IO/Spartalizumab/AML/MBG453/r#r/NCT03066648",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk/Decitabine",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk/Decitabine/*",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk/Decitabine/*/NCT03066648",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453/*",
    "Content/Compounds/IO/Spartalizumab/MDS High Risk/MBG453/*/NCT03066648",
    "Content/Compounds/IO/Spartalizumab/Lymphoma",
    "Content/Compounds/IO/Spartalizumab/Lymphoma/MIW815",
    "Content/Compounds/IO/Spartalizumab/Lymphoma/MIW815/*",
    "Content/Compounds/IO/Spartalizumab/Lymphoma/MIW815/*/NCT03172936",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/NIR178",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/NIR178/DLBCL",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/NIR178/DLBCL/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/LAG525",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/LAG525/DLBCL",
    "Content/Compounds/IO/Spartalizumab/Non-Hodgkin Lymphoma/LAG525/DLBCL/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Brain",
    "Content/Compounds/IO/Spartalizumab/Brain/BLZ945",
    "Content/Compounds/IO/Spartalizumab/Brain/BLZ945/Gliobastoma",
    "Content/Compounds/IO/Spartalizumab/Brain/BLZ945/Gliobastoma/NCT02829723",
    "Content/Compounds/IO/Spartalizumab/Breast",
    "Content/Compounds/IO/Spartalizumab/Breast/*",
    "Content/Compounds/IO/Spartalizumab/Breast/*/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/*/TNBC/NCT02404441",
    "Content/Compounds/IO/Spartalizumab/Breast/CJM112",
    "Content/Compounds/IO/Spartalizumab/Breast/CJM112/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/CJM112/TNBC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Breast/NIR178",
    "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Breast/NIR178/TNBC/NCT03742349",
    "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab",
    "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC/NCT02807844",
    "Content/Compounds/IO/Spartalizumab/Breast/Lacnotuzumab/TNBC/NCT03742349",
    "Content/Compounds/IO/Spartalizumab/Breast/BLZ945",
    "Content/Compounds/IO/Spartalizumab/Breast/BLZ945/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/BLZ945/TNBC/NCT02829723",
    "Content/Compounds/IO/Spartalizumab/Breast/QBM076",
    "Content/Compounds/IO/Spartalizumab/Breast/QBM076/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/QBM076/TNBC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Breast/Nazartinib",
    "Content/Compounds/IO/Spartalizumab/Breast/Nazartinib/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Nazartinib/TNBC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Breast/Everolimus",
    "Content/Compounds/IO/Spartalizumab/Breast/Everolimus/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Everolimus/TNBC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Breast/LCL161",
    "Content/Compounds/IO/Spartalizumab/Breast/LCL161/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/LCL161/TNBC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Breast/DKY709",
    "Content/Compounds/IO/Spartalizumab/Breast/DKY709/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/DKY709/TNBC/NCT03891953",
    "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab",
    "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Breast/Canakinumab/TNBC/NCT03742349",
    "Content/Compounds/IO/Spartalizumab/Breast/LAG525",
    "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03499899",
    "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT02460224",
    "Content/Compounds/IO/Spartalizumab/Breast/LAG525/TNBC/NCT03742349",
    "Content/Compounds/IO/Spartalizumab/Breast/Trametinib",
    "Content/Compounds/IO/Spartalizumab/Breast/Trametinib/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Trametinib/TNBC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Breast/Capmatinib",
    "Content/Compounds/IO/Spartalizumab/Breast/Capmatinib/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Capmatinib/TNBC/NCT03742349",
    "Content/Compounds/IO/Spartalizumab/Breast/Panobinostat",
    "Content/Compounds/IO/Spartalizumab/Breast/Panobinostat/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/Panobinostat/TNBC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Breast/WNT974",
    "Content/Compounds/IO/Spartalizumab/Breast/WNT974/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/WNT974/TNBC/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Breast/NIS793",
    "Content/Compounds/IO/Spartalizumab/Breast/NIS793/TNBC",
    "Content/Compounds/IO/Spartalizumab/Breast/NIS793/TNBC/NCT02947165",
    "Content/Compounds/IO/Spartalizumab/Colorectal",
    "Content/Compounds/IO/Spartalizumab/Colorectal/NIR178",
    "Content/Compounds/IO/Spartalizumab/Colorectal/NIR178/MSS",
    "Content/Compounds/IO/Spartalizumab/Colorectal/NIR178/MSS/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Colorectal/DKY709",
    "Content/Compounds/IO/Spartalizumab/Colorectal/DKY709/MSS",
    "Content/Compounds/IO/Spartalizumab/Colorectal/DKY709/MSS/NCT03891953",
    "Content/Compounds/IO/Spartalizumab/Colorectal/NIS793",
    "Content/Compounds/IO/Spartalizumab/Colorectal/NIS793/MSS",
    "Content/Compounds/IO/Spartalizumab/Colorectal/NIS793/MSS/NCT02947165",
    "Content/Compounds/IO/Spartalizumab/Colorectal/CJM112",
    "Content/Compounds/IO/Spartalizumab/Colorectal/CJM112/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/CJM112/*/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Colorectal/QBM076",
    "Content/Compounds/IO/Spartalizumab/Colorectal/QBM076/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/QBM076/*/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Nazartinib",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Nazartinib/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Nazartinib/*/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Everolimus",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Everolimus/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Everolimus/*/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Colorectal/HDM201",
    "Content/Compounds/IO/Spartalizumab/Colorectal/HDM201/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/HDM201/*/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Colorectal/LCL161",
    "Content/Compounds/IO/Spartalizumab/Colorectal/LCL161/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/LCL161/*/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Canakinumab",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Canakinumab/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Canakinumab/*/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Trametinib",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Trametinib/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Trametinib/*/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Panobinostat",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Panobinostat/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/Panobinostat/*/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Colorectal/TNO155",
    "Content/Compounds/IO/Spartalizumab/Colorectal/TNO155/*",
    "Content/Compounds/IO/Spartalizumab/Colorectal/TNO155/*/NCT04000529",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Esophageal",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Esophageal/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/WNT974",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/WNT974/Esophageal",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/WNT974/Esophageal/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/TNO155",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/TNO155/Esophageal",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/TNO155/Esophageal/NCT04000529",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Gastric Adenocarcinoma",
    "Content/Compounds/IO/Spartalizumab/Gastrointestinal/LAG525/Gastric Adenocarcinoma/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Gynecologic",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/WNT974",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/WNT974/Cervical",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/WNT974/Cervical/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/Lacnotuzumab",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/Lacnotuzumab/Endometrial",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/Lacnotuzumab/Endometrial/NCT02807844",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/LAG525",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/LAG525/Ovarian",
    "Content/Compounds/IO/Spartalizumab/Gynecologic/LAG525/Ovarian/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Head and Neck",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/*",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/*/NPC",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/*/NPC/NCT02605967",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/DKY709",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/DKY709/NPC",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/DKY709/NPC/NCT03891953",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/NIR178",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/NIR178/*",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/NIR178/*/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/WNT974",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/WNT974/*",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/WNT974/*/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/TNO155",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/TNO155/*",
    "Content/Compounds/IO/Spartalizumab/Head and Neck/TNO155/*/NCT04000529",
    "Content/Compounds/IO/Spartalizumab/Liver",
    "Content/Compounds/IO/Spartalizumab/Liver/*",
    "Content/Compounds/IO/Spartalizumab/Liver/*/HCC",
    "Content/Compounds/IO/Spartalizumab/Liver/*/HCC/NCT02795429",
    "Content/Compounds/IO/Spartalizumab/Liver/Capmatinib",
    "Content/Compounds/IO/Spartalizumab/Liver/Capmatinib/HCC",
    "Content/Compounds/IO/Spartalizumab/Liver/Capmatinib/HCC/NCT02795429",
    "Content/Compounds/IO/Spartalizumab/Liver/Sorafenib",
    "Content/Compounds/IO/Spartalizumab/Liver/Sorafenib/HCC",
    "Content/Compounds/IO/Spartalizumab/Liver/Sorafenib/HCC/NCT02988440",
    "Content/Compounds/IO/Spartalizumab/Liver/NIS793",
    "Content/Compounds/IO/Spartalizumab/Liver/NIS793/HCC",
    "Content/Compounds/IO/Spartalizumab/Liver/NIS793/HCC/NCT02947165",
    "Content/Compounds/IO/Spartalizumab/Lung",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525/Mesothelioma",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525/Mesothelioma/NCT02460224",
    "Content/Compounds/IO/Spartalizumab/Lung/*",
    "Content/Compounds/IO/Spartalizumab/Lung/*/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/*/NSCLC/NCT02404441",
    "Content/Compounds/IO/Spartalizumab/Lung/CJM112",
    "Content/Compounds/IO/Spartalizumab/Lung/CJM112/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/CJM112/NSCLC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Lung/NIR178",
    "Content/Compounds/IO/Spartalizumab/Lung/NIR178/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/NIR178/NSCLC/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Lung/NIR178/NSCLC/NCT02403193",
    "Content/Compounds/IO/Spartalizumab/Lung/QBM076",
    "Content/Compounds/IO/Spartalizumab/Lung/QBM076/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/QBM076/NSCLC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Lung/Nazartinib",
    "Content/Compounds/IO/Spartalizumab/Lung/Nazartinib/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Nazartinib/NSCLC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Lung/Everolimus",
    "Content/Compounds/IO/Spartalizumab/Lung/Everolimus/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Everolimus/NSCLC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Lung/Gemcitabine # Cisplatin",
    "Content/Compounds/IO/Spartalizumab/Lung/Gemcitabine # Cisplatin/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Gemcitabine # Cisplatin/NSCLC/NCT03064854",
    "Content/Compounds/IO/Spartalizumab/Lung/LCL161",
    "Content/Compounds/IO/Spartalizumab/Lung/LCL161/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/LCL161/NSCLC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Lung/DKY709",
    "Content/Compounds/IO/Spartalizumab/Lung/DKY709/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/DKY709/NSCLC/NCT03891953",
    "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab",
    "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Lung/Canakinumab/NSCLC/NCT03064854",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525/NSCLC/NCT02460224",
    "Content/Compounds/IO/Spartalizumab/Lung/Trametinib",
    "Content/Compounds/IO/Spartalizumab/Lung/Trametinib/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Trametinib/NSCLC/NCT02900664",
    "Content/Compounds/IO/Spartalizumab/Lung/Capmatinib",
    "Content/Compounds/IO/Spartalizumab/Lung/Capmatinib/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Capmatinib/NSCLC/NCT03647488",
    "Content/Compounds/IO/Spartalizumab/Lung/Paciltaxel # Carboplatin",
    "Content/Compounds/IO/Spartalizumab/Lung/Paciltaxel # Carboplatin/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Paciltaxel # Carboplatin/NSCLC/NCT03064854",
    "Content/Compounds/IO/Spartalizumab/Lung/LXH254",
    "Content/Compounds/IO/Spartalizumab/Lung/LXH254/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/LXH254/NSCLC/NCT02607813",
    "Content/Compounds/IO/Spartalizumab/Lung/Panobinostat",
    "Content/Compounds/IO/Spartalizumab/Lung/Panobinostat/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Panobinostat/NSCLC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Lung/Pemetrexed # Cisplatin",
    "Content/Compounds/IO/Spartalizumab/Lung/Pemetrexed # Cisplatin/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/Pemetrexed # Cisplatin/NSCLC/NCT03064854",
    "Content/Compounds/IO/Spartalizumab/Lung/WNT974",
    "Content/Compounds/IO/Spartalizumab/Lung/WNT974/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/WNT974/NSCLC/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Lung/TNO155",
    "Content/Compounds/IO/Spartalizumab/Lung/TNO155/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/TNO155/NSCLC/NCT04000529",
    "Content/Compounds/IO/Spartalizumab/Lung/NIS793",
    "Content/Compounds/IO/Spartalizumab/Lung/NIS793/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/NIS793/NSCLC/NCT02947165",
    "Content/Compounds/IO/Spartalizumab/Lung/MBG453",
    "Content/Compounds/IO/Spartalizumab/Lung/MBG453/NSCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/MBG453/NSCLC/NCT02608268",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525/SCLC",
    "Content/Compounds/IO/Spartalizumab/Lung/LAG525/SCLC/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Melanoma",
    "Content/Compounds/IO/Spartalizumab/Melanoma/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/*/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/*/*/NCT02404441",
    "Content/Compounds/IO/Spartalizumab/Melanoma/NIR178",
    "Content/Compounds/IO/Spartalizumab/Melanoma/NIR178/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/NIR178/*/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Dabrafenib",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Dabrafenib/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Dabrafenib/*/NCT02967692",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Ribociclib",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Ribociclib/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Ribociclib/*/NCT03484923",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Lacnotuzumab",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Lacnotuzumab/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Lacnotuzumab/*/NCT02807844",
    "Content/Compounds/IO/Spartalizumab/Melanoma/DKY709",
    "Content/Compounds/IO/Spartalizumab/Melanoma/DKY709/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/DKY709/*/NCT03891953",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Canakinumab",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Canakinumab/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Canakinumab/*/NCT03484923",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525/*/NCT03484923",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LAG525/*/NCT02460224",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Trametinib",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Trametinib/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Trametinib/*/NCT02967692",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Capmatinib",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Capmatinib/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/Capmatinib/*/NCT03484923",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LXH254",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LXH254/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/LXH254/*/NCT02607813",
    "Content/Compounds/IO/Spartalizumab/Melanoma/WNT974",
    "Content/Compounds/IO/Spartalizumab/Melanoma/WNT974/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/WNT974/*/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Melanoma/MBG453",
    "Content/Compounds/IO/Spartalizumab/Melanoma/MBG453/*",
    "Content/Compounds/IO/Spartalizumab/Melanoma/MBG453/*/NCT02608268",
    "Content/Compounds/IO/Spartalizumab/Neuroendocrine",
    "Content/Compounds/IO/Spartalizumab/Neuroendocrine/LAG525",
    "Content/Compounds/IO/Spartalizumab/Neuroendocrine/LAG525/*",
    "Content/Compounds/IO/Spartalizumab/Neuroendocrine/LAG525/*/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Pancreatic",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/NIR178",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/NIR178/*",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/NIR178/*/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/Lacnotuzumab",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/Lacnotuzumab/*",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/Lacnotuzumab/*/NCT02807844",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/BLZ945",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/BLZ945/*",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/BLZ945/*/NCT02829723",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/WNT974",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/WNT974/*",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/WNT974/*/NCT01351103",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/NIS793",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/NIS793/*",
    "Content/Compounds/IO/Spartalizumab/Pancreatic/NIS793/*/NCT02947165",
    "Content/Compounds/IO/Spartalizumab/Prostate",
    "Content/Compounds/IO/Spartalizumab/Prostate/LAG525",
    "Content/Compounds/IO/Spartalizumab/Prostate/LAG525/*",
    "Content/Compounds/IO/Spartalizumab/Prostate/LAG525/*/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Renal",
    "Content/Compounds/IO/Spartalizumab/Renal/NIS793",
    "Content/Compounds/IO/Spartalizumab/Renal/NIS793/ccRCC",
    "Content/Compounds/IO/Spartalizumab/Renal/NIS793/ccRCC/NCT02947165",
    "Content/Compounds/IO/Spartalizumab/Renal/NIR178",
    "Content/Compounds/IO/Spartalizumab/Renal/NIR178/RCC",
    "Content/Compounds/IO/Spartalizumab/Renal/NIR178/RCC/NCT03207867",
    "Content/Compounds/IO/Spartalizumab/Renal/HDM201",
    "Content/Compounds/IO/Spartalizumab/Renal/HDM201/RCC",
    "Content/Compounds/IO/Spartalizumab/Renal/HDM201/RCC/NCT02890069",
    "Content/Compounds/IO/Spartalizumab/Renal/LAG525",
    "Content/Compounds/IO/Spartalizumab/Renal/LAG525/RCC",
    "Content/Compounds/IO/Spartalizumab/Renal/LAG525/RCC/NCT02460224",
    "Content/Compounds/IO/Spartalizumab/Renal/MBG453",
    "Content/Compounds/IO/Spartalizumab/Renal/MBG453/RCC",
    "Content/Compounds/IO/Spartalizumab/Renal/MBG453/RCC/NCT02608268",
    "Content/Compounds/IO/Spartalizumab/Sarcoma",
    "Content/Compounds/IO/Spartalizumab/Sarcoma/LAG525",
    "Content/Compounds/IO/Spartalizumab/Sarcoma/LAG525/Soft Tissue Sarcoma",
    "Content/Compounds/IO/Spartalizumab/Sarcoma/LAG525/Soft Tissue Sarcoma/NCT03365791",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/*",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/*/Advanced Solid Tumors/NCT02404441",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIR178",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIR178/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIR178/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NZV930/Advanced Solid Tumors/NCT03549000",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/BLZ945",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/BLZ945/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/BLZ945/Advanced Solid Tumors/NCT02829723",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIZ985",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIZ985/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/NIZ985/Advanced Solid Tumors/NCT02452268",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/LAG525",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/LAG525/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/LAG525/Advanced Solid Tumors/NCT02460224",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/MBG453",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/MBG453/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/MBG453/Advanced Solid Tumors/NCT02608268",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/LHC165",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/LHC165/Advanced Solid Tumors",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/LHC165/Advanced Solid Tumors/NCT03301896",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/MIW815",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/MIW815/*",
    "Content/Compounds/IO/Spartalizumab/Solid Tumors/MIW815/*/NCT03172936",
    "Content/Compounds/IO/Spartalizumab/Thyroid",
    "Content/Compounds/IO/Spartalizumab/Thyroid/*",
    "Content/Compounds/IO/Spartalizumab/Thyroid/*/ATC",
    "Content/Compounds/IO/Spartalizumab/Thyroid/*/ATC/NCT02404441",
    "Content/Compounds/IO/Spartalizumab/Urology",
    "Content/Compounds/IO/Spartalizumab/Urology/NIR178",
    "Content/Compounds/IO/Spartalizumab/Urology/NIR178/Urothelial",
    "Content/Compounds/IO/Spartalizumab/Urology/NIR178/Urothelial/NCT03207867",
    "Content/Compounds/IO/MIW815",
    "Content/Compounds/IO/MIW815/Lymphoma",
    "Content/Compounds/IO/MIW815/Lymphoma/*",
    "Content/Compounds/IO/MIW815/Lymphoma/*/*",
    "Content/Compounds/IO/MIW815/Lymphoma/*/*/NCT02675439",
    "Content/Compounds/IO/MIW815/Lymphoma/Spartalizumab",
    "Content/Compounds/IO/MIW815/Lymphoma/Spartalizumab/*",
    "Content/Compounds/IO/MIW815/Lymphoma/Spartalizumab/*/NCT03172936",
    "Content/Compounds/IO/MIW815/Solid Tumors",
    "Content/Compounds/IO/MIW815/Solid Tumors/*",
    "Content/Compounds/IO/MIW815/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/MIW815/Solid Tumors/*/Advanced Solid Tumors/NCT02675439",
    "Content/Compounds/IO/MIW815/Solid Tumors/Ipilimumab",
    "Content/Compounds/IO/MIW815/Solid Tumors/Ipilimumab/Advanced Solid Tumors",
    "Content/Compounds/IO/MIW815/Solid Tumors/Ipilimumab/Advanced Solid Tumors/NCT02675439",
    "Content/Compounds/IO/MIW815/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/MIW815/Solid Tumors/Spartalizumab/*",
    "Content/Compounds/IO/MIW815/Solid Tumors/Spartalizumab/*/NCT03172936",
    "Content/Compounds/IO/NIS793",
    "Content/Compounds/IO/NIS793/Breast",
    "Content/Compounds/IO/NIS793/Breast/Spartalizumab",
    "Content/Compounds/IO/NIS793/Breast/Spartalizumab/TNBC",
    "Content/Compounds/IO/NIS793/Breast/Spartalizumab/TNBC/NCT02947165",
    "Content/Compounds/IO/NIS793/Colorectal",
    "Content/Compounds/IO/NIS793/Colorectal/Spartalizumab",
    "Content/Compounds/IO/NIS793/Colorectal/Spartalizumab/MSS",
    "Content/Compounds/IO/NIS793/Colorectal/Spartalizumab/MSS/NCT02947165",
    "Content/Compounds/IO/NIS793/Liver",
    "Content/Compounds/IO/NIS793/Liver/Spartalizumab",
    "Content/Compounds/IO/NIS793/Liver/Spartalizumab/HCC",
    "Content/Compounds/IO/NIS793/Liver/Spartalizumab/HCC/NCT02947165",
    "Content/Compounds/IO/NIS793/Lung",
    "Content/Compounds/IO/NIS793/Lung/Spartalizumab",
    "Content/Compounds/IO/NIS793/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/IO/NIS793/Lung/Spartalizumab/NSCLC/NCT02947165",
    "Content/Compounds/IO/NIS793/Pancreatic",
    "Content/Compounds/IO/NIS793/Pancreatic/Spartalizumab",
    "Content/Compounds/IO/NIS793/Pancreatic/Spartalizumab/*",
    "Content/Compounds/IO/NIS793/Pancreatic/Spartalizumab/*/NCT02947165",
    "Content/Compounds/IO/NIS793/Renal",
    "Content/Compounds/IO/NIS793/Renal/Spartalizumab",
    "Content/Compounds/IO/NIS793/Renal/Spartalizumab/ccRCC",
    "Content/Compounds/IO/NIS793/Renal/Spartalizumab/ccRCC/NCT02947165",
    "Content/Compounds/IO/NIS793/Solid Tumors",
    "Content/Compounds/IO/NIS793/Solid Tumors/*",
    "Content/Compounds/IO/NIS793/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/NIS793/Solid Tumors/*/Advanced Solid Tumors/NCT02947165",
    "Content/Compounds/IO/MBG453",
    "Content/Compounds/IO/MBG453/AML",
    "Content/Compounds/IO/MBG453/AML/Decitabine",
    "Content/Compounds/IO/MBG453/AML/Decitabine/de novo",
    "Content/Compounds/IO/MBG453/AML/Decitabine/de novo/NCT03066648",
    "Content/Compounds/IO/MBG453/AML/Spartalizumab",
    "Content/Compounds/IO/MBG453/AML/Spartalizumab/de novo",
    "Content/Compounds/IO/MBG453/AML/Spartalizumab/de novo/NCT03066648",
    "Content/Compounds/IO/MBG453/AML/*",
    "Content/Compounds/IO/MBG453/AML/*/r#r",
    "Content/Compounds/IO/MBG453/AML/*/r#r/NCT03066648",
    "Content/Compounds/IO/MBG453/AML/Decitabine/r#r",
    "Content/Compounds/IO/MBG453/AML/Decitabine/r#r/NCT03066648",
    "Content/Compounds/IO/MBG453/AML/Spartalizumab/r#r",
    "Content/Compounds/IO/MBG453/AML/Spartalizumab/r#r/NCT03066648",
    "Content/Compounds/IO/MBG453/AML/HDM201",
    "Content/Compounds/IO/MBG453/AML/HDM201/*",
    "Content/Compounds/IO/MBG453/AML/HDM201/*/NCT03940352",
    "Content/Compounds/IO/MBG453/MDS High Risk",
    "Content/Compounds/IO/MBG453/MDS High Risk/*",
    "Content/Compounds/IO/MBG453/MDS High Risk/*/*",
    "Content/Compounds/IO/MBG453/MDS High Risk/*/*/NCT03066648",
    "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine",
    "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine/*",
    "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine/*/NCT03066648",
    "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine # Azacitidine",
    "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine # Azacitidine/*",
    "Content/Compounds/IO/MBG453/MDS High Risk/Decitabine # Azacitidine/*/NCT03946670",
    "Content/Compounds/IO/MBG453/MDS High Risk/HDM201",
    "Content/Compounds/IO/MBG453/MDS High Risk/HDM201/*",
    "Content/Compounds/IO/MBG453/MDS High Risk/HDM201/*/NCT03940352",
    "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab",
    "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab/*",
    "Content/Compounds/IO/MBG453/MDS High Risk/Spartalizumab/*/NCT03066648",
    "Content/Compounds/IO/MBG453/MF",
    "Content/Compounds/IO/MBG453/MF/Ruxolitinib",
    "Content/Compounds/IO/MBG453/MF/Ruxolitinib/*",
    "Content/Compounds/IO/MBG453/MF/Ruxolitinib/*/NCT04097821",
    "Content/Compounds/IO/MBG453/Lung",
    "Content/Compounds/IO/MBG453/Lung/Spartalizumab",
    "Content/Compounds/IO/MBG453/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/IO/MBG453/Lung/Spartalizumab/NSCLC/NCT02608268",
    "Content/Compounds/IO/MBG453/Melanoma",
    "Content/Compounds/IO/MBG453/Melanoma/Spartalizumab",
    "Content/Compounds/IO/MBG453/Melanoma/Spartalizumab/*",
    "Content/Compounds/IO/MBG453/Melanoma/Spartalizumab/*/NCT02608268",
    "Content/Compounds/IO/MBG453/Renal",
    "Content/Compounds/IO/MBG453/Renal/Spartalizumab",
    "Content/Compounds/IO/MBG453/Renal/Spartalizumab/RCC",
    "Content/Compounds/IO/MBG453/Renal/Spartalizumab/RCC/NCT02608268",
    "Content/Compounds/IO/MBG453/Solid Tumors",
    "Content/Compounds/IO/MBG453/Solid Tumors/*",
    "Content/Compounds/IO/MBG453/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/MBG453/Solid Tumors/*/Advanced Solid Tumors/NCT02608268",
    "Content/Compounds/IO/MBG453/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/MBG453/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/MBG453/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT02608268",
    "Content/Compounds/IO/LHC165",
    "Content/Compounds/IO/LHC165/Solid Tumors",
    "Content/Compounds/IO/LHC165/Solid Tumors/*",
    "Content/Compounds/IO/LHC165/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/IO/LHC165/Solid Tumors/*/Advanced Solid Tumors/NCT03301896",
    "Content/Compounds/IO/LHC165/Solid Tumors/Spartalizumab",
    "Content/Compounds/IO/LHC165/Solid Tumors/Spartalizumab/Advanced Solid Tumors",
    "Content/Compounds/IO/LHC165/Solid Tumors/Spartalizumab/Advanced Solid Tumors/NCT03301896",
    "Content/Compounds/Targeted",
    "Content/Compounds/Targeted/Asciminib",
    "Content/Compounds/Targeted/Asciminib/ALL",
    "Content/Compounds/Targeted/Asciminib/ALL/*",
    "Content/Compounds/Targeted/Asciminib/ALL/*/Ph+",
    "Content/Compounds/Targeted/Asciminib/ALL/*/Ph+/NCT02081378",
    "Content/Compounds/Targeted/Asciminib/CML",
    "Content/Compounds/Targeted/Asciminib/CML/Dasatinib",
    "Content/Compounds/Targeted/Asciminib/CML/Dasatinib/Ph+",
    "Content/Compounds/Targeted/Asciminib/CML/Dasatinib/Ph+/NCT02081378",
    "Content/Compounds/Targeted/Asciminib/CML/Imatinib",
    "Content/Compounds/Targeted/Asciminib/CML/Imatinib/Ph+",
    "Content/Compounds/Targeted/Asciminib/CML/Imatinib/Ph+/NCT02081378",
    "Content/Compounds/Targeted/Asciminib/CML/Imatinib/Ph+/NCT03578367",
    "Content/Compounds/Targeted/Asciminib/CML/Nilotinib",
    "Content/Compounds/Targeted/Asciminib/CML/Nilotinib/Ph+",
    "Content/Compounds/Targeted/Asciminib/CML/Nilotinib/Ph+/NCT02081378",
    "Content/Compounds/Targeted/Asciminib/CML/*",
    "Content/Compounds/Targeted/Asciminib/CML/*/*",
    "Content/Compounds/Targeted/Asciminib/CML/*/*/NCT02081378",
    "Content/Compounds/Targeted/Asciminib/CML/*/*/NCT03106779",
    "Content/Compounds/Targeted/Dabrafenib",
    "Content/Compounds/Targeted/Dabrafenib/Brain",
    "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib",
    "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Glioma (high and low risk)",
    "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Glioma (high and low risk)/NCT02684058",
    "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Neurofibroma",
    "Content/Compounds/Targeted/Dabrafenib/Brain/Trametinib/Neurofibroma/NCT02124772",
    "Content/Compounds/Targeted/Dabrafenib/Lung",
    "Content/Compounds/Targeted/Dabrafenib/Lung/*",
    "Content/Compounds/Targeted/Dabrafenib/Lung/*/NSCLC",
    "Content/Compounds/Targeted/Dabrafenib/Lung/*/NSCLC/NCT01336634",
    "Content/Compounds/Targeted/Dabrafenib/Lung/Trametinib",
    "Content/Compounds/Targeted/Dabrafenib/Lung/Trametinib/NSCLC",
    "Content/Compounds/Targeted/Dabrafenib/Lung/Trametinib/NSCLC/NCT01336634",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib/*",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib/*/NCT02083354",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Trametinib/*/NCT03551626",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Spartalizumab",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Spartalizumab/*",
    "Content/Compounds/Targeted/Dabrafenib/Melanoma/Spartalizumab/*/NCT02967692",
    "Content/Compounds/Targeted/Ribociclib",
    "Content/Compounds/Targeted/Ribociclib/MF",
    "Content/Compounds/Targeted/Ribociclib/MF/PIM447",
    "Content/Compounds/Targeted/Ribociclib/MF/PIM447/*",
    "Content/Compounds/Targeted/Ribociclib/MF/PIM447/*/NCT02370706",
    "Content/Compounds/Targeted/Ribociclib/MF/Ruxolitinib",
    "Content/Compounds/Targeted/Ribociclib/MF/Ruxolitinib/*",
    "Content/Compounds/Targeted/Ribociclib/MF/Ruxolitinib/*/NCT02370706",
    "Content/Compounds/Targeted/Ribociclib/Breast",
    "Content/Compounds/Targeted/Ribociclib/Breast/Endocrine therapy",
    "Content/Compounds/Targeted/Ribociclib/Breast/Endocrine therapy/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Endocrine therapy/HR+#HER2-/NCT03701334",
    "Content/Compounds/Targeted/Ribociclib/Breast/Everolimus",
    "Content/Compounds/Targeted/Ribociclib/Breast/Everolimus/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Everolimus/HR+#HER2-/NCT01857193",
    "Content/Compounds/Targeted/Ribociclib/Breast/Exemestane",
    "Content/Compounds/Targeted/Ribociclib/Breast/Exemestane/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Exemestane/HR+#HER2-/NCT01857193",
    "Content/Compounds/Targeted/Ribociclib/Breast/Fulvestrant",
    "Content/Compounds/Targeted/Ribociclib/Breast/Fulvestrant/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Fulvestrant/HR+#HER2-/NCT02333370",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole/HR+#HER2-/NCT02333370",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole/HR+#HER2-/NCT03671330",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-/NCT03671330",
    "Content/Compounds/Targeted/Ribociclib/Breast/Letrozole or Anastrazole/HR+#HER2-/NCT03822468",
    "Content/Compounds/Targeted/Ribociclib/Breast/LSZ102",
    "Content/Compounds/Targeted/Ribociclib/Breast/LSZ102/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/LSZ102/HR+#HER2-/NCT02734615",
    "Content/Compounds/Targeted/Ribociclib/Breast/Tamoxifen",
    "Content/Compounds/Targeted/Ribociclib/Breast/Tamoxifen/HR+#HER2-",
    "Content/Compounds/Targeted/Ribociclib/Breast/Tamoxifen/HR+#HER2-/NCT02333370",
    "Content/Compounds/Targeted/Ribociclib/Colorectal",
    "Content/Compounds/Targeted/Ribociclib/Colorectal/Trametinib",
    "Content/Compounds/Targeted/Ribociclib/Colorectal/Trametinib/*",
    "Content/Compounds/Targeted/Ribociclib/Colorectal/Trametinib/*/NCT02703571",
    "Content/Compounds/Targeted/Ribociclib/Colorectal/TNO155",
    "Content/Compounds/Targeted/Ribociclib/Colorectal/TNO155/*",
    "Content/Compounds/Targeted/Ribociclib/Colorectal/TNO155/*/NCT04000529",
    "Content/Compounds/Targeted/Ribociclib/Gastrointestinal",
    "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155",
    "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/Esophageal",
    "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/Esophageal/NCT04000529",
    "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/GIST",
    "Content/Compounds/Targeted/Ribociclib/Gastrointestinal/TNO155/GIST/NCT04000529",
    "Content/Compounds/Targeted/Ribociclib/Head and Neck",
    "Content/Compounds/Targeted/Ribociclib/Head and Neck/TNO155",
    "Content/Compounds/Targeted/Ribociclib/Head and Neck/TNO155/*",
    "Content/Compounds/Targeted/Ribociclib/Head and Neck/TNO155/*/NCT04000529",
    "Content/Compounds/Targeted/Ribociclib/Lung",
    "Content/Compounds/Targeted/Ribociclib/Lung/Nazartinib",
    "Content/Compounds/Targeted/Ribociclib/Lung/Nazartinib/NSCLC",
    "Content/Compounds/Targeted/Ribociclib/Lung/Nazartinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Ribociclib/Lung/TNO155",
    "Content/Compounds/Targeted/Ribociclib/Lung/TNO155/NSCLC",
    "Content/Compounds/Targeted/Ribociclib/Lung/TNO155/NSCLC/NCT04000529",
    "Content/Compounds/Targeted/Ribociclib/Melanoma",
    "Content/Compounds/Targeted/Ribociclib/Melanoma/LXH254",
    "Content/Compounds/Targeted/Ribociclib/Melanoma/LXH254/*",
    "Content/Compounds/Targeted/Ribociclib/Melanoma/LXH254/*/NCT02974725",
    "Content/Compounds/Targeted/Ribociclib/Melanoma/Spartalizumab",
    "Content/Compounds/Targeted/Ribociclib/Melanoma/Spartalizumab/*",
    "Content/Compounds/Targeted/Ribociclib/Melanoma/Spartalizumab/*/NCT03484923",
    "Content/Compounds/Targeted/Ribociclib/Pancreatic",
    "Content/Compounds/Targeted/Ribociclib/Pancreatic/Trametinib",
    "Content/Compounds/Targeted/Ribociclib/Pancreatic/Trametinib/*",
    "Content/Compounds/Targeted/Ribociclib/Pancreatic/Trametinib/*/NCT02703571",
    "Content/Compounds/Targeted/Ribociclib/Solid Tumors",
    "Content/Compounds/Targeted/Ribociclib/Solid Tumors/Trametinib",
    "Content/Compounds/Targeted/Ribociclib/Solid Tumors/Trametinib/Advanced Solid Tumors",
    "Content/Compounds/Targeted/Ribociclib/Solid Tumors/Trametinib/Advanced Solid Tumors/NCT02703571",
    "Content/Compounds/Targeted/QBM076",
    "Content/Compounds/Targeted/QBM076/Breast",
    "Content/Compounds/Targeted/QBM076/Breast/Spartalizumab",
    "Content/Compounds/Targeted/QBM076/Breast/Spartalizumab/TNBC",
    "Content/Compounds/Targeted/QBM076/Breast/Spartalizumab/TNBC/NCT02890069",
    "Content/Compounds/Targeted/QBM076/Colorectal",
    "Content/Compounds/Targeted/QBM076/Colorectal/Spartalizumab",
    "Content/Compounds/Targeted/QBM076/Colorectal/Spartalizumab/*",
    "Content/Compounds/Targeted/QBM076/Colorectal/Spartalizumab/*/NCT02890069",
    "Content/Compounds/Targeted/QBM076/Lung",
    "Content/Compounds/Targeted/QBM076/Lung/Spartalizumab",
    "Content/Compounds/Targeted/QBM076/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/QBM076/Lung/Spartalizumab/NSCLC/NCT02890069",
    "Content/Compounds/Targeted/MAK683",
    "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma",
    "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma/*",
    "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma/*/DLBCL",
    "Content/Compounds/Targeted/MAK683/Non-Hodgkin Lymphoma/*/DLBCL/NCT02900651",
    "Content/Compounds/Targeted/MAK683/Gastrointestinal",
    "Content/Compounds/Targeted/MAK683/Gastrointestinal/*",
    "Content/Compounds/Targeted/MAK683/Gastrointestinal/*/Gastric",
    "Content/Compounds/Targeted/MAK683/Gastrointestinal/*/Gastric/NCT02900651",
    "Content/Compounds/Targeted/MAK683/Gynecologic",
    "Content/Compounds/Targeted/MAK683/Gynecologic/*",
    "Content/Compounds/Targeted/MAK683/Gynecologic/*/Ovarian",
    "Content/Compounds/Targeted/MAK683/Gynecologic/*/Ovarian/NCT02900651",
    "Content/Compounds/Targeted/MAK683/Head and Neck",
    "Content/Compounds/Targeted/MAK683/Head and Neck/*",
    "Content/Compounds/Targeted/MAK683/Head and Neck/*/NPC",
    "Content/Compounds/Targeted/MAK683/Head and Neck/*/NPC/NCT02900651",
    "Content/Compounds/Targeted/MAK683/Prostate",
    "Content/Compounds/Targeted/MAK683/Prostate/*",
    "Content/Compounds/Targeted/MAK683/Prostate/*/*",
    "Content/Compounds/Targeted/MAK683/Prostate/*/*/NCT02900651",
    "Content/Compounds/Targeted/MAK683/Sarcoma",
    "Content/Compounds/Targeted/MAK683/Sarcoma/*",
    "Content/Compounds/Targeted/MAK683/Sarcoma/*/*",
    "Content/Compounds/Targeted/MAK683/Sarcoma/*/*/NCT02900651",
    "Content/Compounds/Targeted/Nazartinib",
    "Content/Compounds/Targeted/Nazartinib/Breast",
    "Content/Compounds/Targeted/Nazartinib/Breast/Spartalizumab",
    "Content/Compounds/Targeted/Nazartinib/Breast/Spartalizumab/TNBC",
    "Content/Compounds/Targeted/Nazartinib/Breast/Spartalizumab/TNBC/NCT02900664",
    "Content/Compounds/Targeted/Nazartinib/Colorectal",
    "Content/Compounds/Targeted/Nazartinib/Colorectal/Spartalizumab",
    "Content/Compounds/Targeted/Nazartinib/Colorectal/Spartalizumab/*",
    "Content/Compounds/Targeted/Nazartinib/Colorectal/Spartalizumab/*/NCT02900664",
    "Content/Compounds/Targeted/Nazartinib/Lung",
    "Content/Compounds/Targeted/Nazartinib/Lung/Ribociclib",
    "Content/Compounds/Targeted/Nazartinib/Lung/Ribociclib/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/Ribociclib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Nazartinib/Lung/Gefitinib",
    "Content/Compounds/Targeted/Nazartinib/Lung/Gefitinib/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/Gefitinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Nazartinib/Lung/Trametinib",
    "Content/Compounds/Targeted/Nazartinib/Lung/Trametinib/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/Trametinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib",
    "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Nazartinib/Lung/Capmatinib/NSCLC/NCT02335944",
    "Content/Compounds/Targeted/Nazartinib/Lung/Nivolumab",
    "Content/Compounds/Targeted/Nazartinib/Lung/Nivolumab/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/Nivolumab/NSCLC/NCT02323126",
    "Content/Compounds/Targeted/Nazartinib/Lung/LXH254",
    "Content/Compounds/Targeted/Nazartinib/Lung/LXH254/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/LXH254/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Nazartinib/Lung/Spartalizumab",
    "Content/Compounds/Targeted/Nazartinib/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/Nazartinib/Lung/Spartalizumab/NSCLC/NCT02900664",
    "Content/Compounds/Targeted/LTT462",
    "Content/Compounds/Targeted/LTT462/Lung",
    "Content/Compounds/Targeted/LTT462/Lung/LXH254",
    "Content/Compounds/Targeted/LTT462/Lung/LXH254/NSCLC",
    "Content/Compounds/Targeted/LTT462/Lung/LXH254/NSCLC/NCT02974725",
    "Content/Compounds/Targeted/HDM201",
    "Content/Compounds/Targeted/HDM201/ALL",
    "Content/Compounds/Targeted/HDM201/ALL/*",
    "Content/Compounds/Targeted/HDM201/ALL/*/*",
    "Content/Compounds/Targeted/HDM201/ALL/*/*/NCT02143635",
    "Content/Compounds/Targeted/HDM201/AML",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/FLT3m-",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/FLT3m-/NCT03760445",
    "Content/Compounds/Targeted/HDM201/AML/Midostaurin",
    "Content/Compounds/Targeted/HDM201/AML/Midostaurin/FLT3m+",
    "Content/Compounds/Targeted/HDM201/AML/Midostaurin/FLT3m+/NCT03760445",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine/r#r",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine/r#r/NCT03760445",
    "Content/Compounds/Targeted/HDM201/AML/*",
    "Content/Compounds/Targeted/HDM201/AML/*/*",
    "Content/Compounds/Targeted/HDM201/AML/*/*/NCT02143635",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/*",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Anthracycline/*/NCT03760445",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Daunorubicin",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Daunorubicin/*",
    "Content/Compounds/Targeted/HDM201/AML/Cytarabine # Daunorubicin/*/NCT03760445",
    "Content/Compounds/Targeted/HDM201/AML/MBG453",
    "Content/Compounds/Targeted/HDM201/AML/MBG453/*",
    "Content/Compounds/Targeted/HDM201/AML/MBG453/*/NCT03940352",
    "Content/Compounds/Targeted/HDM201/AML/Venetoclax",
    "Content/Compounds/Targeted/HDM201/AML/Venetoclax/*",
    "Content/Compounds/Targeted/HDM201/AML/Venetoclax/*/NCT03940352",
    "Content/Compounds/Targeted/HDM201/MDS High Risk",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/*",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/*/*",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/*/*/NCT02143635",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/MBG453",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/MBG453/*",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/MBG453/*/NCT03940352",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/Venetoclax",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/Venetoclax/*",
    "Content/Compounds/Targeted/HDM201/MDS High Risk/Venetoclax/*/NCT03940352",
    "Content/Compounds/Targeted/HDM201/Colorectal",
    "Content/Compounds/Targeted/HDM201/Colorectal/Spartalizumab",
    "Content/Compounds/Targeted/HDM201/Colorectal/Spartalizumab/*",
    "Content/Compounds/Targeted/HDM201/Colorectal/Spartalizumab/*/NCT02890069",
    "Content/Compounds/Targeted/HDM201/Renal",
    "Content/Compounds/Targeted/HDM201/Renal/Spartalizumab",
    "Content/Compounds/Targeted/HDM201/Renal/Spartalizumab/RCC",
    "Content/Compounds/Targeted/HDM201/Renal/Spartalizumab/RCC/NCT02890069",
    "Content/Compounds/Targeted/HDM201/Solid Tumors",
    "Content/Compounds/Targeted/HDM201/Solid Tumors/*",
    "Content/Compounds/Targeted/HDM201/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/Targeted/HDM201/Solid Tumors/*/Advanced Solid Tumors/NCT02143635",
    "Content/Compounds/Targeted/NJH395",
    "Content/Compounds/Targeted/NJH395/Solid Tumors",
    "Content/Compounds/Targeted/NJH395/Solid Tumors/*",
    "Content/Compounds/Targeted/NJH395/Solid Tumors/*/Non-Breast HER2+",
    "Content/Compounds/Targeted/NJH395/Solid Tumors/*/Non-Breast HER2+/NCT03696771",
    "Content/Compounds/Targeted/DKY709",
    "Content/Compounds/Targeted/DKY709/Breast",
    "Content/Compounds/Targeted/DKY709/Breast/*",
    "Content/Compounds/Targeted/DKY709/Breast/*/TNBC",
    "Content/Compounds/Targeted/DKY709/Breast/*/TNBC/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Breast/Spartalizumab",
    "Content/Compounds/Targeted/DKY709/Breast/Spartalizumab/TNBC",
    "Content/Compounds/Targeted/DKY709/Breast/Spartalizumab/TNBC/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Colorectal",
    "Content/Compounds/Targeted/DKY709/Colorectal/*",
    "Content/Compounds/Targeted/DKY709/Colorectal/*/MSS",
    "Content/Compounds/Targeted/DKY709/Colorectal/*/MSS/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Colorectal/Spartalizumab",
    "Content/Compounds/Targeted/DKY709/Colorectal/Spartalizumab/MSS",
    "Content/Compounds/Targeted/DKY709/Colorectal/Spartalizumab/MSS/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Head and Neck",
    "Content/Compounds/Targeted/DKY709/Head and Neck/*",
    "Content/Compounds/Targeted/DKY709/Head and Neck/*/NPC",
    "Content/Compounds/Targeted/DKY709/Head and Neck/*/NPC/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Head and Neck/Spartalizumab",
    "Content/Compounds/Targeted/DKY709/Head and Neck/Spartalizumab/NPC",
    "Content/Compounds/Targeted/DKY709/Head and Neck/Spartalizumab/NPC/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Lung",
    "Content/Compounds/Targeted/DKY709/Lung/*",
    "Content/Compounds/Targeted/DKY709/Lung/*/NSCLC",
    "Content/Compounds/Targeted/DKY709/Lung/*/NSCLC/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Lung/Spartalizumab",
    "Content/Compounds/Targeted/DKY709/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/DKY709/Lung/Spartalizumab/NSCLC/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Melanoma",
    "Content/Compounds/Targeted/DKY709/Melanoma/*",
    "Content/Compounds/Targeted/DKY709/Melanoma/*/*",
    "Content/Compounds/Targeted/DKY709/Melanoma/*/*/NCT03891953",
    "Content/Compounds/Targeted/DKY709/Melanoma/Spartalizumab",
    "Content/Compounds/Targeted/DKY709/Melanoma/Spartalizumab/*",
    "Content/Compounds/Targeted/DKY709/Melanoma/Spartalizumab/*/NCT03891953",
    "Content/Compounds/Targeted/MIK665",
    "Content/Compounds/Targeted/MIK665/Lymphoma",
    "Content/Compounds/Targeted/MIK665/Lymphoma/*",
    "Content/Compounds/Targeted/MIK665/Lymphoma/*/*",
    "Content/Compounds/Targeted/MIK665/Lymphoma/*/*/NCT02992483",
    "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma",
    "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma/*",
    "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma/*/DLBCL",
    "Content/Compounds/Targeted/MIK665/Non-Hodgkin Lymphoma/*/DLBCL/NCT02992483",
    "Content/Compounds/Targeted/MIK665/Multiple Myeloma",
    "Content/Compounds/Targeted/MIK665/Multiple Myeloma/*",
    "Content/Compounds/Targeted/MIK665/Multiple Myeloma/*/*",
    "Content/Compounds/Targeted/MIK665/Multiple Myeloma/*/*/NCT02992483",
    "Content/Compounds/Targeted/Trametinib",
    "Content/Compounds/Targeted/Trametinib/Brain",
    "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib",
    "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Glioma (high and low risk)",
    "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Glioma (high and low risk)/NCT02684058",
    "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Neurofibroma",
    "Content/Compounds/Targeted/Trametinib/Brain/Dabrafenib/Neurofibroma/NCT02124772",
    "Content/Compounds/Targeted/Trametinib/Breast",
    "Content/Compounds/Targeted/Trametinib/Breast/Spartalizumab",
    "Content/Compounds/Targeted/Trametinib/Breast/Spartalizumab/TNBC",
    "Content/Compounds/Targeted/Trametinib/Breast/Spartalizumab/TNBC/NCT02900664",
    "Content/Compounds/Targeted/Trametinib/Colorectal",
    "Content/Compounds/Targeted/Trametinib/Colorectal/Ribociclib",
    "Content/Compounds/Targeted/Trametinib/Colorectal/Ribociclib/*",
    "Content/Compounds/Targeted/Trametinib/Colorectal/Ribociclib/*/NCT02703571",
    "Content/Compounds/Targeted/Trametinib/Colorectal/Spartalizumab",
    "Content/Compounds/Targeted/Trametinib/Colorectal/Spartalizumab/*",
    "Content/Compounds/Targeted/Trametinib/Colorectal/Spartalizumab/*/NCT02900664",
    "Content/Compounds/Targeted/Trametinib/Lung",
    "Content/Compounds/Targeted/Trametinib/Lung/Dabrafenib",
    "Content/Compounds/Targeted/Trametinib/Lung/Dabrafenib/NSCLC",
    "Content/Compounds/Targeted/Trametinib/Lung/Dabrafenib/NSCLC/NCT01336634",
    "Content/Compounds/Targeted/Trametinib/Lung/Nazartinib",
    "Content/Compounds/Targeted/Trametinib/Lung/Nazartinib/NSCLC",
    "Content/Compounds/Targeted/Trametinib/Lung/Nazartinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Trametinib/Lung/LXH254",
    "Content/Compounds/Targeted/Trametinib/Lung/LXH254/NSCLC",
    "Content/Compounds/Targeted/Trametinib/Lung/LXH254/NSCLC/NCT02974725",
    "Content/Compounds/Targeted/Trametinib/Lung/Spartalizumab",
    "Content/Compounds/Targeted/Trametinib/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/Trametinib/Lung/Spartalizumab/NSCLC/NCT02900664",
    "Content/Compounds/Targeted/Trametinib/Melanoma",
    "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib",
    "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib/*",
    "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib/*/NCT02083354",
    "Content/Compounds/Targeted/Trametinib/Melanoma/Dabrafenib/*/NCT03551626",
    "Content/Compounds/Targeted/Trametinib/Melanoma/LXH254",
    "Content/Compounds/Targeted/Trametinib/Melanoma/LXH254/*",
    "Content/Compounds/Targeted/Trametinib/Melanoma/LXH254/*/NCT02974725",
    "Content/Compounds/Targeted/Trametinib/Pancreatic",
    "Content/Compounds/Targeted/Trametinib/Pancreatic/Ribociclib",
    "Content/Compounds/Targeted/Trametinib/Pancreatic/Ribociclib/*",
    "Content/Compounds/Targeted/Trametinib/Pancreatic/Ribociclib/*/NCT02703571",
    "Content/Compounds/Targeted/Trametinib/Solid Tumors",
    "Content/Compounds/Targeted/Trametinib/Solid Tumors/Ribociclib",
    "Content/Compounds/Targeted/Trametinib/Solid Tumors/Ribociclib/Advanced Solid Tumors",
    "Content/Compounds/Targeted/Trametinib/Solid Tumors/Ribociclib/Advanced Solid Tumors/NCT02703571",
    "Content/Compounds/Targeted/Capmatinib",
    "Content/Compounds/Targeted/Capmatinib/Liver",
    "Content/Compounds/Targeted/Capmatinib/Liver/Spartalizumab",
    "Content/Compounds/Targeted/Capmatinib/Liver/Spartalizumab/HCC",
    "Content/Compounds/Targeted/Capmatinib/Liver/Spartalizumab/HCC/NCT02795429",
    "Content/Compounds/Targeted/Capmatinib/Lung",
    "Content/Compounds/Targeted/Capmatinib/Lung/*",
    "Content/Compounds/Targeted/Capmatinib/Lung/*/NSCLC",
    "Content/Compounds/Targeted/Capmatinib/Lung/*/NSCLC/NCT02276027",
    "Content/Compounds/Targeted/Capmatinib/Lung/*/NSCLC/NCT02414139",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib/NSCLC",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nazartinib/NSCLC/NCT02335944",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nivolumab",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nivolumab/NSCLC",
    "Content/Compounds/Targeted/Capmatinib/Lung/Nivolumab/NSCLC/NCT02323126",
    "Content/Compounds/Targeted/Capmatinib/Lung/Spartalizumab",
    "Content/Compounds/Targeted/Capmatinib/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/Capmatinib/Lung/Spartalizumab/NSCLC/NCT03647488",
    "Content/Compounds/Targeted/Capmatinib/Melanoma",
    "Content/Compounds/Targeted/Capmatinib/Melanoma/Spartalizumab",
    "Content/Compounds/Targeted/Capmatinib/Melanoma/Spartalizumab/*",
    "Content/Compounds/Targeted/Capmatinib/Melanoma/Spartalizumab/*/NCT03484923",
    "Content/Compounds/Targeted/Midostaurin",
    "Content/Compounds/Targeted/Midostaurin/AML",
    "Content/Compounds/Targeted/Midostaurin/AML/Chemo",
    "Content/Compounds/Targeted/Midostaurin/AML/Chemo/FLT3m+",
    "Content/Compounds/Targeted/Midostaurin/AML/Chemo/FLT3m+/NCT03591510",
    "Content/Compounds/Targeted/Midostaurin/AML/Chemo/FLT3m+/NCT03379727",
    "Content/Compounds/Targeted/Midostaurin/AML/Daunorubicin#Cytarabine",
    "Content/Compounds/Targeted/Midostaurin/AML/Daunorubicin#Cytarabine/FLT3m+",
    "Content/Compounds/Targeted/Midostaurin/AML/Daunorubicin#Cytarabine/FLT3m+/NCT03280030",
    "Content/Compounds/Targeted/Midostaurin/AML/HDM201",
    "Content/Compounds/Targeted/Midostaurin/AML/HDM201/FLT3m+",
    "Content/Compounds/Targeted/Midostaurin/AML/HDM201/FLT3m+/NCT03760445",
    "Content/Compounds/Targeted/Crizanlizumab",
    "Content/Compounds/Targeted/Crizanlizumab/MF",
    "Content/Compounds/Targeted/Crizanlizumab/MF/Ruxolitinib",
    "Content/Compounds/Targeted/Crizanlizumab/MF/Ruxolitinib/*",
    "Content/Compounds/Targeted/Crizanlizumab/MF/Ruxolitinib/*/NCT04097821",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/Priapism",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/Priapism/NCT03938454",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*/NCT03474965",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*/NCT04053764",
    "Content/Compounds/Targeted/Crizanlizumab/Sickle Cell Disease/*/*/NCT03814746",
    "Content/Compounds/Targeted/LXH254",
    "Content/Compounds/Targeted/LXH254/Gynecologic",
    "Content/Compounds/Targeted/LXH254/Gynecologic/*",
    "Content/Compounds/Targeted/LXH254/Gynecologic/*/Ovarian",
    "Content/Compounds/Targeted/LXH254/Gynecologic/*/Ovarian/NCT02607813",
    "Content/Compounds/Targeted/LXH254/Lung",
    "Content/Compounds/Targeted/LXH254/Lung/*",
    "Content/Compounds/Targeted/LXH254/Lung/*/NSCLC",
    "Content/Compounds/Targeted/LXH254/Lung/*/NSCLC/NCT02607813",
    "Content/Compounds/Targeted/LXH254/Lung/Nazartinib",
    "Content/Compounds/Targeted/LXH254/Lung/Nazartinib/NSCLC",
    "Content/Compounds/Targeted/LXH254/Lung/Nazartinib/NSCLC/NCT03333343",
    "Content/Compounds/Targeted/LXH254/Lung/LTT462",
    "Content/Compounds/Targeted/LXH254/Lung/LTT462/NSCLC",
    "Content/Compounds/Targeted/LXH254/Lung/LTT462/NSCLC/NCT02974725",
    "Content/Compounds/Targeted/LXH254/Lung/Trametinib",
    "Content/Compounds/Targeted/LXH254/Lung/Trametinib/NSCLC",
    "Content/Compounds/Targeted/LXH254/Lung/Trametinib/NSCLC/NCT02974725",
    "Content/Compounds/Targeted/LXH254/Lung/Spartalizumab",
    "Content/Compounds/Targeted/LXH254/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/LXH254/Lung/Spartalizumab/NSCLC/NCT02607813",
    "Content/Compounds/Targeted/LXH254/Melanoma",
    "Content/Compounds/Targeted/LXH254/Melanoma/*",
    "Content/Compounds/Targeted/LXH254/Melanoma/*/*",
    "Content/Compounds/Targeted/LXH254/Melanoma/*/*/NCT02607813",
    "Content/Compounds/Targeted/LXH254/Melanoma/Ribociclib",
    "Content/Compounds/Targeted/LXH254/Melanoma/Ribociclib/*",
    "Content/Compounds/Targeted/LXH254/Melanoma/Ribociclib/*/NCT02974725",
    "Content/Compounds/Targeted/LXH254/Melanoma/Trametinib",
    "Content/Compounds/Targeted/LXH254/Melanoma/Trametinib/*",
    "Content/Compounds/Targeted/LXH254/Melanoma/Trametinib/*/NCT02974725",
    "Content/Compounds/Targeted/LXH254/Melanoma/Spartalizumab",
    "Content/Compounds/Targeted/LXH254/Melanoma/Spartalizumab/*",
    "Content/Compounds/Targeted/LXH254/Melanoma/Spartalizumab/*/NCT02607813",
    "Content/Compounds/Targeted/Alpelisib",
    "Content/Compounds/Targeted/Alpelisib/Breast",
    "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant",
    "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-",
    "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT01219699",
    "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT03056755",
    "Content/Compounds/Targeted/Alpelisib/Breast/Fulvestrant/HR+#HER2-/NCT02437318",
    "Content/Compounds/Targeted/Alpelisib/Breast/Letrozole",
    "Content/Compounds/Targeted/Alpelisib/Breast/Letrozole/HR+#HER2-",
    "Content/Compounds/Targeted/Alpelisib/Breast/Letrozole/HR+#HER2-/NCT03056755",
    "Content/Compounds/Targeted/Alpelisib/Breast/LSZ102",
    "Content/Compounds/Targeted/Alpelisib/Breast/LSZ102/HR+#HER2-",
    "Content/Compounds/Targeted/Alpelisib/Breast/LSZ102/HR+#HER2-/NCT02734615",
    "Content/Compounds/Targeted/Alpelisib/Lung",
    "Content/Compounds/Targeted/Alpelisib/Lung/*",
    "Content/Compounds/Targeted/Alpelisib/Lung/*/NSCLC",
    "Content/Compounds/Targeted/Alpelisib/Lung/*/NSCLC/NCT02276027",
    "Content/Compounds/Targeted/Alpelisib/Solid Tumors",
    "Content/Compounds/Targeted/Alpelisib/Solid Tumors/*",
    "Content/Compounds/Targeted/Alpelisib/Solid Tumors/*/Advanced Solid Tumors",
    "Content/Compounds/Targeted/Alpelisib/Solid Tumors/*/Advanced Solid Tumors/NCT01219699",
    "Content/Compounds/Targeted/WNT974",
    "Content/Compounds/Targeted/WNT974/Breast",
    "Content/Compounds/Targeted/WNT974/Breast/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Breast/Spartalizumab/TNBC",
    "Content/Compounds/Targeted/WNT974/Breast/Spartalizumab/TNBC/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Colorectal",
    "Content/Compounds/Targeted/WNT974/Colorectal/*",
    "Content/Compounds/Targeted/WNT974/Colorectal/*/*",
    "Content/Compounds/Targeted/WNT974/Colorectal/*/*/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Gastrointestinal",
    "Content/Compounds/Targeted/WNT974/Gastrointestinal/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Gastrointestinal/Spartalizumab/Esophageal",
    "Content/Compounds/Targeted/WNT974/Gastrointestinal/Spartalizumab/Esophageal/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Gynecologic",
    "Content/Compounds/Targeted/WNT974/Gynecologic/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Gynecologic/Spartalizumab/Cervical",
    "Content/Compounds/Targeted/WNT974/Gynecologic/Spartalizumab/Cervical/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Head and Neck",
    "Content/Compounds/Targeted/WNT974/Head and Neck/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Head and Neck/Spartalizumab/*",
    "Content/Compounds/Targeted/WNT974/Head and Neck/Spartalizumab/*/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Lung",
    "Content/Compounds/Targeted/WNT974/Lung/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/WNT974/Lung/Spartalizumab/NSCLC/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Melanoma",
    "Content/Compounds/Targeted/WNT974/Melanoma/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Melanoma/Spartalizumab/*",
    "Content/Compounds/Targeted/WNT974/Melanoma/Spartalizumab/*/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Pancreatic",
    "Content/Compounds/Targeted/WNT974/Pancreatic/*",
    "Content/Compounds/Targeted/WNT974/Pancreatic/*/*",
    "Content/Compounds/Targeted/WNT974/Pancreatic/*/*/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Pancreatic/Spartalizumab",
    "Content/Compounds/Targeted/WNT974/Pancreatic/Spartalizumab/*",
    "Content/Compounds/Targeted/WNT974/Pancreatic/Spartalizumab/*/NCT01351103",
    "Content/Compounds/Targeted/WNT974/Solid Tumors",
    "Content/Compounds/Targeted/WNT974/Solid Tumors/*",
    "Content/Compounds/Targeted/WNT974/Solid Tumors/*/Wnt Pathway Tumors",
    "Content/Compounds/Targeted/WNT974/Solid Tumors/*/Wnt Pathway Tumors/NCT01351103",
    "Content/Compounds/Targeted/LSZ102",
    "Content/Compounds/Targeted/LSZ102/Breast",
    "Content/Compounds/Targeted/LSZ102/Breast/*",
    "Content/Compounds/Targeted/LSZ102/Breast/*/HR+#HER2-",
    "Content/Compounds/Targeted/LSZ102/Breast/*/HR+#HER2-/NCT02734615",
    "Content/Compounds/Targeted/LSZ102/Breast/Ribociclib",
    "Content/Compounds/Targeted/LSZ102/Breast/Ribociclib/HR+#HER2-",
    "Content/Compounds/Targeted/LSZ102/Breast/Ribociclib/HR+#HER2-/NCT02734615",
    "Content/Compounds/Targeted/LSZ102/Breast/Alpelisib",
    "Content/Compounds/Targeted/LSZ102/Breast/Alpelisib/HR+#HER2-",
    "Content/Compounds/Targeted/LSZ102/Breast/Alpelisib/HR+#HER2-/NCT02734615",
    "Content/Compounds/Targeted/TNO155",
    "Content/Compounds/Targeted/TNO155/Colorectal",
    "Content/Compounds/Targeted/TNO155/Colorectal/*",
    "Content/Compounds/Targeted/TNO155/Colorectal/*/*",
    "Content/Compounds/Targeted/TNO155/Colorectal/*/*/NCT03114319",
    "Content/Compounds/Targeted/TNO155/Colorectal/Ribociclib",
    "Content/Compounds/Targeted/TNO155/Colorectal/Ribociclib/*",
    "Content/Compounds/Targeted/TNO155/Colorectal/Ribociclib/*/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Colorectal/Spartalizumab",
    "Content/Compounds/Targeted/TNO155/Colorectal/Spartalizumab/*",
    "Content/Compounds/Targeted/TNO155/Colorectal/Spartalizumab/*/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/*",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/*/Esophageal",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/*/Esophageal/NCT03114319",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/Esophageal",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/Esophageal/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Spartalizumab",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Spartalizumab/Esophageal",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Spartalizumab/Esophageal/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/GIST",
    "Content/Compounds/Targeted/TNO155/Gastrointestinal/Ribociclib/GIST/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Head and Neck",
    "Content/Compounds/Targeted/TNO155/Head and Neck/*",
    "Content/Compounds/Targeted/TNO155/Head and Neck/*/*",
    "Content/Compounds/Targeted/TNO155/Head and Neck/*/*/NCT03114319",
    "Content/Compounds/Targeted/TNO155/Head and Neck/Ribociclib",
    "Content/Compounds/Targeted/TNO155/Head and Neck/Ribociclib/*",
    "Content/Compounds/Targeted/TNO155/Head and Neck/Ribociclib/*/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Head and Neck/Spartalizumab",
    "Content/Compounds/Targeted/TNO155/Head and Neck/Spartalizumab/*",
    "Content/Compounds/Targeted/TNO155/Head and Neck/Spartalizumab/*/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Lung",
    "Content/Compounds/Targeted/TNO155/Lung/*",
    "Content/Compounds/Targeted/TNO155/Lung/*/NSCLC",
    "Content/Compounds/Targeted/TNO155/Lung/*/NSCLC/NCT03114319",
    "Content/Compounds/Targeted/TNO155/Lung/Ribociclib",
    "Content/Compounds/Targeted/TNO155/Lung/Ribociclib/NSCLC",
    "Content/Compounds/Targeted/TNO155/Lung/Ribociclib/NSCLC/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab",
    "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab/NSCLC",
    "Content/Compounds/Targeted/TNO155/Lung/Spartalizumab/NSCLC/NCT04000529",
    "Content/Compounds/Targeted/TNO155/Solid Tumors",
    "Content/Compounds/Targeted/TNO155/Solid Tumors/*",
    "Content/Compounds/Targeted/TNO155/Solid Tumors/*/RAS#RAF wild-type",
    "Content/Compounds/Targeted/TNO155/Solid Tumors/*/RAS#RAF wild-type/NCT03114319",
    "Content/Compounds/Targeted/Eltrombopag",
    "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura",
    "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura/*",
    "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura/*/*",
    "Content/Compounds/Targeted/Eltrombopag/Immune Thrombocytopenic Purpura/*/*/NCT03524612",
    "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia",
    "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia/*",
    "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia/*/*",
    "Content/Compounds/Targeted/Eltrombopag/Severe Aplastic Anemia/*/*/NCT03025698"
  ],
  "cohorts": {
    "<b>SERD</b> (LSZ102<sup>1</sup>) + <b>PI3Kα</b> (Alpelisib)": {
      "cards": [
        {
          "file": "LSZ102.png",
          "label": "SERD",
          "compound": "LSZ102"
        },
        {
          "file": "Alpelisib.png",
          "label": "PI3Kα",
          "compound": "Alpelisib"
        }
      ],
      "moas": ["LSZ102.png", "Alpelisib.png"]
    },
    "<b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Docetaxel</i>": {
      "cards": [
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Canakinumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>HDM2-p53</b> (HDM201)": {
      "cards": [
        {
          "file": "Spartalizumab-HDM201.png",
          "label": "PD-1 + HDM2-p53",
          "compound": "Spartalizumab-HDM201"
        }
      ],
      "moas": ["Spartalizumab-HDM201.png"]
    },
    "<b>Porcupine</b> (WNT974<sup>29</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "Porcupine",
          "compound": "WNT974"
        }
      ]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>STING</b> (MIW815<sup>16</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "MIW815.png",
          "label": "STING",
          "compound": "MIW815"
        }
      ],
      "moas": ["Spartalizumab.png", "MIW815.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Decitabine</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>STING</b> (MIW815<sup>16</sup>) + <i>Ipilimumab</i>": {
      "cards": [
        {
          "file": "MIW815.png",
          "label": "STING",
          "compound": "MIW815"
        }
      ],
      "moas": ["MIW815.png"]
    },
    "<b>pan-RAF</b> (LXH254) + <b>ERK</b> (LTT462)": {
      "cards": [
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": "LXH254"
        },
        {
          "file": "LTT462.png",
          "label": "pan-RAF + ERK",
          "compound": "LTT462"
        }
      ],
      "moas": ["LXH254.png", "LTT462.png"]
    },
    "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>)": {
      "cards": [
        {
          "file": "Crizanlizumab.png",
          "label": "P-selectin",
          "compound": "Crizanlizumab"
        }
      ],
      "moas": ["Crizanlizumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>EGFR</b> (Nazartinib<sup>17</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        }
      ],
      "moas": ["Spartalizumab.png", "Nazartinib.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453)": {
      "cards": [
        {
          "file": "Spartalizumab-MBG453.png",
          "label": "PD-1 + TIM-3",
          "compound": "Spartalizumab-MBG453"
        }
      ],
      "moas": ["Spartalizumab-MBG453.png"]
    },
    "<b>TIM-3</b> (MBG453) + <i>Decitabine</i>": {
      "cards": [
        {
          "file": "MBG453.png",
          "label": "TIM-3",
          "compound": "MBG453"
        }
      ],
      "moas": ["MBG453.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        }
      ],
      "moas": ["Spartalizumab.png", "LAG525.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1R</b> (BLZ945)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "BLZ945.png",
          "label": "CSF-1R",
          "compound": "BLZ945"
        }
      ],
      "moas": ["Spartalizumab.png", "BLZ945.png"]
    },
    "<b>CAR-T CD19</b> (YTB323) + <i>Ibrutinib</i>": {
      "cards": [
        {
          "file": "",
          "label": "CAR-T CD19",
          "compound": "YTB323"
        }
      ]
    },
    "<b>BRAF</b> (Dabrafenib<sup>7</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "BRAF",
          "compound": "Dabrafenib"
        }
      ]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Ruxolitinib</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole</i><sup>13</sup>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": ""
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>pan-RAF</b> (LXH254)": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        },
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": "LXH254"
        }
      ],
      "moas": ["Nazartinib.png", "LXH254.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>4</sup>) + <b>MET</b> (Capmatinib)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        },
        {
          "file": "Capmatinib.png",
          "label": "MET",
          "compound": "Capmatinib"
        }
      ],
      "moas": ["Spartalizumab.png", "LAG525.png", "Capmatinib.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>pan-RAF</b> (LXH254)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": "LXH254"
        }
      ],
      "moas": ["Spartalizumab.png", "LXH254.png"]
    },
    "<b>pan-PIM</b> (PIM447) + <i>Ruxolitinib</i>": {
      "cards": [
        {
          "file": "",
          "label": "pan-PIM",
          "compound": "PIM447"
        }
      ]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "",
          "label": "BRAF",
          "compound": "Dabrafenib"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>) + <i>Ibrutinib</i>": {
      "cards": [
        {
          "file": "Tisagenlecleucel.png",
          "label": "CAR-T CD19",
          "compound": "Tisagenlecleucel"
        }
      ],
      "moas": ["Tisagenlecleucel.png"]
    },
    "<b>MCL1</b> (MIK665<sup>15</sup>)": {
      "cards": [
        {
          "file": "MIK665.png",
          "label": "MCL1",
          "compound": "MIK665"
        }
      ],
      "moas": ["MIK665.png"]
    },
    "<b>MET</b> (Capmatinib<sup>4</sup>) + <i>Nivolumab</i>": {
      "cards": [
        {
          "file": "Capmatinib.png",
          "label": "MET",
          "compound": "Capmatinib"
        }
      ],
      "moas": ["Capmatinib.png"]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Everolimus</i><sup>9</sup> + <i>Exemestane</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>P-selectin</b> (Crizanlizumab<sup>5</sup>) + <i>Ruxolitinib</i>": {
      "cards": [
        {
          "file": "Crizanlizumab.png",
          "label": "P-selectin",
          "compound": "Crizanlizumab"
        }
      ],
      "moas": ["Crizanlizumab.png"]
    },
    "<b>SERD</b> (LSZ102<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)": {
      "cards": [
        {
          "file": "LSZ102.png",
          "label": "SERD",
          "compound": "LSZ102"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ],
      "moas": ["LSZ102.png"]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        }
      ],
      "moas": ["Nazartinib.png"]
    },
    "<b>SHP2</b> (TNO155)": {
      "cards": [
        {
          "file": "TNO155.png",
          "label": "SHP2",
          "compound": "TNO155"
        }
      ],
      "moas": ["TNO155.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>HDM2-p53</b> (HDM201<sup>14</sup>) + <b>Multikinase</b> (Midostaurin) + <i>Cytarabine / Anthracycline</i>": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        },
        {
          "file": "",
          "label": "Multikinase",
          "compound": "Midostaurin"
        }
      ],
      "moas": ["HDM201.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CD73</b> (NZV930<sup>22</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "NZV930.png",
          "label": "CD73",
          "compound": "NZV930"
        }
      ],
      "moas": ["Spartalizumab.png", "NZV930.png"]
    },
    "<b>ERK</b> (LTT462)": {
      "cards": [
        {
          "file": "LTT462.png",
          "label": "pan-RAF + ERK",
          "compound": "LTT462"
        },
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": ""
        }
      ],
      "moas": ["LTT462.png", "LXH254.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-15</b> (NIZ985<sup>21</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "NIZ985.png",
          "label": "IL-15",
          "compound": "NIZ985"
        }
      ],
      "moas": ["Spartalizumab.png", "NIZ985.png"]
    },
    "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Cabozantinib</i>": {
      "cards": [
        {
          "file": "",
          "label": "IL-1β",
          "compound": "Gevokizumab"
        }
      ]
    },
    "<b>CXCR2</b> (QBM076)": {
      "cards": [
        {
          "file": "",
          "label": "CXCR2",
          "compound": "QBM076"
        },
        {
          "file": "",
          "label": "PD-1",
          "compound": ""
        }
      ],
      "moas": [""]
    },
    "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine</i>": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        }
      ],
      "moas": ["HDM201.png"]
    },
    "<b>CD123 x CD3</b> (SQZ622<sup>26</sup>)": {
      "cards": [
        {
          "file": "SQZ622.png",
          "label": "CD123 x CD3",
          "compound": "SQZ622"
        }
      ],
      "moas": ["SQZ622.png"]
    },
    "<b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Pembrolizumab</i>": {
      "cards": [
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Canakinumab.png"]
    },
    "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Paciltaxel</i> + <i>Ramucirumab</i>": {
      "cards": [
        {
          "file": "",
          "label": "IL-1β",
          "compound": "Gevokizumab"
        }
      ]
    },
    "<b>BAFF-R</b> (VAY736)": {
      "cards": [
        {
          "file": "VAY736.png",
          "label": "BAFF-R",
          "compound": "VAY736"
        }
      ],
      "moas": ["VAY736.png"]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Fulvestrant</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine / Anthracycline</i>": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        }
      ],
      "moas": ["HDM201.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>Porcupine</b> (WNT974<sup>29</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "",
          "label": "Porcupine",
          "compound": "WNT974"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>)": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        },
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": ""
        }
      ],
      "moas": ["Nazartinib.png", "Spartalizumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>TPO receptor</b> (Eltrombopag<sup>8</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "TPO receptor",
          "compound": "Eltrombopag"
        }
      ]
    },
    "<b>TIM-3</b> (MBG453)": {
      "cards": [
        {
          "file": "MBG453.png",
          "label": "TIM-3",
          "compound": "MBG453"
        }
      ],
      "moas": ["MBG453.png"]
    },
    "<b>LAG-3</b> (LAG525)": {
      "cards": [
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        }
      ],
      "moas": ["LAG525.png"]
    },
    "<b>TGF-β</b> (NIS793<sup>20</sup>)": {
      "cards": [
        {
          "file": "NIS793.png",
          "label": "TGF-β",
          "compound": "NIS793"
        }
      ],
      "moas": ["NIS793.png"]
    },
    "<b>EED</b> (MAK683)": {
      "cards": [
        {
          "file": "MAK683.png",
          "label": "EED",
          "compound": "MAK683"
        }
      ],
      "moas": ["MAK683.png"]
    },
    "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Bevacizumab</i> + <i>FOLFIRI</i>": {
      "cards": [
        {
          "file": "",
          "label": "IL-1β",
          "compound": "Gevokizumab"
        }
      ]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        },
        {
          "file": "Capmatinib.png",
          "label": "MET",
          "compound": "Capmatinib"
        }
      ],
      "moas": ["Nazartinib.png", "Capmatinib.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>MET</b> (Capmatinib<sup>4</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "Capmatinib.png",
          "label": "MET",
          "compound": "Capmatinib"
        }
      ],
      "moas": ["Spartalizumab.png", "Capmatinib.png"]
    },
    "<b>HDM2-p53</b> (HDM201) + <b>TIM-3</b> (MBG453)": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        },
        {
          "file": "MBG453.png",
          "label": "TIM-3",
          "compound": "MBG453"
        }
      ],
      "moas": ["HDM201.png", "MBG453.png"]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Endocrine therapy</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>pan-RAF</b> (LXH254)": {
      "cards": [
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": "LXH254"
        }
      ],
      "moas": ["LXH254.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IKZF2</b> (DKY709)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "",
          "label": "IKZF2",
          "compound": "DKY709"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        }
      ]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>1L-17A</b> (CJM112)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>BRAF</b> (Dabrafenib<sup>7</sup>) + <b>MEK</b> (Trametinib<sup>28</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "BRAF",
          "compound": "Dabrafenib"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        }
      ]
    },
    "<b>IL-1β</b> (Gevokizumab<sup>10</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "IL-1β",
          "compound": "Gevokizumab"
        }
      ]
    },
    "<b>Multikinase</b> (Midostaurin<sup>14</sup>) + <i>Daunorubicin/Cytarabine</i>": {
      "cards": [
        {
          "file": "",
          "label": "Multikinase",
          "compound": "Midostaurin"
        }
      ]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Paciltaxel / Carboplatin</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Letrozole</i><sup>13</sup>": {
      "cards": [
        {
          "file": "Alpelisib.png",
          "label": "PI3Kα",
          "compound": "Alpelisib"
        }
      ],
      "moas": ["Alpelisib.png"]
    },
    "<b>TIM-3</b> (MBG453) + <i>Decitabine / Azacitidine</i>": {
      "cards": [
        {
          "file": "MBG453.png",
          "label": "TIM-3",
          "compound": "MBG453"
        }
      ],
      "moas": ["MBG453.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Gemcitabine / Cisplatin</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Nilotinib</i><sup>18</sup>": {
      "cards": [
        {
          "file": "Asciminib.png",
          "label": "BCR-ABL",
          "compound": "Asciminib"
        }
      ],
      "moas": ["Asciminib.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>SHP2</b> (TNO155)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "TNO155.png",
          "label": "SHP2",
          "compound": "TNO155"
        }
      ],
      "moas": ["Spartalizumab.png", "TNO155.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IAP</b> (LCL161)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>) + <b>CD73</b> (NZV930<sup>22</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "NIR178.png",
          "label": "A2AR",
          "compound": "NIR178"
        },
        {
          "file": "NZV930.png",
          "label": "CD73",
          "compound": "NZV930"
        }
      ],
      "moas": ["Spartalizumab.png", "NIR178.png", "NZV930.png"]
    },
    "<b>PI3Kα</b> (Alpelisib<sup>1</sup>)": {
      "cards": [
        {
          "file": "Alpelisib.png",
          "label": "PI3Kα",
          "compound": "Alpelisib"
        }
      ],
      "moas": ["Alpelisib.png"]
    },
    "<b>IL-1β</b> (Canakinumab<sup>3</sup>)": {
      "cards": [
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Canakinumab.png"]
    },
    "<b>CD73</b> (NZV930<sup>22</sup>)": {
      "cards": [
        {
          "file": "NZV930.png",
          "label": "CD73",
          "compound": "NZV930"
        }
      ],
      "moas": ["NZV930.png"]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <i>Gefitinib</i>": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        }
      ],
      "moas": ["Nazartinib.png"]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <i>Nivolumab</i>": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        }
      ],
      "moas": ["Nazartinib.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Panobinostat</i><sup>23</sup>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>pan-PIM</b> (PIM447<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib) + <i>Ruxolitinib</i>": {
      "cards": [
        {
          "file": "",
          "label": "pan-PIM",
          "compound": "PIM447"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>TLR7</b> (LHC165)": {
      "cards": [
        {
          "file": "LHC165.png",
          "label": "TLR7",
          "compound": "LHC165"
        }
      ],
      "moas": ["LHC165.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab-NIR178.png",
          "label": "PD-1 + Adenosine 2A receptor",
          "compound": "Spartalizumab-NIR178"
        }
      ],
      "moas": ["Spartalizumab-NIR178.png"]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Letrozole or Anastrazole</i> + <i>Goserlin</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Pembrolizumab</i> + <i>Platinum-based doublet chemotherapy</i>": {
      "cards": [
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Canakinumab.png"]
    },
    "<b>LAG-3</b> (LAG525) + <i>Carboplatin</i>": {
      "cards": [
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        }
      ],
      "moas": ["LAG525.png"]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Exemestane</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)": {
      "cards": [
        {
          "file": "Lacnotuzumab.png",
          "label": "CSF-1",
          "compound": "Lacnotuzumab"
        },
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": ""
        }
      ],
      "moas": ["Lacnotuzumab.png", "Spartalizumab.png"]
    },
    "<b>HDM2-p53</b> (HDM201)": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        }
      ],
      "moas": ["HDM201.png"]
    },
    "<b>STING</b> (MIW815<sup>16</sup>)": {
      "cards": [
        {
          "file": "MIW815.png",
          "label": "STING",
          "compound": "MIW815"
        }
      ],
      "moas": ["MIW815.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TGF-β</b> (NIS793<sup>20</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "NIS793.png",
          "label": "TGF-β",
          "compound": "NIS793"
        }
      ],
      "moas": ["Spartalizumab.png", "NIS793.png"]
    },
    "<b>SERD</b> (LSZ102)": {
      "cards": [
        {
          "file": "LSZ102.png",
          "label": "SERD",
          "compound": "LSZ102"
        }
      ],
      "moas": ["LSZ102.png"]
    },
    "<b>Multikinase</b> (Midostaurin<sup>14</sup>) + <i>Chemo</i>": {
      "cards": [
        {
          "file": "",
          "label": "Multikinase",
          "compound": "Midostaurin"
        }
      ]
    },
    "<b>Multikinase</b> (Midostaurin<sup>14</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "Multikinase",
          "compound": "Midostaurin"
        },
        {
          "file": "",
          "label": "HDM2-p53",
          "compound": ""
        }
      ],
      "moas": [""]
    },
    "<b>CDK4/6</b> (Ribociclib<sup>24</sup>) + <i>Tamoxifen</i>": {
      "cards": [
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ]
    },
    "<b>MET</b> (Capmatinib<sup>4</sup>)": {
      "cards": [
        {
          "file": "Capmatinib.png",
          "label": "MET",
          "compound": "Capmatinib"
        }
      ],
      "moas": ["Capmatinib.png"]
    },
    "<b>IKZF2</b> (DKY709)": {
      "cards": [
        {
          "file": "",
          "label": "IKZF2",
          "compound": "DKY709"
        }
      ]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>12</sup>) + <b>CSF-1</b> (Lacnotuzumab)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        },
        {
          "file": "Lacnotuzumab.png",
          "label": "CSF-1",
          "compound": "Lacnotuzumab"
        }
      ],
      "moas": ["Spartalizumab.png", "LAG525.png", "Lacnotuzumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TIM-3</b> (MBG453) + <i>Decitabine</i>": {
      "cards": [
        {
          "file": "Spartalizumab-MBG453.png",
          "label": "PD-1 + TIM-3",
          "compound": "Spartalizumab-MBG453"
        }
      ],
      "moas": ["Spartalizumab-MBG453.png"]
    },
    "<b>CSF-1R</b> (BLZ945)": {
      "cards": [
        {
          "file": "BLZ945.png",
          "label": "CSF-1R",
          "compound": "BLZ945"
        }
      ],
      "moas": ["BLZ945.png"]
    },
    "<b>BAFF-R</b> (VAY736) + <i>Ibrutinib</i>": {
      "cards": [
        {
          "file": "VAY736.png",
          "label": "BAFF-R",
          "compound": "VAY736"
        }
      ],
      "moas": ["VAY736.png"]
    },
    "<b>SHP2</b> (TNO155<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)": {
      "cards": [
        {
          "file": "TNO155.png",
          "label": "SHP2",
          "compound": "TNO155"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ],
      "moas": ["TNO155.png"]
    },
    "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Dasatinib</i>": {
      "cards": [
        {
          "file": "Asciminib.png",
          "label": "BCR-ABL",
          "compound": "Asciminib"
        }
      ],
      "moas": ["Asciminib.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>3</sup>) + <b>IL-1β</b> (Canakinumab)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        },
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Spartalizumab.png", "LAG525.png", "Canakinumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525<sup>19</sup>) + <b>A2AR</b> (NIR178)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        },
        {
          "file": "NIR178.png",
          "label": "A2AR",
          "compound": "NIR178"
        }
      ],
      "moas": ["Spartalizumab.png", "LAG525.png", "NIR178.png"]
    },
    "<b>EGFR</b> (Nazartinib<sup>17</sup>) + <b>CDK4/6</b> (Ribociclib<sup>24</sup>)": {
      "cards": [
        {
          "file": "Nazartinib.png",
          "label": "EGFR",
          "compound": "Nazartinib"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ],
      "moas": ["Nazartinib.png"]
    },
    "<b>pan-RAF</b> (LXH254<sup>28</sup>) + <b>MEK</b> (Trametinib)": {
      "cards": [
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": "LXH254"
        },
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        }
      ],
      "moas": ["LXH254.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CDK4/6</b> (Ribociclib<sup>24</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>IL-1β</b> (Gevokizumab<sup>10</sup>) + <i>Bevacizumab</i> + <i>FOLFOX6</i>": {
      "cards": [
        {
          "file": "",
          "label": "IL-1β",
          "compound": "Gevokizumab"
        }
      ]
    },
    "<b>HER2-TLR7</b> (NJH395)": {
      "cards": [
        {
          "file": "NJH395.png",
          "label": "HER2-TLR7",
          "compound": "NJH395"
        }
      ],
      "moas": ["NJH395.png"]
    },
    "<b>CD73</b> (NZV930<sup>22</sup>) + <b>A2AR</b> (NIR178<sup>19</sup>)": {
      "cards": [
        {
          "file": "NZV930.png",
          "label": "CD73",
          "compound": "NZV930"
        },
        {
          "file": "NIR178.png",
          "label": "A2AR",
          "compound": "NIR178"
        }
      ],
      "moas": ["NZV930.png", "NIR178.png"]
    },
    "<b>BCR-ABL</b> (Asciminib<sup>2</sup>)": {
      "cards": [
        {
          "file": "Asciminib.png",
          "label": "BCR-ABL",
          "compound": "Asciminib"
        }
      ],
      "moas": ["Asciminib.png"]
    },
    "<b>HDM2-p53</b> (HDM201) + <i>Venetoclax</i>": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        }
      ],
      "moas": ["HDM201.png"]
    },
    "<b>TIM-3</b> (MBG453) + <i>Ruxolitinib</i>": {
      "cards": [
        {
          "file": "MBG453.png",
          "label": "TIM-3",
          "compound": "MBG453"
        }
      ],
      "moas": ["MBG453.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Spartalizumab.png", "Canakinumab.png"]
    },
    "<b>BCR-ABL</b> (Asciminib<sup>2</sup>) + <i>Imatinib</i><sup>11</sup>": {
      "cards": [
        {
          "file": "Asciminib.png",
          "label": "BCR-ABL",
          "compound": "Asciminib"
        }
      ],
      "moas": ["Asciminib.png"]
    },
    "<b>HDM2-p53</b> (HDM201) + <i>Cytarabine / Daunorubicin</i>": {
      "cards": [
        {
          "file": "HDM201.png",
          "label": "HDM2-p53",
          "compound": "HDM201"
        }
      ],
      "moas": ["HDM201.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Everolimus</i><sup>9</sup>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>IL-1β</b> (Canakinumab<sup>3</sup>) + <i>Pemetrexed / Cisplatin or Carboplatin</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "Canakinumab.png",
          "label": "IL-1β",
          "compound": "Canakinumab"
        }
      ],
      "moas": ["Spartalizumab.png", "Canakinumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Pemetrexed / Cisplatin</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>MEK</b> (Trametinib<sup>28</sup>)": {
      "cards": [
        {
          "file": "",
          "label": "MEK",
          "compound": "Trametinib"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": ""
        }
      ],
      "moas": ["LXH254.png"]
    },
    "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>)": {
      "cards": [
        {
          "file": "Tisagenlecleucel.png",
          "label": "CAR-T CD19",
          "compound": "Tisagenlecleucel"
        }
      ],
      "moas": ["Tisagenlecleucel.png"]
    },
    "<b>PI3Kα</b> (Alpelisib<sup>1</sup>) + <i>Fulvestrant</i>": {
      "cards": [
        {
          "file": "Alpelisib.png",
          "label": "PI3Kα",
          "compound": "Alpelisib"
        }
      ],
      "moas": ["Alpelisib.png"]
    },
    "<b>CAR-T CD19</b> (Tisagenlecleucel<sup>27</sup>) + <i>Pembrolizumab</i>": {
      "cards": [
        {
          "file": "Tisagenlecleucel.png",
          "label": "CAR-T CD19",
          "compound": "Tisagenlecleucel"
        }
      ],
      "moas": ["Tisagenlecleucel.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>TLR7</b> (LHC165)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LHC165.png",
          "label": "TLR7",
          "compound": "LHC165"
        }
      ],
      "moas": ["Spartalizumab.png", "LHC165.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <i>Sorafenib</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>A2AR</b> (NIR178<sup>19</sup>)": {
      "cards": [
        {
          "file": "NIR178.png",
          "label": "A2AR",
          "compound": "NIR178"
        }
      ],
      "moas": ["NIR178.png"]
    },
    "<b>IL-15</b> (NIZ985<sup>21</sup>)": {
      "cards": [
        {
          "file": "NIZ985.png",
          "label": "IL-15",
          "compound": "NIZ985"
        }
      ],
      "moas": ["NIZ985.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CSF-1</b> (Lacnotuzumab<sup>12</sup>)": {
      "cards": [
        {
          "file": "Spartalizumab-Lacnotuzumab.png",
          "label": "PD-1 + CSF-1",
          "compound": "Spartalizumab-Lacnotuzumab"
        }
      ],
      "moas": ["Spartalizumab-Lacnotuzumab.png"]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>CXCR2</b> (QBM076)": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "",
          "label": "CXCR2",
          "compound": "QBM076"
        }
      ],
      "moas": ["Spartalizumab.png"]
    },
    "<b>CAR-T CD19</b> (YTB323)": {
      "cards": [
        {
          "file": "",
          "label": "CAR-T CD19",
          "compound": "YTB323"
        }
      ]
    },
    "<b>PD-1</b> (Spartalizumab<sup>25</sup>) + <b>LAG-3</b> (LAG525) + <i>Carboplatin</i>": {
      "cards": [
        {
          "file": "Spartalizumab.png",
          "label": "PD-1",
          "compound": "Spartalizumab"
        },
        {
          "file": "LAG525.png",
          "label": "LAG-3",
          "compound": "LAG525"
        }
      ],
      "moas": ["Spartalizumab.png", "LAG525.png"]
    },
    "<b>pan-RAF</b> (LXH254<sup>24</sup>) + <b>CDK4/6</b> (Ribociclib)": {
      "cards": [
        {
          "file": "LXH254.png",
          "label": "pan-RAF + ERK",
          "compound": "LXH254"
        },
        {
          "file": "",
          "label": "CDK4/6",
          "compound": "Ribociclib"
        }
      ],
      "moas": ["LXH254.png"]
    }
  },
  "studies": {
    "NCT03822468": "https://ClinicalTrials.gov/show/NCT03822468",
    "NCT03696771": "https://ClinicalTrials.gov/show/NCT03696771",
    "NCT03814746": "https://ClinicalTrials.gov/show/NCT03814746",
    "NCT02605967": "https://ClinicalTrials.gov/show/NCT02605967",
    "NCT02124772": "https://ClinicalTrials.gov/show/NCT02124772",
    "NCT03578367": "https://ClinicalTrials.gov/show/NCT03578367",
    "NCT03876028": "https://ClinicalTrials.gov/show/NCT03876028",
    "NCT02414139": "https://ClinicalTrials.gov/show/NCT02414139",
    "NCT03333343": "https://ClinicalTrials.gov/show/NCT03333343",
    "NCT02730312": "https://ClinicalTrials.gov/show/NCT02730312",
    "NCT01336634": "https://ClinicalTrials.gov/show/NCT01336634",
    "NCT03671330": "https://ClinicalTrials.gov/show/NCT03671330",
    "NCT03524612": "https://ClinicalTrials.gov/show/NCT03524612",
    "NCT02684058": "https://ClinicalTrials.gov/show/NCT02684058",
    "NCT03207867": "https://ClinicalTrials.gov/show/NCT03207867",
    "NCT02323126": "https://ClinicalTrials.gov/show/NCT02323126",
    "NCT03968419": "https://ClinicalTrials.gov/show/NCT03968419",
    "NCT03960840": "https://ClinicalTrials.gov/show/NCT03960840",
    "NCT03301896": "https://ClinicalTrials.gov/show/NCT03301896",
    "NCT02734615": "https://ClinicalTrials.gov/show/NCT02734615",
    "NCT02437318": "https://ClinicalTrials.gov/show/NCT02437318",
    "NCT03025698": "https://ClinicalTrials.gov/show/NCT03025698",
    "NCT02452268": "https://ClinicalTrials.gov/show/NCT02452268",
    "NCT03106779": "https://ClinicalTrials.gov/show/NCT03106779",
    "NCT03630159": "https://ClinicalTrials.gov/show/NCT03630159",
    "NCT02276027": "https://ClinicalTrials.gov/show/NCT02276027",
    "NCT01351103": "https://ClinicalTrials.gov/show/NCT01351103",
    "NCT02335944": "https://ClinicalTrials.gov/show/NCT02335944",
    "NCT03280030": "https://ClinicalTrials.gov/show/NCT03280030",
    "NCT02890069": "https://ClinicalTrials.gov/show/NCT02890069",
    "NCT03447769": "https://ClinicalTrials.gov/show/NCT03447769",
    "NCT03876769": "https://ClinicalTrials.gov/show/NCT03876769",
    "NCT03570892": "https://ClinicalTrials.gov/show/NCT03570892",
    "NCT03742349": "https://ClinicalTrials.gov/show/NCT03742349",
    "NCT02974725": "https://ClinicalTrials.gov/show/NCT02974725",
    "NCT03499899": "https://ClinicalTrials.gov/show/NCT03499899",
    "NCT03760445": "https://ClinicalTrials.gov/show/NCT03760445",
    "NCT03798626": "https://ClinicalTrials.gov/show/NCT03798626",
    "NCT03610724": "https://ClinicalTrials.gov/show/NCT03610724",
    "NCT02460224": "https://ClinicalTrials.gov/show/NCT02460224",
    "NCT02675439": "https://ClinicalTrials.gov/show/NCT02675439",
    "NCT02083354": "https://ClinicalTrials.gov/show/NCT02083354",
    "NCT03056755": "https://ClinicalTrials.gov/show/NCT03056755",
    "NCT03379727": "https://ClinicalTrials.gov/show/NCT03379727",
    "NCT03114319": "https://ClinicalTrials.gov/show/NCT03114319",
    "NCT02795429": "https://ClinicalTrials.gov/show/NCT02795429",
    "NCT03591510": "https://ClinicalTrials.gov/show/NCT03591510",
    "NCT03474965": "https://ClinicalTrials.gov/show/NCT03474965",
    "NCT03891953": "https://ClinicalTrials.gov/show/NCT03891953",
    "NCT02143635": "https://ClinicalTrials.gov/show/NCT02143635",
    "NCT04053764": "https://ClinicalTrials.gov/show/NCT04053764",
    "NCT03064854": "https://ClinicalTrials.gov/show/NCT03064854",
    "NCT03551626": "https://ClinicalTrials.gov/show/NCT03551626",
    "NCT02081378": "https://ClinicalTrials.gov/show/NCT02081378",
    "NCT03484923": "https://ClinicalTrials.gov/show/NCT03484923",
    "NCT03066648": "https://ClinicalTrials.gov/show/NCT03066648",
    "NCT04097821": "https://ClinicalTrials.gov/show/NCT04097821",
    "NCT04000529": "https://ClinicalTrials.gov/show/NCT04000529",
    "NCT01857193": "https://ClinicalTrials.gov/show/NCT01857193",
    "NCT03172936": "https://ClinicalTrials.gov/show/NCT03172936",
    "NCT02370706": "https://ClinicalTrials.gov/show/NCT02370706",
    "NCT02403193": "https://ClinicalTrials.gov/show/NCT02403193",
    "NCT02947165": "https://ClinicalTrials.gov/show/NCT02947165",
    "NCT03946670": "https://ClinicalTrials.gov/show/NCT03946670",
    "NCT02967692": "https://ClinicalTrials.gov/show/NCT02967692",
    "NCT02703571": "https://ClinicalTrials.gov/show/NCT02703571",
    "NCT03938454": "https://ClinicalTrials.gov/show/NCT03938454",
    "NCT02608268": "https://ClinicalTrials.gov/show/NCT02608268",
    "NCT03549000": "https://ClinicalTrials.gov/show/NCT03549000",
    "NCT02988440": "https://ClinicalTrials.gov/show/NCT02988440",
    "NCT02404441": "https://ClinicalTrials.gov/show/NCT02404441",
    "NCT02900651": "https://ClinicalTrials.gov/show/NCT02900651",
    "NCT02333370": "https://ClinicalTrials.gov/show/NCT02333370",
    "NCT02829723": "https://ClinicalTrials.gov/show/NCT02829723",
    "NCT02807844": "https://ClinicalTrials.gov/show/NCT02807844",
    "NCT03568461": "https://ClinicalTrials.gov/show/NCT03568461",
    "NCT01219699": "https://ClinicalTrials.gov/show/NCT01219699",
    "NCT02900664": "https://ClinicalTrials.gov/show/NCT02900664",
    "NCT03647488": "https://ClinicalTrials.gov/show/NCT03647488",
    "NCT03940352": "https://ClinicalTrials.gov/show/NCT03940352",
    "NCT03626545": "https://ClinicalTrials.gov/show/NCT03626545",
    "NCT03701334": "https://ClinicalTrials.gov/show/NCT03701334",
    "NCT02607813": "https://ClinicalTrials.gov/show/NCT02607813",
    "NCT02992483": "https://ClinicalTrials.gov/show/NCT02992483",
    "NCT03400176": "https://ClinicalTrials.gov/show/NCT03400176",
    "NCT03365791": "https://ClinicalTrials.gov/show/NCT03365791",
    "NCT03631199": "https://ClinicalTrials.gov/show/NCT03631199"
  }
}
